Loading organization details...
Loading organization details...
TO PROVIDE HIGH QUALITY EDUCATIONAL SERVICES, RESEARCH, AND COMMUNITY SERVICE.
Source: IRS Form 990 (Tax Year 2023)
Source: IRS e-Filed Form 990 (from the IRS e-File system), Tax Year 2022
Total Revenue
▼$3.1B
Program Spending
90%
of total expenses go to program services
Total Contributions
$565.5M
Total Expenses
▼$3.1B
Total Assets
$9.7B
Total Liabilities
▼$2.8B
Net Assets
$6.9B
Officer Compensation
→$7.3M
Other Salaries
$1.3B
Investment Income
$141.3M
Fundraising
▼$227.8K
Tax Year 2022 · Source: IRS Form 990, Schedule I (Grants and Other Assistance)
Total grants awarded: $146.6M
| Recipient | Location | Amount | Type | Purpose |
|---|---|---|---|---|
CARNEGIE MELLON UNIVERSITY25-0969449 | PITTSBURGH, PA | $9.3M | Cash | RESEARCH- SUBCONTRACT |
REGENTS OF THE UNIVERSITY OF CALIFORNIA94-3067788 | OAKLAND, CA | $8.7M | Cash | RESEARCH- SUBCONTRACT |
NEW YORK UNIVERSITY13-5562308 | NEW YORK, NY | $7.5M | Cash | RESEARCH- SUBCONTRACT |
REGENTS OF THE UNIVERSITY OF MICHIGAN38-6006309 | ANN ARBOR, MI | $4.9M | Cash | RESEARCH- SUBCONTRACT |
WASHINGTON UNIVERSITY IN ST LOUIS43-0653611 | CLAYTON, MO | $4.5M | Cash | RESEARCH- SUBCONTRACT |
UNIVERSITY OF ILLINOIS37-6000511 | URBANA, IL | $4.2M | Cash | RESEARCH- SUBCONTRACT |
BRIGHAM AND WOMENS HOSPITAL INC | BOSTON, MA | $3.2M | Cash | RESEARCH- SUBCONTRACT |
UNIVERSITY OF SOUTHERN CALIFORNIA95-1642394 | LOS ANGELES, CA | $3.1M | Cash | RESEARCH- SUBCONTRACT |
JOHNS HOPKINS UNIVERSITY52-0595110 | BALTIMORE, MD | $2.8M | Cash | RESEARCH- SUBCONTRACT |
UNIVERSITY OF CHICAGO36-2177139 | CHICAGO, IL | $2.6M | Cash | RESEARCH- SUBCONTRACT |
MASSACHUSETTS GENERAL HOSPITAL | BOSTON, MA | $2.5M | Cash | RESEARCH- SUBCONTRACT |
INDIANA UNIVERSITY35-6001673 | BLOOMINGTON, IN | $2.4M | Cash | RESEARCH- SUBCONTRACT |
| MADISON, WI | $2.2M | Cash | RESEARCH- SUBCONTRACT | |
UNIVERSITY OF MARYLAND52-6002033 | BALTIMORE, MD | $2.2M | Cash | RESEARCH- SUBCONTRACT |
NORTHEASTERN UNIVERSITY | BOSTON, MA | $2.1M | Cash | RESEARCH- SUBCONTRACT |
OHIO STATE UNIVERSITY31-6025986 | COLUMBUS, OH | $2.1M | Cash | RESEARCH- SUBCONTRACT |
UNIVERSITY OF DELAWARE51-6000297 | NEWARK, DE | $2M | Cash | RESEARCH- SUBCONTRACT |
| CHAPEL HILL, NC | $1.9M | Cash | RESEARCH- SUBCONTRACT | |
HARVARD UNIVERSITY | CAMBRIDGE, MA | $1.8M | Cash | RESEARCH- SUBCONTRACT |
CONSORTIUM FOR PUBLIC EDUCATION25-1533592 | MCKEESPORT, PA | $1.8M | Cash | RESEARCH- SUBCONTRACT |
TRUSTEES OF COLUMBIA UNIVERSITY13-5598093 | NEW YORK, NY | $1.7M | Cash | RESEARCH- SUBCONTRACT |
UNIVERSITY OF IOWA42-6004813 | IOWA CITY, IA | $1.5M | Cash | RESEARCH- SUBCONTRACT |
| PHILADELPHIA, PA | $1.5M | Cash | RESEARCH- SUBCONTRACT | |
UNIVERSITY OF CINCINNATI31-6000989 | CINCINNATI, OH | $1.4M | Cash | RESEARCH- SUBCONTRACT |
MOUNT SINAI SCHOOL OF MEDICINE13-6171197 | NEW YORK, NY | $1.4M | Cash | RESEARCH- SUBCONTRACT |
BROAD INSTITUTE INC26-3428781 | CAMBRIDGE, MA | $1.4M | Cash | RESEARCH- SUBCONTRACT |
ALBERT EINSTEIN COLLEGE OF MEDICINE23-7075620 | NEW YORK, NY | $1.2M | Cash | RESEARCH- SUBCONTRACT |
VANDERBILT UNIVERSITY MEDICAL CENTER35-2528741 | NASHVILLE, TN | $1.2M | Cash | RESEARCH- SUBCONTRACT |
UNIVERSITY OF MASSACHUSETTS | BOSTON, MA | $1.1M | Cash | RESEARCH- SUBCONTRACT |
YALE UNIVERSITY | NEW HAVEN, CT | $1.1M | Cash | RESEARCH- SUBCONTRACT |
| PITTSBURGH, PA | $1.1M | Cash | RESEARCH- SUBCONTRACT | |
UNIVERSITY OF CALIFORNIA DAVIS94-6036494 | DAVIS, CA | $1.1M | Cash | RESEARCH- SUBCONTRACT |
COMMUNITY HUMAN SERVICES CORP25-1219610 | PITTSBURGH, PA | $1.1M | Cash | RESEARCH- SUBCONTRACT |
| COLUMBUS, OH | $1M | Cash | RESEARCH- SUBCONTRACT | |
| SAN ANTONIO, TX | $994K | Cash | RESEARCH- SUBCONTRACT | |
MAYO CLINIC ROCHESTER41-6011702 | ROCHESTER, MN | $975.1K | Cash | RESEARCH- SUBCONTRACT |
| HOUSTON, TX | $943.6K | Cash | RESEARCH- SUBCONTRACT | |
UNIVERSITY OF FLORIDA59-6002052 | GAINESVILLE, FL | $942K | Cash | RESEARCH- SUBCONTRACT |
| PHILADELPHIA, PA | $863K | Cash | RESEARCH- SUBCONTRACT | |
THERMAQUIL INC82-3445801 | PHILADELPHIA, PA | $846.4K | Cash | RESEARCH- SUBCONTRACT |
CHILDREN'S HOSPITAL OF PHILADELPHIA23-1352166 | PHILADELPHIA, PA | $844.9K | Cash | RESEARCH- SUBCONTRACT |
UNIVERSITY OF UTAH87-6000525 | SALT LAKE CITY, UT | $808.8K | Cash | RESEARCH- SUBCONTRACT |
CASE WESTERN RESERVE UNIVERSITY34-1018992 | CLEVELAND, OH | $799.1K | Cash | RESEARCH- SUBCONTRACT |
EMORY UNIVERSITY58-0566256 | ATLANTA, GA | $797.1K | Cash | RESEARCH- SUBCONTRACT |
VERSITI WISCONSIN INC39-0807235 | MILWAUKEE, WI | $797.1K | Cash | RESEARCH- SUBCONTRACT |
PENNSYLVANIA STATE UNIVERSITY24-6000376 | UNIVERSITY PARK, PA | $795.9K | Cash | RESEARCH- SUBCONTRACT |
| PALO ALTO, CA | $795.5K | Cash | RESEARCH- SUBCONTRACT | |
| SEATTLE, WA | $777.8K | Cash | RESEARCH- SUBCONTRACT | |
WEST VIRGINIA UNIVERSITY RESEARCH CORP55-0665758 | MORGANTOWN, WV | $775.3K | Cash | RESEARCH- SUBCONTRACT |
RUSH UNIVERSITY MEDICAL CENTER36-2174823 | CHICAGO, IL | $754.2K | Cash | RESEARCH- SUBCONTRACT |
HENRY M JACKSON FOUNDATION52-1317896 | BETHESDA, MD | $724.3K | Cash | RESEARCH- SUBCONTRACT |
DUKE UNIVERSITY56-0532129 | DURHAM, NC | $713.3K | Cash | RESEARCH- SUBCONTRACT |
DANA-FARBER CANCER INSTITUTE | BOSTON, MA | $712.9K | Cash | RESEARCH- SUBCONTRACT |
SCRIPPS RESEARCH INSTITUTE33-0435954 | LA JOLLA, CA | $701.4K | Cash | RESEARCH- SUBCONTRACT |
| LEXINGTON, KY | $683.4K | Cash | RESEARCH- SUBCONTRACT | |
RESEARCH FOUNDATION FOR MENTAL HYGIENE14-1410842 | MENANDS, NY | $654.7K | Cash | RESEARCH- SUBCONTRACT |
UNIVERSITY OF CALIFORNIA SAN DIEGO95-6006144 | SAN DIEGO, CA | $651.9K | Cash | RESEARCH- SUBCONTRACT |
BOSTON UNIVERSITY | BOSTON, MA | $647.4K | Cash | RESEARCH- SUBCONTRACT |
WEILL MEDICAL COLLEGE13-1623978 | NEW YORK, NY | $637.3K | Cash | RESEARCH- SUBCONTRACT |
UNIVERSITY OF NEBRASKA MEDICAL CENTER47-0771713 | OMAHA, NE | $625.3K | Cash | RESEARCH- SUBCONTRACT |
KUMC RESEARCH INSTITUTE INC48-1108830 | WEST ORANGE, NJ | $604.1K | Cash | RESEARCH- SUBCONTRACT |
UNIVERSITY OF WASHINGTON91-6001537 | SEATTLE, WA | $598.9K | Cash | RESEARCH- SUBCONTRACT |
WILLIAM MARSH RICE UNIVERSITY74-1109620 | HOUSTON, TX | $586.1K | Cash | RESEARCH- SUBCONTRACT |
AMIDA TECHNOLOGY SOLUTIONS INC46-2882019 | WASHINGTON, DC | $562.5K | Cash | RESEARCH- SUBCONTRACT |
UNIVERSITY OF ROCHESTER16-0743209 | ROCHESTER, NY | $553.7K | Cash | RESEARCH- SUBCONTRACT |
TURTLE CREEK VALLEY MHMR INC25-1250510 | BRADDOCK, PA | $538.2K | Cash | RESEARCH- SUBCONTRACT |
UNIVERSITY OF ALABAMA AT BIRMINGHAM63-6005396 | BIRMINGHAM, AL | $537.4K | Cash | RESEARCH- SUBCONTRACT |
MED-ALLY LLC45-4662780 | GOOSE CREEK, SC | $531.1K | Cash | RESEARCH- SUBCONTRACT |
JACKSON LABORATORY | BAR HARBOR, ME | $518.1K | Cash | RESEARCH- SUBCONTRACT |
| PISCATAWAY, NJ | $517.3K | Cash | RESEARCH- SUBCONTRACT | |
CITY OF HOPE95-3435919 | DUARTE, CA | $510.1K | Cash | RESEARCH- SUBCONTRACT |
| PORTLAND, OR | $498.7K | Cash | RESEARCH- SUBCONTRACT | |
UNIVERSITY OF ARIZONA74-2652689 | TUCSON, AZ | $495.6K | Cash | RESEARCH- SUBCONTRACT |
HEALTH FEDERATION OF PHILADELPHIA23-2244355 | PHILADELPHIA, PA | $468.6K | Cash | RESEARCH- SUBCONTRACT |
UNIVERSITY OF MISSOURI COLUMBIA43-6003859 | COLUMBIA, MO | $462.2K | Cash | RESEARCH- SUBCONTRACT |
NEW YORK GENOME CENTER INC80-0631734 | NEW YORK, NY | $458K | Cash | RESEARCH- SUBCONTRACT |
| STANFORD, CA | $457.4K | Cash | RESEARCH- SUBCONTRACT | |
UNIVERSITY OF CALIFORNIA SAN FRANCISCO94-6036493 | SAN FRANCISCO, CA | $454.7K | Cash | RESEARCH- SUBCONTRACT |
UNIVERSITY OF COLORADO84-6000555 | DENVER, CO | $441.3K | Cash | RESEARCH- SUBCONTRACT |
REGENTS OF THE UNIVERSITY OF MINNESOTA41-6007513 | MINNEAPOLIS, MN | $440.3K | Cash | RESEARCH- SUBCONTRACT |
| LOUISVILLE, KY | $423.4K | Cash | RESEARCH- SUBCONTRACT | |
| FORT WORTH, TX | $419.7K | Cash | RESEARCH- SUBCONTRACT | |
FOCUS ON RENEWAL23-7181440 | MCKEES ROCKS, PA | $413.1K | Cash | RESEARCH- SUBCONTRACT |
INOVA HEALTH CARE SERVICES54-0620889 | FAIRFAX, VA | $407.8K | Cash | RESEARCH- SUBCONTRACT |
BAYLOR COLLEGE OF MEDICINE74-1613878 | HOUSTON, TX | $400.3K | Cash | RESEARCH- SUBCONTRACT |
WEST VIRGINIA UNIVERSITY55-6000842 | MORGANTOWN, WV | $389.2K | Cash | RESEARCH- SUBCONTRACT |
MASSACHUSETTS INSTITUTE OF TECHNOLOGY | CAMBRIDGE, MA | $376.9K | Cash | RESEARCH- SUBCONTRACT |
VIRGINIA COMMONWEALTH UNIVERSITY54-6001758 | RICHMOND, VA | $374.1K | Cash | RESEARCH- SUBCONTRACT |
NORTHWESTERN UNIVERSITY36-2167817 | EVANSTON, IL | $363.7K | Cash | RESEARCH- SUBCONTRACT |
GEORGETOWN UNIVERSITY53-0196603 | WASHINGTON, DC | $363.2K | Cash | RESEARCH- SUBCONTRACT |
WAKE FOREST UNIVERSITY56-0532138 | WINSTONSALEM, NC | $361.2K | Cash | RESEARCH- SUBCONTRACT |
ARIZONA STATE UNIVERSITY86-0196696 | TEMPE, AZ | $359.2K | Cash | RESEARCH- SUBCONTRACT |
HOWARD UNIVERSITY53-0204707 | WASHINGTON, DC | $354K | Cash | RESEARCH- SUBCONTRACT |
CHILDRENS RESEARCH INSTITUTE31-4379441 | COLUMBUS, OH | $351.7K | Cash | RESEARCH- SUBCONTRACT |
MAYO CLINIC ARIZONA86-0800150 | ROCHESTER, MN | $349.6K | Cash | RESEARCH- SUBCONTRACT |
VITALANT86-0098929 | SCOTTSDALE, AZ | $345.3K | Cash | RESEARCH- SUBCONTRACT |
VANDERBILT UNIVERSITY62-0476822 | NASHVILLE, TN | $333.3K | Cash | RESEARCH- SUBCONTRACT |
UNIVERSITY OF MIAMI59-0624458 | CORAL GABLES, FL | $329.2K | Cash | RESEARCH- SUBCONTRACT |
| LOS ANGELES, CA | $320.4K | Cash | RESEARCH- SUBCONTRACT | |
THOMAS JEFFERSON UNIVERSITY23-1352651 | PHILADELPHIA, PA | $317.1K | Cash | RESEARCH- SUBCONTRACT |
UNIVERSITY OF VIRGINIA54-6001786 | CHARLOTTESVILLE, VA | $316.9K | Cash | RESEARCH- SUBCONTRACT |
THE MIRIAM HOSPITAL | PROVIDENCE, RI | $315.2K | Cash | RESEARCH- SUBCONTRACT |
CLEVELAND STATE UNIVERSITY34-0966056 | CLEVELAND, OH | $303.5K | Cash | RESEARCH- SUBCONTRACT |
EAST CAROLINA UNIVERSITY56-6000403 | GREENVILLE, NC | $299.7K | Cash | RESEARCH- SUBCONTRACT |
TRUSTEES OF PRINCETON UNIVERSITY21-0634501 | PRINCETON, NJ | $293.7K | Cash | RESEARCH- SUBCONTRACT |
HEKTOEN INSTITUTE FOR MEDICAL RESEARCH36-2244897 | CHICAGO, IL | $291.7K | Cash | RESEARCH- SUBCONTRACT |
UNIVERSITY OF NEBRASKA-LINCOLN47-0491233 | LINCOLN, NE | $286.8K | Cash | RESEARCH- SUBCONTRACT |
GE GLOBAL OPERATIONS14-0689340 | FAIRFIELD, CT | $282.1K | Cash | RESEARCH- SUBCONTRACT |
UNIVERSITY OF MISSISSIPPI MEDICAL CENTER64-6008520 | JACKSON, MS | $280.2K | Cash | RESEARCH- SUBCONTRACT |
| PITTSBURGH, PA | $265K | Cash | RESEARCH- SUBCONTRACT | |
| SALT LAKE CITY, UT | $262K | Cash | RESEARCH- SUBCONTRACT | |
| CLEVELAND HEIGHTS, OH | $257.3K | Cash | RESEARCH- SUBCONTRACT | |
| ALBANY, NY | $255.6K | Cash | RESEARCH- SUBCONTRACT | |
UNIVERSITY OF VERMONT | BURLINGTON, VT | $253.9K | Cash | RESEARCH- SUBCONTRACT |
| DETROIT, MI | $253.8K | Cash | RESEARCH- SUBCONTRACT | |
UNIVERSITY OF NEVADA RENO88-6000024 | RENO, NV | $252.6K | Cash | RESEARCH- SUBCONTRACT |
GEORGE MASON UNIVERSITY54-0836354 | FAIRFAX, VA | $243.5K | Cash | RESEARCH- SUBCONTRACT |
NORTH CAROLINA STATE UNIVERSITY56-6000756 | RALEIGH, NC | $238.3K | Cash | RESEARCH- SUBCONTRACT |
GEISINGER CLINIC23-6291113 | DANVILLE, PA | $237.2K | Cash | RESEARCH- SUBCONTRACT |
UPMC CENTER FOR HIGH-VALUE HEALTHCARE45-2178782 | PITTSBURGH, PA | $235K | Cash | RESEARCH- SUBCONTRACT |
CHRISTIANA CARE HEALTH SERVICES51-0103684 | WILMINGTON, DE | $232.6K | Cash | RESEARCH- SUBCONTRACT |
| LAWRENCE, KS | $230K | Cash | RESEARCH- SUBCONTRACT | |
UNIVERSITY OF TENNESSEE62-6001636 | KNOXVILLE, TN | $225.4K | Cash | RESEARCH- SUBCONTRACT |
SEATTLE CHILDREN'S HOSPITAL91-0564748 | SEATTLE, WA | $216.2K | Cash | RESEARCH- SUBCONTRACT |
PINNACLE HEALTH MEDICAL SERVICES25-1709054 | HARRISBURG, PA | $213.9K | Cash | RESEARCH- SUBCONTRACT |
BROWN UNIVERSITY | PROVIDENCE, RI | $213.3K | Cash | RESEARCH- SUBCONTRACT |
SALK INSTITUTE95-2160097 | LA JOLLA, CA | $209.6K | Cash | RESEARCH- SUBCONTRACT |
CURATORS OF THE UNIVERSITY OF MISSOURI26-6440629 | COLUMBIA, MO | $201.7K | Cash | RESEARCH- SUBCONTRACT |
HOUSTON METHODIST RESEARCH INSTITUTE87-0721923 | HOUSTON, TX | $200.5K | Cash | RESEARCH- SUBCONTRACT |
| WINSTONSALEM, NC | $200K | Cash | RESEARCH- SUBCONTRACT | |
TULANE UNIVERSITY72-0423889 | NEW ORLEANS, LA | $199.8K | Cash | RESEARCH- SUBCONTRACT |
ST LUKES HOSPITAL OF KANSAS CITY44-0545297 | KANSAS CITY, MO | $199.3K | Cash | RESEARCH- SUBCONTRACT |
| HOUSTON, TX | $190.8K | Cash | RESEARCH- SUBCONTRACT | |
AKRON CHILDRENS HOSPITAL34-0714357 | YOUNGSTOWN, OH | $188.6K | Cash | RESEARCH- SUBCONTRACT |
UNIVERSITY OF NOTRE DAME DU LAC35-0868188 | NOTRE DAME, IN | $186.3K | Cash | RESEARCH- SUBCONTRACT |
ALLEGHENY-SINGER RESEARCH INSTITUTE25-1320493 | PITTSBURGH, PA | $180.6K | Cash | RESEARCH- SUBCONTRACT |
NRECA RESEARCH84-2724646 | ARLINGTON, VA | $180.4K | Cash | RESEARCH- SUBCONTRACT |
| CINCINNATI, OH | $175.2K | Cash | RESEARCH- SUBCONTRACT | |
CURADA BIO INC88-0712517 | ARLINGTON, MA | $174.7K | Cash | RESEARCH- SUBCONTRACT |
GEORGIA TECH RESEARCH CORP58-0603146 | ATLANTA, GA | $172K | Cash | RESEARCH- SUBCONTRACT |
MOREHOUSE SCHOOL OF MEDICINE INC58-1438873 | ATLANTA, GA | $171.1K | Cash | RESEARCH- SUBCONTRACT |
CHILDREN'S MERCY HOSPITAL44-0605373 | KANSAS CITY, MO | $168.5K | Cash | RESEARCH- SUBCONTRACT |
THE GOG FOUNDATION INC | EDGEWATER, MD | $167.4K | Cash | RESEARCH- SUBCONTRACT |
UNIVERSITY OF TEXAS AT AUSTIN74-6000203 | AUSTIN, TX | $165.6K | Cash | RESEARCH- SUBCONTRACT |
| PITTSBURGH, PA | $156.1K | Cash | RESEARCH- SUBCONTRACT | |
BOSTON CHILDREN'S HOSPITAL | BOSTON, MA | $149.3K | Cash | RESEARCH- SUBCONTRACT |
UNIVERSITY OF TEXAS MEDICAL BRANCH74-6000949 | HOUSTON, TX | $139.9K | Cash | RESEARCH- SUBCONTRACT |
MICHIGAN STATE UNIVERSITY38-6005984 | EAST LANSING, MI | $136.5K | Cash | RESEARCH- SUBCONTRACT |
TUFTS UNIVERSITY | SOMERVILLE, MA | $136.3K | Cash | RESEARCH- SUBCONTRACT |
| ATHENS, GA | $134.8K | Cash | RESEARCH- SUBCONTRACT | |
SHARP MEMORIAL HOSPITAL95-3782169 | SAN DIEGO, CA | $133.4K | Cash | RESEARCH- SUBCONTRACT |
DREXEL UNIVERSITY23-1352630 | PHILADELPHIA, PA | $133.3K | Cash | RESEARCH- SUBCONTRACT |
OREGON STATE UNIVERSITY61-1730890 | CORVALLIS, OR | $128.6K | Cash | RESEARCH- SUBCONTRACT |
AMERICAN INSTITUTES FOR RESEARCH25-0965219 | WASHINGTON, DC | $127.6K | Cash | RESEARCH- SUBCONTRACT |
UNIVERSITY OF CALIFORNIA AT LOS ANGELES95-6006143 | LOS ANGELES, CA | $124.6K | Cash | RESEARCH- SUBCONTRACT |
BLOMGREN CONSULTING SERVICES LTD34-1878550 | CLEVELAND, OH | $124K | Cash | RESEARCH- SUBCONTRACT |
| OAKLAND, CA | $123.6K | Cash | RESEARCH- SUBCONTRACT | |
NATIONAL MARROW DONOR PROGRAM84-0865803 | MINNEAPOLIS, MN | $123.4K | Cash | RESEARCH- SUBCONTRACT |
UNIVERSITY OF TOLEDO34-6401483 | TOLEDO, OH | $121.3K | Cash | RESEARCH- SUBCONTRACT |
INTERNATIONAL AIDS VACCINE INITATIVE13-3870223 | NEW YORK, NY | $120.8K | Cash | RESEARCH- SUBCONTRACT |
BOSTON MEDICAL CENTER | BOSTON, MA | $119.4K | Cash | RESEARCH- SUBCONTRACT |
UNIVERSITY OF NEW MEXICO85-6000642 | ALBUQUERQUE, NM | $119K | Cash | RESEARCH- SUBCONTRACT |
CLINTON HEALTH ACCESS INITIATIVE INC27-1414646 | BOSTON, MA | $111.6K | Cash | RESEARCH- SUBCONTRACT |
AUGUSTA UNIVERSITY58-6002053 | AUGUSTA, GA | $110K | Cash | RESEARCH- SUBCONTRACT |
FLORIDA INTERNATIONAL UNIVERSITY65-0177616 | MIAMI, FL | $107.7K | Cash | RESEARCH- SUBCONTRACT |
COMMUNITY-CAMPUS PARTNERSHIPS FOR HEALTH94-3285533 | RALEIGH, NC | $105.2K | Cash | RESEARCH- SUBCONTRACT |
UNIVERSITY OF OREGON93-6001786 | EUGENE, OR | $103.8K | Cash | RESEARCH- SUBCONTRACT |
COLD SPRING HARBOR LABORATORY11-2013303 | COLD SPRING HARBOR, NY | $103.1K | Cash | RESEARCH- SUBCONTRACT |
UPMC25-1423657 | PITTSBURGH, PA | $100.6K | Cash | RESEARCH- SUBCONTRACT |
OAKLAND BUSINESS IMPROVEMENT DISTRICT25-1833743 | PITTSBURGH, PA | $100K | Cash | SPONSORSHIP |
| PITTSBURGH, PA | $100K | Cash | SPONSORSHIP | |
RENSSELAER POLYTECHNIC INSTITUTE14-1340095 | TROY, NY | $99.5K | Cash | RESEARCH- SUBCONTRACT |
STATE UNIVERSITY OF NEW YORK14-6013200 | ALBANY, NY | $93.6K | Cash | RESEARCH- SUBCONTRACT |
| MOBILE, AL | $91.9K | Cash | RESEARCH- SUBCONTRACT | |
MICHAEL BAKER INTERNATIONAL INC25-1228638 | PITTSBURGH, PA | $91.2K | Cash | RESEARCH- SUBCONTRACT |
| MERCED, CA | $89.1K | Cash | RESEARCH- SUBCONTRACT | |
| GREENSBORO, NC | $86.7K | Cash | RESEARCH- SUBCONTRACT | |
MAYO CLINIC JACKSONVILLE59-3337028 | ROCHESTER, MN | $86.4K | Cash | RESEARCH- SUBCONTRACT |
UNIVERSITY OF ARKANSAS SYSTEM71-6003252 | FAYETTEVILLE, AR | $85.8K | Cash | RESEARCH- SUBCONTRACT |
CORNERSTONE CARE INC25-1346194 | GREENSBORO, PA | $84.9K | Cash | RESEARCH- SUBCONTRACT |
CORNELL UNIVERSITY15-0532082 | ITHACA, NY | $83.7K | Cash | RESEARCH- SUBCONTRACT |
BIRMINGHAM AIDS OUTREACH INC63-0948495 | BIRMINGHAM, AL | $83.3K | Cash | RESEARCH- SUBCONTRACT |
NEW ENGLAND RESEARCH INSTITUTES INC | WATERTOWN, MA | $81.6K | Cash | RESEARCH- SUBCONTRACT |
| DALLAS, TX | $80.7K | Cash | RESEARCH- SUBCONTRACT | |
HACKENSACK MERIDIAN HEALTH INC22-1487576 | EDISON, NJ | $80K | Cash | RESEARCH- SUBCONTRACT |
| CHARLOTTE, NC | $79.6K | Cash | RESEARCH- SUBCONTRACT | |
| LUBBOCK, TX | $79.6K | Cash | RESEARCH- SUBCONTRACT | |
SAGE BIONETWORKS26-4489946 | SEATTLE, WA | $79.2K | Cash | RESEARCH- SUBCONTRACT |
WAYNE STATE UNIVERSITY38-3555142 | DETROIT, MI | $79.1K | Cash | RESEARCH- SUBCONTRACT |
OREGON RESEARCH INSTITUTE93-0495655 | EUGENE, OR | $78.7K | Cash | RESEARCH- SUBCONTRACT |
LOYOLA UNIVERSITY CHICAGO36-1408475 | CHICAGO, IL | $77.5K | Cash | RESEARCH- SUBCONTRACT |
SAN FRANCISCO STATE UNIVERSITY93-1137247 | SAN FRANCISCO, CA | $77.1K | Cash | RESEARCH- SUBCONTRACT |
ALTA BATES SUMMIT MEDICAL CENTER94-0562680 | OAKLAND, CA | $76.2K | Cash | RESEARCH- SUBCONTRACT |
UNIVERSITY OF TEXAS AT SAN ANTONIO74-1717115 | SAN ANTONIO, TX | $74.5K | Cash | RESEARCH- SUBCONTRACT |
FLUIDFORM INC83-2027523 | WALTHAM, MA | $72.6K | Cash | RESEARCH- SUBCONTRACT |
BAYSTATE MEDICAL CENTER | SPRINGFIELD, MA | $72.5K | Cash | RESEARCH- SUBCONTRACT |
STEM EQUITY INITIATIVE INC83-1909902 | PARKVILLE, MD | $71.5K | Cash | RESEARCH- SUBCONTRACT |
US NAVAL ACADEMY 152-1261462 | ANNAPOLIS, MD | $66.8K | Cash | RESEARCH- SUBCONTRACT |
INSIGHT POLICY RESEARCH INC52-2300796 | ARLINGTON, VA | $63.3K | Cash | RESEARCH- SUBCONTRACT |
UNIVERSITY OF MISSISSIPPI64-6001159 | UNIVERSITY, MS | $62.4K | Cash | RESEARCH- SUBCONTRACT |
UNIVERSITY OF CALIFORNIA IRVINE95-2226406 | IRVINE, CA | $61.5K | Cash | RESEARCH- SUBCONTRACT |
ALLEGHENY COUNTY TREASURER | PITTSBURGH, PA | $61.3K | Cash | RESEARCH- SUBCONTRACT |
DUQUESNE UNIVERSITY OF THE HOLY SPIRIT25-1035663 | PITTSBURGH, PA | $61K | Cash | RESEARCH- SUBCONTRACT |
| PITTSBURGH, PA | $60.2K | Cash | RESEARCH- SUBCONTRACT | |
RESEARCH TRIANGLE INSTITUTE56-0686338 | RESEARCH TRIANGLE PARK, NC | $58K | Cash | RESEARCH- SUBCONTRACT |
URBANKIND INSTITUTE | PITTSBURGH, PA | $57.4K | Cash | RESEARCH- SUBCONTRACT |
ALBERT EINSTEIN HEALTHCARE NETWORK23-2290323 | PHILADELPHIA, PA | $55.7K | Cash | RESEARCH- SUBCONTRACT |
SICKLE CELL 10146-4141467 | SAN JOSE, CA | $54.5K | Cash | RESEARCH- SUBCONTRACT |
DIGITAL PROMISE GLOBAL46-5460594 | NEW CASTLE, PA | $53.2K | Cash | RESEARCH- SUBCONTRACT |
AMERICAN HEART ASSOCIATION13-5613797 | PITTSBURGH, PA | $53.1K | Cash | SPONSORSHIP |
BUCK INSTITUTE FOR RESEARCH ON AGING94-3030609 | NOVATO, CA | $52.2K | Cash | RESEARCH- SUBCONTRACT |
USDA72-0564834 | WASHINGTON, DC | $51.6K | Cash | RESEARCH- SUBCONTRACT |
METROHEALTH SYSTEM34-6004382 | CLEVELAND, OH | $50K | Cash | RESEARCH- SUBCONTRACT |
CARNEGIE MELLON UNIVERSITY25-0969449 | PITTSBURGH, PA | $50K | Cash | SPONSORSHIP |
RHODE ISLAND COLLEGE | PROVIDENCE, RI | $49.7K | Cash | RESEARCH- SUBCONTRACT |
CATHOLIC UNIVERSITY OF AMERICA53-0196583 | WASHINGTON, DC | $49.4K | Cash | RESEARCH- SUBCONTRACT |
THE GENEVA FOUNDATION91-1593913 | TAACOMA, WA | $49.1K | Cash | RESEARCH- SUBCONTRACT |
ST VINCENT COLLEGE25-0964126 | LATROBE, PA | $49K | Cash | RESEARCH- SUBCONTRACT |
FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH11-2673595 | WESTBURY, NY | $48.7K | Cash | RESEARCH- SUBCONTRACT |
CLEMSON UNIVERSITY57-6000254 | CLEMSON, SC | $47.6K | Cash | RESEARCH- SUBCONTRACT |
YOUNGSTOWN STATE UNIVERSITY34-1011998 | YOUNGSTOWN, OH | $46.5K | Cash | RESEARCH- SUBCONTRACT |
OKLAHOMA MEDICAL RESEARCH FOUNDATION73-0580274 | OKLAHOMA CITY, OK | $45.5K | Cash | RESEARCH- SUBCONTRACT |
BENAROYA RESEARCH INSTITUTE91-0653422 | SEATTLE, WA | $44.7K | Cash | RESEARCH- SUBCONTRACT |
UNIVERSITY OF SOUTH CAROLINA57-6001153 | COLUMBIA, SC | $44.7K | Cash | RESEARCH- SUBCONTRACT |
J CRAIG VENTER INSTITUTE INC52-1842938 | LA JOLLA, CA | $43.9K | Cash | RESEARCH- SUBCONTRACT |
DARTMOUTH COLLEGE | HANOVER, NH | $43.5K | Cash | RESEARCH- SUBCONTRACT |
RAYTHEON TECHNOLOGIES RESEARCH CENTER | FARMINGTON, CT | $42.8K | Cash | RESEARCH- SUBCONTRACT |
PITTSBURGH BUSINESS TIMES43-1366184 | PITTSBURGH, PA | $42.5K | Cash | SPONSORSHIP |
| FALLS CHURCH, VA | $42.2K | Cash | RESEARCH- SUBCONTRACT | |
MEDICAL UNIVERSITY OF SOUTH CAROLINA57-6007222 | CHARLESTON, SC | $41.2K | Cash | RESEARCH- SUBCONTRACT |
NOMA AI INC84-3658407 | PITTSBURGH, PA | $40.4K | Cash | RESEARCH- SUBCONTRACT |
CAVE CANEM13-3932909 | BROOKLYN, NY | $40K | Cash | SPONSORSHIP |
BATTELLE MEMORIAL INSTITUTE31-4379427 | COLUMBUS, OH | $40K | Cash | RESEARCH- SUBCONTRACT |
ALBERT SCHWEITZER FELLOWSHIP PITTSBURGH46-3414778 | PITTSBURGH, PA | $40K | Cash | SPONSORSHIP |
CORPORATION FOR A SKILLED WORKFORCE38-2991143 | ANN ARBOR, MI | $39.2K | Cash | RESEARCH- SUBCONTRACT |
NYU GROSSMAN SCHOOL OF MEDICINE13-5562309 | NEW YORK, NY | $36.8K | Cash | RESEARCH- SUBCONTRACT |
INSTITUTE FOR CANCER RESEARCH23-6296135 | PHILADELPHIA, PA | $35.9K | Cash | RESEARCH- SUBCONTRACT |
SICKLE CELL CONSORTIUM INC47-4771677 | CUMMING, GA | $35K | Cash | RESEARCH- SUBCONTRACT |
UNIVERSITY OF CALIFORNIA SANTA BARBARA95-6006145 | SANTA BARBARA, CA | $34.5K | Cash | RESEARCH- SUBCONTRACT |
| NEW YORK, NY | $34.1K | Cash | RESEARCH- SUBCONTRACT | |
TEXAS A&M RESEARCH FOUNDATION74-1238434 | COLLEGE STATION, TX | $33.2K | Cash | RESEARCH- SUBCONTRACT |
URBAN LEAGUE OF GREATER PITTSBURGH25-0965592 | PITTSBURGH, PA | $32.9K | Cash | RESEARCH- SUBCONTRACT |
MEDICAL COLLEGE OF WISCONSIN39-0806261 | MILWAUKEE, WI | $32.7K | Cash | RESEARCH- SUBCONTRACT |
HARVARD EYE ASSOCIATES95-3873981 | LAGUNA HILLS, CA | $32.6K | Cash | RESEARCH- SUBCONTRACT |
MASSACHUSETTS EYE AND EAR INFIRMARY | SOMERVILLE, MA | $31.9K | Cash | RESEARCH- SUBCONTRACT |
LOS ALAMOS NATIONAL LABORATORY74-2853972 | ESPANOLA, NM | $31.7K | Cash | RESEARCH- SUBCONTRACT |
ROBERT MORRIS UNIVERSITY25-1120678 | MOON TOWNSHIP, PA | $31.5K | Cash | RESEARCH- SUBCONTRACT |
MEHARRY MEDICAL COLLEGE62-0488046 | NASHVILLE, TN | $30.7K | Cash | RESEARCH- SUBCONTRACT |
LEGACY EMANUEL MEDICAL CENTER93-0386823 | PORTLAND, OR | $30.4K | Cash | RESEARCH- SUBCONTRACT |
UNIVERSITY OF CONNECTICUT HEALTH CENTER52-1725543 | FARMINGTON, CT | $30.3K | Cash | RESEARCH- SUBCONTRACT |
NORTH DAKOTA STATE UNIVERSITY45-6002439 | FARGO, ND | $30K | Cash | RESEARCH- SUBCONTRACT |
| VALHALLA, NY | $30K | Cash | RESEARCH- SUBCONTRACT | |
HEALTHPARTNERS INSTITUTE41-1670163 | MINNEAPOLIS, MN | $30K | Cash | RESEARCH- SUBCONTRACT |
| PALO ALTO, CA | $29.5K | Cash | RESEARCH- SUBCONTRACT | |
RAND CORPORATION95-1958142 | SANTA MONICA, CA | $28.7K | Cash | RESEARCH- SUBCONTRACT |
ALLEGHENY COUNTY HEALTH DEPARTMENT | PITTSBURGH, PA | $28.5K | Cash | RESEARCH- SUBCONTRACT |
SUNRISE COMMUNITY COUNSELING CENTER95-3128532 | LOS ANGELES, CA | $28.3K | Cash | RESEARCH- SUBCONTRACT |
| ATLANTA, GA | $26.2K | Cash | RESEARCH- SUBCONTRACT | |
ICAN TALK CLINIC27-2398365 | CARNEGIE, PA | $26.2K | Cash | RESEARCH- SUBCONTRACT |
ATTUNE HEALTH RESEARCH INC82-1842765 | BEVERLY HILLS, CA | $25.7K | Cash | RESEARCH- SUBCONTRACT |
VAN ANDEL RESEARCH INSTITUTE52-2000823 | GRAND RAPIDS, MI | $25.1K | Cash | RESEARCH- SUBCONTRACT |
IRELAND FUNDS AMERICA25-1306992 | BOSTON, MA | $25K | Cash | SPONSORSHIP |
HEALTHY START INC25-1691864 | PITTSBURGH, PA | $25K | Cash | RESEARCH- SUBCONTRACT |
PITTSBURGH PROMISE26-1982661 | PITTSBURGH, PA | $25K | Cash | SPONSORSHIP |
RUSH TO CRUSH CANCER87-4771624 | PITTSBURGH, PA | $24.7K | Cash | SPONSORSHIP |
ADVENTIST HEALTH SYSTEM-SUNBELT INC59-0724459 | ORLANDO, FL | $24.6K | Cash | RESEARCH- SUBCONTRACT |
ARISTOSYS LLC82-0893712 | VENETIA, PA | $23.6K | Cash | RESEARCH- SUBCONTRACT |
SPOKANE EYE CLINICAL RESEARCH45-2887234 | SPOKANE, WA | $22.6K | Cash | RESEARCH- SUBCONTRACT |
ACADEMYHEALTH52-1260918 | WASHINGTON, DC | $22.6K | Cash | RESEARCH- SUBCONTRACT |
UNIVERSITY OF HAWAII99-6000354 | HONOLULU, HI | $22.2K | Cash | RESEARCH- SUBCONTRACT |
CEDARS-SINAI MEDICAL CENTER95-1644600 | LOS ANGELES, CA | $21.8K | Cash | RESEARCH- SUBCONTRACT |
DONALD GUTHRIE FOUNDATION24-6022957 | SAYRE, PA | $21K | Cash | RESEARCH- SUBCONTRACT |
CHILDREN'S HOSPITAL OF PITTSBURGH25-0402510 | PITTSBURGH, PA | $21K | Cash | SPONSORSHIP |
ROWAN UNIVERSITY22-2764819 | GLASSBORO, NJ | $20.9K | Cash | RESEARCH- SUBCONTRACT |
UNIVERSITY OF CALIFORNIA SANTA CRUZ94-1539563 | SANTA CRUZ, CA | $20.6K | Cash | RESEARCH- SUBCONTRACT |
BOISE STATE UNIVERSITY82-0290701 | BOISE, ID | $20.1K | Cash | RESEARCH- SUBCONTRACT |
WESTED94-3233542 | SAN FRANCISCO, CA | $20K | Cash | RESEARCH- SUBCONTRACT |
SOUTHERN UNIVERSITY LAW CENTER72-6000817 | SHREVEPORT, LA | $20K | Cash | RESEARCH- SUBCONTRACT |
THE COOPER HEALTH SYSTEM21-0634462 | CAMDEN, NJ | $20K | Cash | RESEARCH- SUBCONTRACT |
ST LOUIS UNIVERSITY43-0654872 | ST LOUIS, MO | $20K | Cash | RESEARCH- SUBCONTRACT |
COREPOWER MAGNETICS INC85-2354132 | PITTSBURGH, PA | $20K | Cash | RESEARCH- SUBCONTRACT |
OPHTHALMOLOGY ASSOCIATES75-2664866 | DALLAS, TX | $19.8K | Cash | RESEARCH- SUBCONTRACT |
| COLUMBUS, OH | $19.4K | Cash | RESEARCH- SUBCONTRACT | |
UNIVERSITY OF MAINE SYSTEM | BANGOR, ME | $19.3K | Cash | RESEARCH- SUBCONTRACT |
ASSOCIATION OF AMERICAN MEDICAL COLLEGES36-2169124 | WASHINGTON, DC | $18.3K | Cash | RESEARCH- SUBCONTRACT |
PLANETARY SCIENCE INSTITUTE33-0175263 | TUCSON, AZ | $18.1K | Cash | RESEARCH- SUBCONTRACT |
ST JOSEPH'S HOSPITAL AND MEDICAL CENTER72-1561134 | PHOENIX, AZ | $17.7K | Cash | RESEARCH- SUBCONTRACT |
THE FORUM FOR YOUTH INVESTMENT52-2242472 | WASHINGTON, DC | $17.3K | Cash | RESEARCH- SUBCONTRACT |
PPD DEVELOPMENT LP74-2325267 | CHICAGO, IL | $16.3K | Cash | RESEARCH- SUBCONTRACT |
HEALTH RESEARCH INC14-1402155 | MENANDS, NY | $16.3K | Cash | RESEARCH- SUBCONTRACT |
CLEVELAND CLINIC34-0714585 | CLEVELAND, OH | $16.1K | Cash | RESEARCH- SUBCONTRACT |
COLLEGE OF NEW JERSEY22-2797398 | EWING TOWNSHIP, NJ | $16K | Cash | RESEARCH- SUBCONTRACT |
KEAN UNIVERSITY22-2960726 | UNION, NJ | $15.5K | Cash | RESEARCH- SUBCONTRACT |
UNIVERSITY OF CONNECTICUT | STORRS, CT | $15.5K | Cash | RESEARCH- SUBCONTRACT |
STOP THE VIOLENCE PITTSBURGH | PITTSBURGH, PA | $15K | Cash | SPONSORSHIP |
AMERICAN ACADEMY OF NURSING52-2213870 | WASHINGTON, DC | $15K | Cash | SPONSORSHIP |
| WASHINGTON, PA | $15K | Cash | RESEARCH- SUBCONTRACT | |
NEIGHBORHOOD LEGAL SERVICES ASSOCIATION25-1157129 | PITTSBURGH, PA | $15K | Cash | RESEARCH- SUBCONTRACT |
CENTER OF LIFE | PITTSBURGH, PA | $15K | Cash | RESEARCH- SUBCONTRACT |
ZYLO THERAPEUTICS INC83-3038824 | GREENVILLE, SC | $15K | Cash | RESEARCH- SUBCONTRACT |
UNIVERSITY OF TEXAS AT EL PASO74-6000813 | EL PASO, TX | $14.9K | Cash | RESEARCH- SUBCONTRACT |
WILLS EYE HOSPITAL23-6000204 | PHILADELPHIA, PA | $13.9K | Cash | RESEARCH- SUBCONTRACT |
STEADMAN PHILIPPON RESEARCH INSTITUTE88-0245022 | VAIL, CO | $13.5K | Cash | RESEARCH- SUBCONTRACT |
PITTSBURGH SYMPHONY ORCHESTRA25-0986052 | PITTSBURGH, PA | $13.5K | Cash | SPONSORSHIP |
NASPAA52-1080991 | WASHINGTON, DC | $13.5K | Cash | SPONSORSHIP |
MGH INSTITUTE OF HEALTH PROFESSIONS INC | BOSTON, MA | $13.3K | Cash | RESEARCH- SUBCONTRACT |
NATIONAL JEWISH HEALTH74-2044647 | DENVER, CO | $13K | Cash | RESEARCH- SUBCONTRACT |
GEORGE WASHINGTON UNIVERSITY53-0196584 | ASHBURN, VA | $12.8K | Cash | RESEARCH- SUBCONTRACT |
EMMA PENDLETON BRADLEY HOSPITAL | RIVERSIDE, RI | $12.6K | Cash | RESEARCH- SUBCONTRACT |
ART OF DEMOCRACY LLC81-0775443 | PITTSBURGH, PA | $12.2K | Cash | RESEARCH- SUBCONTRACT |
PA CHAMBER OF BUS & INDUSTRY23-0961100 | HARRISBURG, PA | $12K | Cash | SPONSORSHIP |
US GEOLOGICAL SURVEY USGS53-0196958 | RESTON, VA | $11.7K | Cash | RESEARCH- SUBCONTRACT |
FASTWATT LLC | CLIFTON PARK, NY | $11.5K | Cash | RESEARCH- SUBCONTRACT |
PITTSBURGH PARKS CONSERVANCY23-2882145 | PITTSBURGH, PA | $11K | Cash | SPONSORSHIP |
ARRHYTHMIA RESEARCH GROUP LLC83-3328484 | JONESBORO, AK | $10.6K | Cash | RESEARCH- SUBCONTRACT |
| HARRISBURG, PA | $10.4K | Cash | RESEARCH- SUBCONTRACT | |
AMERICAN CANCER SOCIETY25-1798733 | PITTSBURGH, PA | $10.3K | Cash | SPONSORSHIP |
UNIVERSITY OF TEXAS AT ARLINGTON75-6000121 | ARLINGTON, TX | $10.2K | Cash | RESEARCH- SUBCONTRACT |
SWARTHMORE COLLEGE23-1352683 | SWARTHMORE, PA | $10.1K | Cash | RESEARCH- SUBCONTRACT |
UNIVERSITY OF CALIFORNIA BERKELEY94-6002123 | BERKELEY, CA | $10K | Cash | RESEARCH- SUBCONTRACT |
TEMS JOINT AMBULANCE DISTRICT76-0712710 | TORONTO, OH | $10K | Cash | RESEARCH- SUBCONTRACT |
WINTERSVILLE VOL FIRE DEPT INC51-0172600 | WINTERSVILLE, OH | $10K | Cash | RESEARCH- SUBCONTRACT |
HAZELWOOD INITIATIVE INC25-1825591 | PITTSBURGH, PA | $10K | Cash | RESEARCH- SUBCONTRACT |
SHAPIRO DAVIS INAUGURATION92-1042075 | PHILADELPHIA, PA | $10K | Cash | SPONSORSHIP |
PITTSBURGH DOWNTOWN PARTNERSHIP25-1728064 | PITTSBURGH, PA | $10K | Cash | SPONSORSHIP |
INDEPENDENCE VISITOR CENTER CORPORATION23-2952488 | PHILADELPHIA, PA | $10K | Cash | SPONSORSHIP |
PENNSYLVANIA INNOCENCE PROJECT26-3176893 | PHILADELPHIA, PA | $10K | Cash | SPONSORSHIP |
STATE SCIENCE & TECHNOLOGY INSTITUTE31-1448843 | WESTERVILLE, OH | $10K | Cash | SPONSORSHIP |
HILLEL JEWISH UNIVERSITY CENTER25-6065236 | PITTSBURGH, PA | $10K | Cash | SPONSORSHIP |
CITY OF STEUBENVILLE34-6002729 | STEUBENVILLE, OH | $10K | Cash | RESEARCH- SUBCONTRACT |
VILLAGE OF MINGO JUNCTION34-6001908 | MINGO JUNCTION, OH | $10K | Cash | RESEARCH- SUBCONTRACT |
| SEATTLE, WA | $9,800 | Cash | RESEARCH- SUBCONTRACT | |
COLORADO SCHOOL OF MINES84-6000551 | GOLDEN, CO | $9,598 | Cash | RESEARCH- SUBCONTRACT |
UNIVERSITY OF ALASKA92-6000147 | ANCHORAGE, AK | $9,000 | Cash | RESEARCH- SUBCONTRACT |
UNIVERSITY MEDICAL CENTER INC61-1293786 | LOUISVILLE, KY | $8,990 | Cash | RESEARCH- SUBCONTRACT |
JULIE FRANTSVE-HAWLEY CONSULTING LLC | KENILWORTH, IL | $8,742 | Cash | RESEARCH- SUBCONTRACT |
KYIV SCHOOL OF ECONOMICS52-2264611 | BROOKLYN, NY | $8,500 | Cash | SPONSORSHIP |
MARY FURLONG & ASSOCIATES25-1902889 | LAFAYETTE, CA | $8,500 | Cash | SPONSORSHIP |
SPARROW CLINICAL RESEARCH INSTITUTE38-3075242 | LANSING, MI | $8,309 | Cash | RESEARCH- SUBCONTRACT |
GRANTMAKERS OF WESTERN PA25-1496312 | PITTSBURGH, PA | $8,000 | Cash | SPONSORSHIP |
OKLAHOMA STATE UNIVERSITY73-1383996 | STILLWATER, OK | $7,814 | Cash | RESEARCH- SUBCONTRACT |
CHILDRENS MUSEUM OF PITTSBURGH25-1379704 | PITTSBURGH, PA | $7,500 | Cash | SPONSORSHIP |
| NEW YORK, NY | $7,500 | Cash | SPONSORSHIP | |
| WASHINGTON, DC | $7,500 | Cash | SPONSORSHIP | |
GREATER PITTSBURGH CHAMBER OF COMMERCE25-0399620 | PITTSBURGH, PA | $7,500 | Cash | SPONSORSHIP |
LOUISIANA STATE UNIVERSITY72-6000848 | BATON ROUGE, LA | $7,300 | Cash | RESEARCH- SUBCONTRACT |
HENRY FORD HEALTH SYSTEM38-1357020 | DETROIT, MI | $7,072 | Cash | RESEARCH- SUBCONTRACT |
WASHINGTON STATE UNIVERSITY91-6001108 | PULLMAN, WA | $6,581 | Cash | RESEARCH- SUBCONTRACT |
WHITWORTH UNIVERSITY91-0473310 | SPOKANE, WA | $6,229 | Cash | RESEARCH- SUBCONTRACT |
RHODE ISLAND HOSPITAL | PROVIDENCE, RI | $6,065 | Cash | RESEARCH- SUBCONTRACT |
| PITTSBURGH, PA | $6,000 | Cash | SPONSORSHIP | |
AMERICAN RED CROSS25-0965231 | PITTSBURGH, PA | $6,000 | Cash | SPONSORSHIP |
HELLO NEIGHBOR82-3695047 | PITTSBURGH, PA | $6,000 | Cash | SPONSORSHIP |
MARCH OF DIMES INC13-1846366 | ARLINGTON, VA | $5,856 | Cash | SPONSORSHIP |
| WASHINGTON, DC | $5,500 | Cash | SPONSORSHIP | |
URBAN LEAGUE OF GREATER PITTSBURGH25-0965592 | PITTSBURGH, PA | $5,260 | Cash | SPONSORSHIP |
METIS FOUNDATION47-2219464 | SAN ANTONIO, TX | $5,134 | Cash | RESEARCH- SUBCONTRACT |
BRIGHAM YOUNG UNIVERSITY87-0217280 | PROVO, UT | $5,100 | Cash | RESEARCH- SUBCONTRACT |
| Total | $146.6M | |||
PITTSBURGH, PA
$9.3M
OAKLAND, CA
$8.7M
NEW YORK, NY
$7.5M
ANN ARBOR, MI
$4.9M
CLAYTON, MO
$4.5M
URBANA, IL
$4.2M
BRIGHAM AND WOMENS HOSPITAL INC
BOSTON, MA
$3.2M
LOS ANGELES, CA
$3.1M
BALTIMORE, MD
$2.8M
CHICAGO, IL
$2.6M
MASSACHUSETTS GENERAL HOSPITAL
BOSTON, MA
$2.5M
BLOOMINGTON, IN
$2.4M
$2.2M
BALTIMORE, MD
$2.2M
NORTHEASTERN UNIVERSITY
BOSTON, MA
$2.1M
COLUMBUS, OH
$2.1M
NEWARK, DE
$2M
CHAPEL HILL, NC
$1.9M
HARVARD UNIVERSITY
CAMBRIDGE, MA
$1.8M
MCKEESPORT, PA
$1.8M
NEW YORK, NY
$1.7M
IOWA CITY, IA
$1.5M
PHILADELPHIA, PA
$1.5M
CINCINNATI, OH
$1.4M
NEW YORK, NY
$1.4M
CAMBRIDGE, MA
$1.4M
NEW YORK, NY
$1.2M
NASHVILLE, TN
$1.2M
UNIVERSITY OF MASSACHUSETTS
BOSTON, MA
$1.1M
YALE UNIVERSITY
NEW HAVEN, CT
$1.1M
PITTSBURGH, PA
$1.1M
DAVIS, CA
$1.1M
PITTSBURGH, PA
$1.1M
COLUMBUS, OH
$1M
SAN ANTONIO, TX
$994K
ROCHESTER, MN
$975.1K
$943.6K
GAINESVILLE, FL
$942K
PHILADELPHIA, PA
$863K
PHILADELPHIA, PA
$846.4K
PHILADELPHIA, PA
$844.9K
SALT LAKE CITY, UT
$808.8K
CLEVELAND, OH
$799.1K
ATLANTA, GA
$797.1K
MILWAUKEE, WI
$797.1K
UNIVERSITY PARK, PA
$795.9K
PALO ALTO, CA
$795.5K
SEATTLE, WA
$777.8K
MORGANTOWN, WV
$775.3K
CHICAGO, IL
$754.2K
BETHESDA, MD
$724.3K
DURHAM, NC
$713.3K
DANA-FARBER CANCER INSTITUTE
BOSTON, MA
$712.9K
LA JOLLA, CA
$701.4K
LEXINGTON, KY
$683.4K
MENANDS, NY
$654.7K
SAN DIEGO, CA
$651.9K
BOSTON UNIVERSITY
BOSTON, MA
$647.4K
NEW YORK, NY
$637.3K
$625.3K
WEST ORANGE, NJ
$604.1K
SEATTLE, WA
$598.9K
HOUSTON, TX
$586.1K
WASHINGTON, DC
$562.5K
ROCHESTER, NY
$553.7K
BRADDOCK, PA
$538.2K
BIRMINGHAM, AL
$537.4K
GOOSE CREEK, SC
$531.1K
JACKSON LABORATORY
BAR HARBOR, ME
$518.1K
PISCATAWAY, NJ
$517.3K
DUARTE, CA
$510.1K
$498.7K
TUCSON, AZ
$495.6K
PHILADELPHIA, PA
$468.6K
COLUMBIA, MO
$462.2K
NEW YORK, NY
$458K
$457.4K
SAN FRANCISCO, CA
$454.7K
DENVER, CO
$441.3K
MINNEAPOLIS, MN
$440.3K
LOUISVILLE, KY
$423.4K
FORT WORTH, TX
$419.7K
MCKEES ROCKS, PA
$413.1K
FAIRFAX, VA
$407.8K
HOUSTON, TX
$400.3K
MORGANTOWN, WV
$389.2K
MASSACHUSETTS INSTITUTE OF TECHNOLOGY
CAMBRIDGE, MA
$376.9K
RICHMOND, VA
$374.1K
EVANSTON, IL
$363.7K
WASHINGTON, DC
$363.2K
WINSTONSALEM, NC
$361.2K
TEMPE, AZ
$359.2K
WASHINGTON, DC
$354K
COLUMBUS, OH
$351.7K
ROCHESTER, MN
$349.6K
SCOTTSDALE, AZ
$345.3K
NASHVILLE, TN
$333.3K
CORAL GABLES, FL
$329.2K
LOS ANGELES, CA
$320.4K
PHILADELPHIA, PA
$317.1K
CHARLOTTESVILLE, VA
$316.9K
THE MIRIAM HOSPITAL
PROVIDENCE, RI
$315.2K
CLEVELAND, OH
$303.5K
GREENVILLE, NC
$299.7K
PRINCETON, NJ
$293.7K
CHICAGO, IL
$291.7K
LINCOLN, NE
$286.8K
FAIRFIELD, CT
$282.1K
JACKSON, MS
$280.2K
PITTSBURGH, PA
$265K
SALT LAKE CITY, UT
$262K
CLEVELAND HEIGHTS, OH
$257.3K
$255.6K
UNIVERSITY OF VERMONT
BURLINGTON, VT
$253.9K
$253.8K
RENO, NV
$252.6K
FAIRFAX, VA
$243.5K
RALEIGH, NC
$238.3K
DANVILLE, PA
$237.2K
PITTSBURGH, PA
$235K
WILMINGTON, DE
$232.6K
LAWRENCE, KS
$230K
KNOXVILLE, TN
$225.4K
SEATTLE, WA
$216.2K
HARRISBURG, PA
$213.9K
BROWN UNIVERSITY
PROVIDENCE, RI
$213.3K
LA JOLLA, CA
$209.6K
COLUMBIA, MO
$201.7K
HOUSTON, TX
$200.5K
WINSTONSALEM, NC
$200K
NEW ORLEANS, LA
$199.8K
KANSAS CITY, MO
$199.3K
$190.8K
YOUNGSTOWN, OH
$188.6K
NOTRE DAME, IN
$186.3K
PITTSBURGH, PA
$180.6K
ARLINGTON, VA
$180.4K
CINCINNATI, OH
$175.2K
ARLINGTON, MA
$174.7K
ATLANTA, GA
$172K
ATLANTA, GA
$171.1K
KANSAS CITY, MO
$168.5K
THE GOG FOUNDATION INC
EDGEWATER, MD
$167.4K
AUSTIN, TX
$165.6K
PITTSBURGH, PA
$156.1K
BOSTON CHILDREN'S HOSPITAL
BOSTON, MA
$149.3K
HOUSTON, TX
$139.9K
EAST LANSING, MI
$136.5K
TUFTS UNIVERSITY
SOMERVILLE, MA
$136.3K
$134.8K
SAN DIEGO, CA
$133.4K
PHILADELPHIA, PA
$133.3K
CORVALLIS, OR
$128.6K
WASHINGTON, DC
$127.6K
LOS ANGELES, CA
$124.6K
CLEVELAND, OH
$124K
$123.6K
MINNEAPOLIS, MN
$123.4K
TOLEDO, OH
$121.3K
NEW YORK, NY
$120.8K
BOSTON MEDICAL CENTER
BOSTON, MA
$119.4K
ALBUQUERQUE, NM
$119K
BOSTON, MA
$111.6K
AUGUSTA, GA
$110K
MIAMI, FL
$107.7K
RALEIGH, NC
$105.2K
EUGENE, OR
$103.8K
COLD SPRING HARBOR, NY
$103.1K
PITTSBURGH, PA
$100.6K
PITTSBURGH, PA
$100K
PITTSBURGH, PA
$100K
TROY, NY
$99.5K
ALBANY, NY
$93.6K
$91.9K
PITTSBURGH, PA
$91.2K
$89.1K
GREENSBORO, NC
$86.7K
ROCHESTER, MN
$86.4K
FAYETTEVILLE, AR
$85.8K
GREENSBORO, PA
$84.9K
ITHACA, NY
$83.7K
BIRMINGHAM, AL
$83.3K
NEW ENGLAND RESEARCH INSTITUTES INC
WATERTOWN, MA
$81.6K
$80.7K
EDISON, NJ
$80K
CHARLOTTE, NC
$79.6K
LUBBOCK, TX
$79.6K
SEATTLE, WA
$79.2K
DETROIT, MI
$79.1K
EUGENE, OR
$78.7K
CHICAGO, IL
$77.5K
SAN FRANCISCO, CA
$77.1K
OAKLAND, CA
$76.2K
SAN ANTONIO, TX
$74.5K
WALTHAM, MA
$72.6K
BAYSTATE MEDICAL CENTER
SPRINGFIELD, MA
$72.5K
PARKVILLE, MD
$71.5K
ANNAPOLIS, MD
$66.8K
ARLINGTON, VA
$63.3K
UNIVERSITY, MS
$62.4K
IRVINE, CA
$61.5K
ALLEGHENY COUNTY TREASURER
PITTSBURGH, PA
$61.3K
PITTSBURGH, PA
$61K
PITTSBURGH, PA
$60.2K
RESEARCH TRIANGLE PARK, NC
$58K
URBANKIND INSTITUTE
PITTSBURGH, PA
$57.4K
PHILADELPHIA, PA
$55.7K
SAN JOSE, CA
$54.5K
NEW CASTLE, PA
$53.2K
PITTSBURGH, PA
$53.1K
NOVATO, CA
$52.2K
WASHINGTON, DC
$51.6K
CLEVELAND, OH
$50K
PITTSBURGH, PA
$50K
RHODE ISLAND COLLEGE
PROVIDENCE, RI
$49.7K
WASHINGTON, DC
$49.4K
TAACOMA, WA
$49.1K
LATROBE, PA
$49K
WESTBURY, NY
$48.7K
CLEMSON, SC
$47.6K
YOUNGSTOWN, OH
$46.5K
OKLAHOMA CITY, OK
$45.5K
SEATTLE, WA
$44.7K
COLUMBIA, SC
$44.7K
LA JOLLA, CA
$43.9K
DARTMOUTH COLLEGE
HANOVER, NH
$43.5K
RAYTHEON TECHNOLOGIES RESEARCH CENTER
FARMINGTON, CT
$42.8K
PITTSBURGH, PA
$42.5K
FALLS CHURCH, VA
$42.2K
CHARLESTON, SC
$41.2K
PITTSBURGH, PA
$40.4K
BROOKLYN, NY
$40K
COLUMBUS, OH
$40K
PITTSBURGH, PA
$40K
ANN ARBOR, MI
$39.2K
NEW YORK, NY
$36.8K
PHILADELPHIA, PA
$35.9K
CUMMING, GA
$35K
SANTA BARBARA, CA
$34.5K
$34.1K
COLLEGE STATION, TX
$33.2K
PITTSBURGH, PA
$32.9K
MILWAUKEE, WI
$32.7K
LAGUNA HILLS, CA
$32.6K
MASSACHUSETTS EYE AND EAR INFIRMARY
SOMERVILLE, MA
$31.9K
ESPANOLA, NM
$31.7K
MOON TOWNSHIP, PA
$31.5K
NASHVILLE, TN
$30.7K
PORTLAND, OR
$30.4K
FARMINGTON, CT
$30.3K
FARGO, ND
$30K
VALHALLA, NY
$30K
MINNEAPOLIS, MN
$30K
PALO ALTO, CA
$29.5K
SANTA MONICA, CA
$28.7K
ALLEGHENY COUNTY HEALTH DEPARTMENT
PITTSBURGH, PA
$28.5K
LOS ANGELES, CA
$28.3K
ATLANTA, GA
$26.2K
CARNEGIE, PA
$26.2K
BEVERLY HILLS, CA
$25.7K
GRAND RAPIDS, MI
$25.1K
BOSTON, MA
$25K
PITTSBURGH, PA
$25K
PITTSBURGH, PA
$25K
PITTSBURGH, PA
$24.7K
ORLANDO, FL
$24.6K
VENETIA, PA
$23.6K
SPOKANE, WA
$22.6K
WASHINGTON, DC
$22.6K
HONOLULU, HI
$22.2K
LOS ANGELES, CA
$21.8K
SAYRE, PA
$21K
PITTSBURGH, PA
$21K
GLASSBORO, NJ
$20.9K
SANTA CRUZ, CA
$20.6K
BOISE, ID
$20.1K
SAN FRANCISCO, CA
$20K
SHREVEPORT, LA
$20K
CAMDEN, NJ
$20K
ST LOUIS, MO
$20K
PITTSBURGH, PA
$20K
DALLAS, TX
$19.8K
$19.4K
UNIVERSITY OF MAINE SYSTEM
BANGOR, ME
$19.3K
WASHINGTON, DC
$18.3K
TUCSON, AZ
$18.1K
PHOENIX, AZ
$17.7K
WASHINGTON, DC
$17.3K
CHICAGO, IL
$16.3K
MENANDS, NY
$16.3K
CLEVELAND, OH
$16.1K
EWING TOWNSHIP, NJ
$16K
UNION, NJ
$15.5K
UNIVERSITY OF CONNECTICUT
STORRS, CT
$15.5K
STOP THE VIOLENCE PITTSBURGH
PITTSBURGH, PA
$15K
WASHINGTON, DC
$15K
WASHINGTON, PA
$15K
PITTSBURGH, PA
$15K
CENTER OF LIFE
PITTSBURGH, PA
$15K
GREENVILLE, SC
$15K
EL PASO, TX
$14.9K
PHILADELPHIA, PA
$13.9K
$13.5K
PITTSBURGH, PA
$13.5K
WASHINGTON, DC
$13.5K
MGH INSTITUTE OF HEALTH PROFESSIONS INC
BOSTON, MA
$13.3K
DENVER, CO
$13K
ASHBURN, VA
$12.8K
EMMA PENDLETON BRADLEY HOSPITAL
RIVERSIDE, RI
$12.6K
PITTSBURGH, PA
$12.2K
HARRISBURG, PA
$12K
RESTON, VA
$11.7K
FASTWATT LLC
CLIFTON PARK, NY
$11.5K
PITTSBURGH, PA
$11K
JONESBORO, AK
$10.6K
HARRISBURG, PA
$10.4K
PITTSBURGH, PA
$10.3K
ARLINGTON, TX
$10.2K
SWARTHMORE, PA
$10.1K
BERKELEY, CA
$10K
TORONTO, OH
$10K
WINTERSVILLE, OH
$10K
PITTSBURGH, PA
$10K
PHILADELPHIA, PA
$10K
PITTSBURGH, PA
$10K
PHILADELPHIA, PA
$10K
PHILADELPHIA, PA
$10K
WESTERVILLE, OH
$10K
PITTSBURGH, PA
$10K
STEUBENVILLE, OH
$10K
MINGO JUNCTION, OH
$10K
$9,800
GOLDEN, CO
$9,598
ANCHORAGE, AK
$9,000
LOUISVILLE, KY
$8,990
JULIE FRANTSVE-HAWLEY CONSULTING LLC
KENILWORTH, IL
$8,742
BROOKLYN, NY
$8,500
LAFAYETTE, CA
$8,500
LANSING, MI
$8,309
PITTSBURGH, PA
$8,000
STILLWATER, OK
$7,814
PITTSBURGH, PA
$7,500
$7,500
WASHINGTON, DC
$7,500
PITTSBURGH, PA
$7,500
BATON ROUGE, LA
$7,300
DETROIT, MI
$7,072
PULLMAN, WA
$6,581
SPOKANE, WA
$6,229
RHODE ISLAND HOSPITAL
PROVIDENCE, RI
$6,065
PITTSBURGH, PA
$6,000
PITTSBURGH, PA
$6,000
PITTSBURGH, PA
$6,000
ARLINGTON, VA
$5,856
WASHINGTON, DC
$5,500
PITTSBURGH, PA
$5,260
SAN ANTONIO, TX
$5,134
PROVO, UT
$5,100
Source: USAspending.gov · Searched by organization name
VA/DoD Awards
$124.8M
VA/DoD Award Count
12
Funding from the Department of Veterans Affairs and/or Department of Defense.
Total Federal Funding (partial)
$3.2B
Awards Found
200+
Additional awards may exist. View all on USAspending.gov →
Department of Health and Human Services
$128.8M
UNIVERSITY OF PITTSBURGH CLINICAL AND TRANSLATIONAL SCIENCE INSTITUTE
Department of Health and Human Services
$103.7M
ALZHEIMER BIOMARKER CONSORTIUM - DOWN SYNDROME (ABC-DS)
Department of Education
$58M
HIGHER EDUCATION EMERGENCY RELIEF FUND - IHES
Department of Health and Human Services
$52.3M
UNIVERSITY OF PITTSBURGH CLINICAL AND TRANSLATIONAL SCIENCE INSTITUTE
Department of Health and Human Services
$50.1M
UNIVERSITY OF PITTSBURGH CLINICAL AND TRANSLATIONAL SCIENCE INSTITUTE
Department of Health and Human Services
$48.9M
MULTICENTER AIDS COHORT STUDY
Department of Education
$48.6M
HIGHER EDUCATION EMERGENCY RELIEF FUND - IHES
Department of Health and Human Services
$46.9M
IN VIVOPIB PET AMYLOID IMAGING: NORMALS, MCI & DEMENTIA
Department of Health and Human Services
$45M
UNIVERSITY OF PITTSBURGH CENTER FOR HIV PROTEIN INTERACTIONS (PCHPI)
Department of Health and Human Services
$43.1M
THE STUDY OF WOMEN'S HEALTH ACROSS THE NATION (SWAN): THE IMPACT OF MIDLIFE AND THE MENOPAUSE TRANSITION ON HEALTH AND FUNCTIONING IN EARLY OLD AGE
Department of Health and Human Services
$41.1M
LONGITUDINAL MULTICENTER HEAD-TO-HEAD HARMONIZATION OF TAU PET TRACERS - PROJECT SUMMARY/ABSTRACT: THE DEVELOPMENT OF TAU POSITRON EMISSION TOMOGRAPHY (PET) TRACERS HAS YIELDED THE OPPORTUNITY TO BETTER UNDERSTAND THE TAU ACCUMULATION ASSOCIATED WITH THE DEVELOPMENT OF ALZHEIMER’S DISEASE (AD), IMPROVE THE DIAGNOSTIC ACCURACY OF AD, AND TEST THE EFFECTS OF THERAPEUTIC INTERVENTIONS IN TAU DEPOSITION. OUR GROUP AND OTHERS HAVE SHOWN THAT [18F]FLORTAUCIPIR HAS DISTRIBUTION PATTERNS SIMILAR TO THOSE REPORTED IN POSTMORTEM STUDIES AND SHOWS SIGNIFICANT RATES OF TAU ACCUMULATION OVER TIME DESPITE BRAIN OFF-TARGET SIGNAL IN WHITE MATTER, BASAL GANGLIA, AND CHOROID PLEXUS. [18F]MK-6240, A SECOND-GENERATION TAU TRACER, HAS ~6-FOLD GREATER AFFINITY FOR TAU TANGLES THAN [18F]FLORTAUCIPIR AND NEGLIGIBLE BRAIN OFF-TARGET SIGNAL. HOWEVER, [18F]MK-6240 HAS OFF-TARGET UPTAKE IN THE MENINGES ADJACENT TO THE ENTIRE CORTEX, WHICH CAN COMPROMISE THE SIGNAL WITHIN BRAIN REGIONS. WE HAVE SHOWN THAT [18F]MK-6240 HAS SIMILAR PATTERNS OF UPTAKE AS POSTMORTEM AND [18F]FLORTAUCIPIR STUDIES. HOWEVER, [18F]MK-6240 HAS A HIGHER DYNAMIC RANGE AND, ALTHOUGH MEASURED IN DIFFERENT COHORTS, THE ANNUAL CHANGE IN TAU USING [18F]MK-6240 APPEARS TO BE GREATER THAN CHANGES MEASURED USING [18F]FLORTAUCIPIR. TO DATE, MORE THAN 95% OF SITES IN THE US PERFORMING TAU PET STUDIES ARE USING ONE OF THESE TRACERS. ALTHOUGH BOTH TRACERS OFFER ROBUST TAU ESTIMATES, THESE LARGE DIFFERENCES IN BINDING CHARACTERISTICS BETWEEN THEM CAN LEAD TO MISLEADING INTERPRETATIONS OF THEIR OUTCOMES AND PRECLUDE THE MERGING OF THEIR DATASETS USING SIMPLE CONVERSION METHODS. THUS, A WELL-POWERED LONGITUDINAL STUDY ASSESSING HEAD-TO-HEAD [18F]FLORTAUCIPIR AND [18F]MK-6240 SCANS HAS THE POTENTIAL TO: (1) STANDARDIZE THEIR ANALYSIS, ALLOWING DATASETS TO BE COMBINED, (2) COMPARE THEIR RATES OF LONGITUDINAL DEPOSITION TO ELUCIDATE THEIR ADVANTAGES AND LIMITATIONS FOR RESEARCH, TRIALS, AND PRACTICE, AND (3) PRODUCE A BENCHMARK DATASET TO BE USED BY THE SCIENTIFIC COMMUNITY TO DEVELOP METHODS FOR PET QUANTIFICATION AND HARMONIZATION. HERE, WE PROPOSE A MULTI-SITE LONGITUDINAL STUDY IN WHICH 620 SUBJECTS (40 YOUNG CONTROLS, 280 COGNITIVELY UNIMPAIRED ELDERLY, 200 MILD COGNITIVE IMPAIRMENT, 100 AD DEMENTIA) WILL RECEIVE [18F]FLORTAUCIPIR AND [18F]MK6240 SCANS AT BASELINE AND 18 MONTHS LATER. AT EACH TIME POINT, SUBJECTS WILL ALSO HAVE AN AMYLOID- SS (ASS) PET SCAN, MAGNETIC RESONANCE IMAGING, COGNITIVE TESTS, AND A BLOOD DRAW FOR PLASMA TAU ANALYSES. METHODS WILL BE HARMONIZED WITH ADNI AND THE ADRC PROGRAM. IN AIM 1, WE WILL (1) STANDARDIZE PROCESSING METHODS, (2) CONVERT TO A COMMON SCALE, (3) COMPARE ASSOCIATIONS WITH ASS, ATROPHY, AND COGNITION, AND (4) COMPARE BRAAK STAGING BETWEEN TAU TRACERS USING CROSS-SECTIONAL DATA. IN AIM 2, WE WILL (1) ASCERTAIN THE OPTIMAL PROCESSING METHOD FOR LONGITUDINAL ANALYSIS AND (2) COMPARE LONGITUDINAL ACCUMULATION BETWEEN TAU TRACERS AND ITS ASSOCIATIONS WITH CHANGES IN ASS, ATROPHY, AND COGNITION. AS RECENT RESULTS FROM OUR GROUP AND OTHERS HAVE SHOWN THAT THE NEW P-TAU PLASMA ASSAYS IDENTIFY BRAIN TAU PATHOLOGY, IN EXPLORATORY AIM 3, WE WILL COMPARE CROSS-SECTIONAL AND LONGITUDINAL [18F]FLORTAUCIPIR AND [18F]MK6240 ESTIMATES WITH PLASMA P-TAU OUTCOMES.
Department of Health and Human Services
$38.1M
MITOCHONDRIAL TARGETING AGAINST RADIATION DAMAGE
Department of Health and Human Services
$38M
UNIVERSITY OF PITTSBURGH CLINICAL TRIALS UNIT
Department of Health and Human Services
$35.4M
SPORE IN HEAD AND NECK CANCER
Department of Health and Human Services
$32.3M
GENETIC FACTORS TO ORAL HEALTH DISPARITIES IN APPALACHIA
Department of Health and Human Services
$30.7M
COVID-19 AND THE MWCCS: PATHOPHYSIOLOGY, IMPACT AND OUTCOMES
Department of the Interior
$29.6M
REGENERATIVE ELECTRONIC PLATFORM THROUGH ADVANCED INTELLIGENT REGULATION
Department of Health and Human Services
$28.4M
GENERATION, CHARACTERIZATION, AND VALIDATION OF MARMOSET MODELS OF ALZHEIMER'S DISEASE - PROJECT SUMMARY OVERALL ALZHEIMER’S DISEASE (AD) IS A DEVASTATING NEURODEGENERATIVE DISORDER AFFECTING NEARLY 6 MILLION AMERICANS AND IS EXPECTED TO INCREASE OVER THE NEXT SEVERAL YEARS. OUR LIMITED UNDERSTANDING OF THE MECHANISMS THAT TRIGGER THE EMERGENCE OF AD HAS CONTRIBUTED TO THE LACK OF INTERVENTIONS THAT STOP, PREVENT, OR FULLY TREAT THIS DISEASE. WE PROPOSE TO ESTABLISH THE MARMOSET AS THE FIRST PRIMATE-SPECIFIC MODEL TO REVEAL THE EARLIEST CELLULAR AND MOLECULAR EVENTS OF AD PROCESSES AND ALLOW CHARTING AD PROGRESSION FROM ITS INCEPTION. TO DO SO, WE WILL DRAW FROM A SELF-SUFFICIENT AND LARGE COLONY OF RESEARCH MARMOSETS WITH DEDICATED VETERINARY AND HUSBANDRY TEAMS, STATE-OF-THE-ART IN VIVO NEUROIMAGING AND MOLECULAR ASSAYS, AND A MULTIDISCIPLINARY TEAM OF EXPERTS IN AGING BIOLOGY, AD GENETICS AND GENOMICS, ANIMAL MODEL DEVELOPMENT AND CHARACTERIZATION, BEHAVIORAL AND COGNITIVE PHENOTYPING, AND MARMOSET GENE-EDITING TECHNOLOGIES. OUR PROPOSAL’S OVERARCHING GOALS ARE TO DEVELOP MARMOSET MODELS OF EARLY-ONSET AD (EOAD) AND LATE-ONSET AD (LOAD) TO ENABLE THE INVESTIGATION OF THE UNDERLYING CELLULAR AND MOLECULAR ROOT CAUSES OF THE PATHOGENESIS AND PROGRESSION OF AD AND SUPPORT FUTURE TRANSLATIONAL STUDIES. WE BELIEVE THAT THE SIMULTANEOUS ASSESSMENT OF GENETIC, MOLECULAR, FUNCTIONAL, BEHAVIORAL, AND PATHOLOGICAL PHENOTYPES IN MARMOSETS WILL PROVIDE TRANSLATABLE KNOWLEDGE OF THE ORIGINS AND PROGRESSION OF AD IN HUMAN POPULATIONS. FURTHERMORE, WE POSIT THAT THE COMPREHENSIVE STUDY OF GENE-EDITED MARMOSET MODELS OF AD FROM NEURODEVELOPMENT THROUGH AGING WILL IDENTIFY EMERGING PHENOTYPES THAT PRECEDE FRANK NEUROPATHOLOGY. OUR PROPOSAL CONSISTS OF 3 INTEGRATED RESEARCH PROJECTS THAT AIM TO: (1) CONDUCT CHARACTERIZATION AND VALIDATION OF PSEN1 MUTATIONS IN MARMOSETS AS A MODEL FOR THE STUDY OF EOAD, AND INVESTIGATE EARLY LIFE MOLECULAR DETERMINANTS OF AD DISEASE PATHOGENESIS ASSOCIATED WITH GENETIC RISK FOR EOAD; (2) IDENTIFY AND ENHANCE LOAD-RELATED SIGNATURES IN OUTBRED AND GENETICALLY-ENGINEERED MARMOSETS; AND (3) CONDUCT A COMPARATIVE MULTIMODAL PHENOTYPIC CHARACTERIZATION OF MARMOSET MODELS OF AD. THESE PROJECTS WILL BE SUPPORTED BY 5 RESEARCH CORES FOCUSED ON PROJECT ADMINISTRATION, BIOINFORMATICS, GENETIC ENGINEERING, MULTIMODAL DISEASE CHARACTERIZATION, AND VETERINARY AND COLONY MANAGEMENT. THESE SUPPORTING CORES WILL INTEGRATE MARMOSET AND HUMAN GENOMIC SIGNATURES AND PROVIDE DATA DISSEMINATION AND RESOURCES TO THE GREATER RESEARCH COMMUNITY AS PART OF OUR COMMITMENT TO OPEN SCIENCE, GENERATE NOVEL GENE-EDITED MARMOSET MODELS OF AD, DEVELOP OPTIMIZED PROTOCOLS FOR STUDYING DISEASE ONSET AND TRAJECTORY IN LINE WITH CLINICAL PROTOCOLS, EVALUATE THERAPEUTIC STRATEGIES, AND PROVIDE SPECIALIZED ANIMAL CARE AND SUPPORT, RESPECTIVELY, ALLOWING COMPLETE CHARACTERIZATION OF THE MARMOSET MODELS. AT THE CONCLUSION OF THIS PROJECT, WE WILL HAVE GENETICALLY ENGINEERED THREE AD RISK VARIANTS INTO MARMOSET MODELS, ESTABLISHED A DISEASE CHARACTERIZATION PIPELINE FOR COMPREHENSIVE PHENOTYPING, AND SHARED THESE RESOURCES WITH THE GREATER RESEARCH COMMUNITY.
Department of Health and Human Services
$28.1M
ALZHEIMER'S DISEASE RESEARCH CENTER
Department of Health and Human Services
$27.7M
CLINICAL ONCOLOGY PROGRAM BIOSTATISTICAL CENTER
Department of Health and Human Services
$27.5M
INVESTIGATING GAINS IN NEUROCOGNITION IN AN INTERVENTION TRIAL OF EXERCISE
Department of Health and Human Services
$27M
AIDS EDUCATION TRAINING CENTER
Department of Health and Human Services
$26.3M
STUDY/WOMEN/HEALTH ACROSS NATION III/COORDINATING CENTER
Department of Health and Human Services
$26.1M
VASCULAR SUBPHENOTYPES OF LUNG DISEASE
Department of Defense
$25.5M
NAVAL SPECIAL WARFARE TACTICAL ATHLETE PROGRAM HUMAN PERFORMANCE AND INJURY PREVENTION RESEARCH INITIATIVE
Department of Health and Human Services
$25.3M
SYNERGIES AMONG INHIBITORY RECEPTORS IN TOLERANCE, CANCER AND ANTIVIRAL IMMUNITY
Department of Health and Human Services
$25.3M
HEPATITIS B CLINICAL RESEARCH NETWORK - DATA COORDINATING CENTER
Department of Health and Human Services
$24.9M
COMPARISON OF TAU-PET TRACERS: PROGRESS TOWARDS A UNIVERSAL MEASURE
Department of Energy
$23.4M
PARTICLE PHYSICS AT THE UNIVERSITY OF PITTSBURGH
Department of Health and Human Services
$23.3M
ENACT: TRANSLATING HEALTH INFORMATICS TOOLS TO RESEARCH AND CLINICAL DECISION MAKING - SEVERAL CHALLENGES EXIST IN THE CONDUCT OF EHR-BASED TRANSLATIONAL RESEARCH. FIRST, CTSA HUBS VARY SUBSTANTIALLY IN THEIR CAPACITY TO ADDRESS CHALLENGES IN EHR DATA COLLECTION, DATA QUALITY, DATA HARMONIZATION, METHODOLOGY FOR DEEP PHENOTYPING, MAINTAINING PATIENT PRIVACY, VARIABILITY IN ONTOLOGY, AND LIMITED ABILITY TO TRANSFER DATA BEYOND INSTITUTIONAL FIREWALLS. SECOND, THERE IS AN UNMET NEED FOR READILY AVAILABLE, EASILY ACCESSED INFORMATICS TOOLS THAT FACILITATE EHR-BASED RESEARCH AND CAN BE RAPIDLY DISSEMINATED AND IMPLEMENTED ACROSS ALL CTSA HUBS. THIRD, CTSA HUBS SEEK GUIDANCE ON THE COMPLICATED DATA USE AGREEMENTS (DUAS) AND GOVERNANCE NEEDED TO ENABLE DATA SHARING AND ANALYSIS OF SHARED DATA. WITH FUNDING FROM NCATS, WE CREATED A FEDERATED SYSTEM, THE ACT NETWORK, THAT CRAFTED A BROAD DUA AND STOOD-UP LOCAL CLINICAL DATA WAREHOUSES (CDWS) AT 57 CTSA HUBS, CREATED AN INFORMATION SUPERHIGHWAY TO QUERY THE CDWS THAT INCLUDE >142M PATIENTS, AND DEMOCRATIZED DATA ACCESS FOR COHORT DISCOVERY TO ALL CTSA HUB INVESTIGATORS. WE INITIALLY DEVELOPED ACT TO SUPPORT THE PLANNING AND DESIGN OF MULTISITE CLINICAL TRIALS, WHICH IT DID WELL AND ADDITIONALLY HIGHLIGHTED THE POTENTIAL VALUE OF EHR DATA FOR DEEPER ANALYSIS. WHILE THE ACT NETWORK HAS LIMITED ANALYTIC CAPACITY IN ITS PRESENT FORM, WE WILL NOW ADDRESS THIS OPPORTUNITY TO FULLY LEVERAGE THE RESEARCH POTENTIAL OF EHR DATA FROM ALMOST HALF THE US POPULATION THROUGH EVOLVE TO NEXT-GEN ACT (ENACT). WE WILL CREATE A USER-FRIENDLY COLLABORATIVE RESEARCH AND COMPUTING ENVIRONMENT WITH CUTTING EDGE ANALYTICAL METHODS. WE WILL START WITH TOOLS AND A DASHBOARD TO MONITOR DATA QUALITY, PROVIDE GUIDANCE TO INDIVIDUAL SITES TO IMPROVE DATA QUALITY, AND PROVIDE CONTEXTUAL REPORTS THAT HELP INVESTIGATORS INTERPRET THEIR DATA. WE WILL ALSO APPLY NATURAL LANGUAGE PROCESSING TO EXTRACT CLINICAL CONCEPT DATA FROM REPORTS AND NOTES IN THE EHR, PROVIDE USER- FRIENDLY INTERFACES THAT ARE INTEROPERABLE WITH COMMON DATA MODELS (I2B2, OMOP, PCORNET), EXPAND ONTOLOGIES (LIFESTYLE FACTORS, GENETIC VARIANTS, RETIRED CODES), AND PROVIDE OTHER SOPHISTICATED INFORMATICS TOOLS, INCLUDING THOSE DEVELOPED BY OUR TEAM AND BY OTHERS. IN PARALLEL, WE WILL CREATE A PLATFORM AND PROVIDE STATISTICAL AND MACHINE LEARNING CAPACITY THAT CLINICAL AND TRANSLATIONAL SCIENTISTS CAN APPLY TO EHR DATA, EITHER THROUGH FEDERATED ANALYSES OR, FOR MORE COMPLEX COMPUTE-INTENSIVE ANALYSES, IN A TEMPORARY ENCLAVE. WE ENVISION LEVERAGING THESE INFORMATICS TOOLS AND EHR DATA TO ENABLE CLINICIANS TO GENERATE EVIDENCE THAT CAN BE APPLIED TO IMPROVE PATIENT CARE. WITH EVERY STEP, WE WILL DESIGN FOR DISSEMINATION AND SUSTAINABILITY TO FOSTER A LEARNING INFORMATICS SYSTEM. WE WILL PRIORITIZE UNMET NEEDS AMONG STAKEHOLDERS, SOLICIT INPUT ON THE DESIRED FEATURES, AND ENSURE THAT ENACT SATISFIES THE NEEDS OF TARGETED END USERS. WE WILL LEVERAGE THE I-CORPS@ NCATS PROGRAM FOR CUSTOMER DISCOVERY, BETA TESTING, AND BUSINESS MODEL DEVELOPMENT FOR SUSTAINABILITY. WE WILL COLLECT DATA THROUGH PILOT TRIALS OF EACH TOOL AND RESOURCE THAT WILL BE USED TO CREATE MARKETING MATERIALS AND TO DEVELOP SUSTAINABILITY MODELS THAT INCLUDE COST-RECOVERY BASED ON REAL-WORLD TIME AND EFFORT REQUIRED.
Department of Health and Human Services
$21.7M
INFLUENCE OF INFLAMMATION-RELATED GENETIC VARIANTS ON PT TREATMENT RESPONSE IN A POPULATION AFFECTED BY CLBP
Department of Health and Human Services
$21.2M
CELLULAR SENESCENCE NETWORK (SENNET) CONSORTIUM ORGANIZATION AND DATA COORDINATING CENTER (CODCC) - ABSTRACT THE CELLULAR SENESCENCE NETWORK CONSORTIUM (SENNET) PRESENTS UNIQUE NEW REQUIREMENTS AND OPPORTUNITIES FOR ORGANIZATION AND DATA COORDINATION RELATIVE TO THE RAPIDLY GROWING COMMUNITY OF SINGLE-CELL GENOMICS MAPPING CONSORTIA INCLUDING THE HUMAN BIOMOLECULAR ATLAS PROGRAM CONSORTIUM (HUBMAP), THE HUMAN CELL ATLAS (HCA) AND THE HUMAN TUMOR ATLAS NETWORK (HTAN). IN PARTICULAR, SENNET FOCUSES ON DISCOVERY, INDUCTION, AND MAPPING OF SPECIFIC PHYSIOLOGY AT THE CELLULAR AND MOLECULAR LEVEL, UNDER A VARIETY OF NORMAL, EXPERIMENTAL AND DISEASE CONDITIONS, NOT “JUST” A CATALOG OF NORMAL, MURINE, OR CANCER TISSUES. THIS SUBSTANTIALLY INCREASES THE VALUE OF ENGAGEMENT AND COLLABORATION AMONG THE TEAMS THAT CONSTITUTE SENNET. SPECIFICALLY, INVESTIGATORS AMONG THE CONSORTIUM ORGANIZATION AND DATA COORDINATION CENTER (CODCC), TISSUE MANAGEMENT CENTERS (TMCS), AND TECHNOLOGY DEVELOPMENT (TTDS), AS WELL AS THE BROADER COMMUNITY OF CELLULAR SENESCENCE (CS) SCIENTISTS AND INNOVATORS, WILL NEED TO WORK TOGETHER TO COMMON PURPOSE TO ACHIEVE A MULTIYEAR STRATEGY OF HUMAN IMPACT. SENNET WILL ALSO NEED SENESCENT CELLS TO COOPERATE TO REVEAL THEIR BIOLOGY. THESE ARE AN UNDERSTUDIED SET OF CELLS AND PHENOTYPES THAT ARE FLUID IN MANY WAYS WE DO NOT YET UNDERSTAND, BUT YET MAY HAVE PROFOUND IMPACT ON OUR ABILITY TO ADDRESS A VARIETY OF CONDITIONS WITH TREMENDOUS BURDEN OF DISEASE ACROSS ORGAN SYSTEMS (E.G. NEUROLOGICAL DETERIORATION, CANCER CONTROL, AND EVEN AGING). SENNET, DISTINCT FROM OTHER SINGLE-CELL GENOMICS CONSORTIA, WILL NEED MORE SHARED FOCUS UPON PRIORITIZING EXPERIMENTS JOINTLY PERFORMED AND/OR REPLICATED AMONG LABORATORIES, PRIORITIZING TIGHT FOCUS ON SPECIFIC CELLS, AND ADDRESSING CHANGES, PATHWAYS, AND TRAJECTORIES CELLS MAY TAKE OVER TIME. SENNET WILL ULTIMATELY REQUIRE CHANGING THE CONCEPTION OF SINGLE-CELL -OMICS MAPS TO INCLUDE DYNAMICS IN TIME, SPACE AND FUNCTION, AND WILL FEED THESE BACK ONTO THE OTHER EFFORTS.
Department of Health and Human Services
$21M
MILD COGNITIVE IMPAIRMENT: A PROSPECTIVE COMMUNITY STUDY
Department of Health and Human Services
$20.9M
PITTSBURGH CENTER FOR HIV PROTEIN INTERACTIONS (PCHPI) - OVERALL ANTIRETROVIRAL THERAPY HAS TURNED HIV/AIDS INTO A CHRONIC DISEASE, YET THE EMERGENCE OF DRUG-RESISTANT VARIANTS AND COMORBIDITIES AFTER LONG-TERM ART REMAIN A CONCERN. THEREFORE, ALTERNATIVE APPROACHES TO INHIBIT INFECTION AND CURE AIDS ARE NEEDED. THE PROPOSED “PITTSBURGH CENTER FOR HIV PROTEIN INTERACTIONS” (U54 PCHPI) IS WELL- POSITIONED TO SUCCEED IN THE SEARCH FOR THE MUCH-NEEDED ALTERNATIVE TARGETS FOR HIV-1 SUPPRESSION. THE U54 PCHPI IS A HIGHLY INTEGRATED, COLLABORATIVE EFFORT, BUILDING ON ESTABLISHED PRODUCTIVE COLLABORATIONS. THE FUNDAMENTAL RESEARCH PROGRAM WILL FOCUS ON STRUCTURALLY CHARACTERIZING HIV-1 PROTEIN AND PROTEIN-NUCLEIC ACID COMPLEXES INVOLVED IN THREE ASPECTS OF INFECTION: HIV-1 ASSEMBLY AND MATURATION, INGRESS AND NUCLEAR ENTRY, AND INTEGRATION. STUDIES TO ADDRESS THESE STAGES OF THE INFECTION CYCLE WILL BE CARRIED OUT IN THREE PROJECTS, EACH FOCUSED ON ONE OF THESE AREAS, AND IN FOUR SCIENTIFIC CORES (COMPUTATIONAL, CRYO-EM/ET, NMR AND VIROLOGY) ALONG WITH ADMINISTRATIVE AND DEVELOPMENTAL CORES. IMPORTANTLY, OUR PROGRAM WILL WORK TO DEFINE THE STRUCTURAL BASIS UNDERLYING MATURATION AND ALLOSTERIC INTEGRASE INHIBITOR ACTIVITIES TO PROMOTE A MECHANISTIC UNDERSTANDING AND SEEKS TO IDENTIFY PATHS OF RESISTANCE DEVELOPMENT. FURTHER, WE WILL IDENTIFY NEW TARGETS FOR INHIBITION OF HIV- 1 BY DEFINING INTERACTION INTERFACES WITHIN CAPSID-HOST PROTEIN/NUCLEIC ACID COMPLEXES INVOLVED IN TRAFFICKING, NUCLEAR ENTRY, AND INTEGRATION, WITH A PARTICULAR FOCUS ON NATIVE PRE-INTEGRATION COMPLEXES (PICS). WE WILL ALSO DEVELOP TOOLS FOR EXAMINING CAPSID INTERACTIONS UNDER NEAR-NATIVE CONDITIONS (IN SITU NMR SPECTROSCOPY AND SINGLE-MOLECULE CLEM FOR HIV-1). IN ADDITION, A ROBUST MANAGEMENT PLAN, IMPLEMENTED VIA AN ADMINISTRATIVE CORE, WILL ENSURE A COHESIVE EFFORT WITH FREQUENT AND TRANSPARENT COMMUNICATIONS, WHILE OUR MISSION TO FACILITATE RESEARCH CAREER DEVELOPMENT WILL BE ENABLED BY A COLLABORATIVE DEVELOPMENT PROGRAM, A MENTORING PROGRAM, AND A RESEARCHER EMBEDDING PROGRAM, AMONG OTHER INITIATIVES IN THE DEVELOPMENTAL CORE. UPON COMPLETION OF OUR AIMS, WE EXPECT TO HAVE IDENTIFIED AND CHARACTERIZED, AT HIGH RESOLUTION, SEVERAL PREVIOUSLY UNKNOWN/UNCHARACTERIZED INTERACTION INTERFACES IN HIV-1 PROTEIN COMPLEXES, ALONE AND WITH INHIBITORS, BETWEEN HIV-1 RNA AND PROTEINS, AND WITHIN PIC COMPONENTS, INCLUDING RETROVIRAL INTASOME INTERACTIONS WITH HOST CHROMATIN. DETAILED KNOWLEDGE OF SUCH INTERFACES WILL ENABLE STRUCTURE-GUIDED IMPROVEMENTS IN INHIBITOR DESIGN AS WELL AS IDENTIFY POTENTIAL NEW TARGETS FOR INHIBITION.
Department of Health and Human Services
$20.5M
CENTER FOR ADOLESCENT REWARD, RHYTHMS AND SLEEP (CARRS)
Department of Health and Human Services
$20.5M
BIOSTATISTICAL CENTER FOR THE NSABP
Department of Health and Human Services
$20.4M
CLARIFYING THE OPTIMAL APPLICATION OF SLT THERAPY (COAST) TRIAL
Department of Health and Human Services
$20.3M
MILD COGNITIVE IMPAIRMENT: A PROSPECTIVE COMMUNITY STUDY - MILD COGNITIVE IMPAIRMENT: A PROSPECTIVE COMMUNITY STUDY. DEMENTIA IS A LEADING CAUSE OF DISABILITY AND DEATH IN OLDER ADULTS. ITS INCIDENCE INCREASES EXPONENTIALLY WITH AGE. IDENTIFYING INDEPENDENT RISK FACTORS AND VALID DISEASE MARKERS ARE CRITICAL STEPS TOWARDS PREVENTION, IMPROVED DIAGNOSIS, AND TREATMENT. TO ENHANCE CLINICAL AND PUBLIC HEALTH CARE, THESE FACTORS MUST BE IDENTIFIED IN POPULATION SETTINGS. WE SEEK TO EXTEND, FOR A FURTHER FIVE YEARS, A 15-YEAR PROSPECTIVE POPULATION-BASED STUDY OF MILD COGNITIVE IMPAIRMENT (MCI) AND DEMENTIA IN A LOW SES-AREA OF SOUTHWESTERN PENNSYLVANIA. THE ORIGINAL RICHLY CHARACTERIZED COHORT IS NOW AGED 80+, AND AT MAXIMUM RISK FOR DEMENTIA; WE HAVE REPLENISHED THE COHORT BY RECRUITING ADDITIONAL PARTICIPANTS CURRENTLY AGED 65-74, FOR A TOTAL CURRENT SAMPLE ~1100. OUR OBJECTIVE REMAINS TO IDENTIFY, AT THE POPULATION LEVEL, RISK FACTORS FOR CLINICALLY RELEVANT ADVERSE COGNITIVE OUTCOMES OF MCI, COGNITIVE DECLINE, AND PROGRESSION TO DEMENTIA. WE PROPOSE A NEW SET OF SPECIFIC AIMS INVESTIGATING NOVEL DISEASE MARKERS IN RELATION TO THESE OUTCOMES. OUR NEW HIGH PERFORMING MASS-SPECTROMETRY-BASED PLASMA SS AMYLOID (ASS) ASSAY HOLDS POTENTIAL FOR AFFORDABLE NON-INVASIVE SCREENING FOR ALZHEIMER'S DISEASE. 7T MRI BRAIN SCANS WILL ALLOW IN-DEPTH IMAGING OF CEREBROVASCULAR INTEGRITY IN A SUBGROUP AND HELP UNDERSTAND THE ROLE OF SMALL VESSEL DISEASE (SVD) IN COGNITIVE DECLINE AND DEMENTIA. NON- INVASIVE WRIST ACTIGRAPHY WILL MEASURE SLEEP-WAKE RHYTHMS WHICH WE WILL EXAMINE IN RELATION TO THE COGNITIVE OUTCOMES, ASS AND SVD. GWAS AND TRANSCRIPTOMICS WILL ALLOW US TO EXAMINE GENOME-WIDE GENETIC AND GENE EXPRESSION DATA. WE WILL ASSESS THE RELATIONSHIPS OF THESE THREE BIOMARKERS (ASS, SVD, SLEEP), ALONG WITH GENOMICS AND GENE EXPRESSION, AND THEIR MUTUAL INTERACTIONS, TO THE CLINICALLY RELEVANT OUTCOMES OF COGNITIVE DECLINE AND DEMENTIA. NEW LIGHT SHED ON MECHANISMS UNDERLYING THESE DISORDERS, USING MODELING TECHNIQUES TO ACCOUNT FOR BIASES AND GENERALIZE RESULTS FROM SUB-SAMPLES BACK TO THE ENTIRE COHORT, WILL LEAD TO NEW INSIGHTS TO HELP REDUCE THE PUBLIC HEALTH BURDEN OF DEMENTIA.
Department of Health and Human Services
$19.9M
PITTSBURGH OLDER AMERICANS INDEPENDENCE CENTER
Department of Health and Human Services
$19.1M
NEURODEGENERATION IN AGING DOWN SYNDROME (NIAD): A LONGITUDINAL STUDY OF COGNITION AND BIOMARKERS OF ALZHEIMER'S DISEASE
Department of Health and Human Services
$19.1M
THE CENTER FOR ENHANCING TRIAGE AND UTILIZATION FOR DEPRESSION AND EMERGENT SUICIDALITY (ETUDES) IN PEDIATRIC PRIMARY CARE
Department of Health and Human Services
$18.7M
EXTENDING THE PHENOTYPE OF NONSYMDROMIC OROFACIAL CLEFTS
Department of Health and Human Services
$18.5M
A MULTI-CENTER GROUP TO STUDY ACUTE LIVER FAILURE IN CHILDREN
Department of Health and Human Services
$18M
NATIONAL MESOTHELIOMA VIRTUAL BANK FOR TRANSLATIONAL RESEARCH
Department of Health and Human Services
$17.5M
BIOBEHAVIORAL STUDIES OF CARDIOVASCULAR DISEASE
Department of Health and Human Services
$17.5M
PITTSBURGH BIOMEDICAL INFORMATICS TRAINING PROGRAM
Department of Health and Human Services
$17M
IMMUNE AIRWAY-EPITHELIAL INTERACTIONS IN STEROID-REFRACTORY SEVERE ASTHMA
Department of Health and Human Services
$16.8M
NETWORK MANAGEMENT CORE (NEMO) FOR THE PULMONARY TRIALS COOPERATIVE (PTC)
Department of Health and Human Services
$16.7M
COMPUTATIONAL MODELS OF INFECTIOUS DISEASE THREATS
Department of Health and Human Services
$16.2M
HIGH PERFORMANCE COMPUTING FOR MULTISCALE MODELING OF BIOLOGICAL SYSTEMS
Department of Health and Human Services
$16.1M
AIDS EDUCATION AND TRAINING CENTERS PROGRAM
Department of Health and Human Services
$15.5M
UNIVERSITY OF PITTSBURGH CLINICAL AND TRANSLATIONAL SCIENCE INSTITUTE
Department of Health and Human Services
$15.3M
CHILDREN OF BIPOLAR PARENTS: A HIGH RISK FOLLOW-UP STUDY
Department of Health and Human Services
$15.3M
NATIONAL NETWORK OF LIBRARIES OF MEDICINE MIDATLANTIC (REGION 1) AND WEB SERVICES OFFICE
Department of Commerce
$15M
FOUNDATIONS FOR EXPANDED EXCELLENCE IN NANOSCIENCE AND EXPERIMENTAL PHYSICS AT THE UNIVERSITY OF PITTSBURGH.
Department of Health and Human Services
$14.5M
PLASMA BRAIN-DERIVED TAU: A NOVEL ALZHEIMER?S DISEASE-TYPE NEURODEGENERATION BIOMARKER WITH POTENTIAL TO COMPLETE THE AT(N) SCHEME IN BLOOD - WHILE THE AMYLOID(A)/TAU(T)/NEURODEGENERATION(N) FRAMEWORK HAS BEEN VALIDATED AGAINST NEUROPATHOLOGY, CEREBROSPINAL FLUID (CSF) AND NEUROIMAGING BIOMARKERS, ITS IMPLEMENTATION IN BLOOD IS INCOMPLETE. WE NOW HAVE HIGH-PERFORMANCE PLASMA A AND T MARKERS THAT BECOME ABNORMAL ACCORDING TO AD PATHOPHYSIOLOGY. HOWEVER, THE CURRENT N MARKER – NEUROFILAMENT LIGHT (NFL) – IS A NON-DISEASE-SPECIFIC INDICATOR OF NEURODEGENERATION/NEURONAL INJURY. MOREOVER, PLASMA TOTAL-TAU (T-TAU) HAS LARGE OVERLAPS BETWEEN DIAGNOSTIC GROUPS AND DOES NOT CORRELATE WITH CSF T-TAU. WE HAVE DEVELOPED AND VALIDATED A NOVEL AD-TYPE NEURODEGENERATION BIOMARKER (REFERRED TO AS BRAIN-DERIVED TAU [BD-TAU]) WITH CAPACITY TO COMPLETE THE AT(N) FRAMEWORK IN BLOOD. OUR OVERALL GOAL IS TO PERFORM A LARGE-SCALE CLINICAL AND PATHOPHYSIOLOGICAL VALIDATION OF PLASMA BD-TAU. WE WILL LEVERAGE FIVE LONGITUDINAL, ALREADY EXISTING, RACIALLY/ETHNICALLY DIVERSE SPORADIC AD COHORTS (N = 2,594) WITH CLINICAL, IN VIVO, AND POST-MORTEM EVALUATIONS TO ANSWER THE FOLLOWING SPECIFIC AIMS: AIM 1. TO COMPARE ASSOCIATIONS OF PLASMA BD-TAU, NFL AND T-TAU WITH CLINICAL DIAGNOSIS OF AD AND LONGITUDINAL COGNITIVE CHANGE; AIM 2. TO COMPARE AT(N) PROFILES AND ASSOCIATIONS FOR PLASMA BD-TAU VS. NFL AND T-TAU; AIM 3. TO COMPARE THE (ADDED) DIAGNOSTIC VALUE OF PLASMA BD-TAU VS. NFL AND T-TAU FOR AUTOPSY CONFIRMATION OF AD; AND EXPLORATORY AIM 4: TO COMPARE PERFORMANCES OF PLASMA BD-TAU VS. NFL AND T-TAU IN DIFFERENT RACIAL/ETHNIC GROUPS. IF PROVEN, BD-TAU WILL COMPLETE THE AT(N) SCHEME IN BLOOD, IMPROVING DIAGNOSTIC AND PROGNOSTIC ACCURACIES AND CONFIDENCE, AS WELL AS THE PREDICTION OF LONGITUDINAL COGNITIVE CHANGE THAT ARE DIRECTLY TRANSLATABLE TO ANTI-AD CLINICAL TRIALS.
Department of Health and Human Services
$14.1M
PITTSBURGH CENTER FOR HIV PROTEIN INTERACTIONS (PCHPI)
Department of Health and Human Services
$14M
THOMAS E. STARZL BIOMEDICAL SCIENCE TOWER 12TH FLOOR LABORATORY RENOVATIONS PROJE
Department of Health and Human Services
$13.9M
ABCD-USA CONSORTIUM:RESEARCH PROJECT
Department of Health and Human Services
$13.8M
INSTITUTIONAL CAREER DEVELOPMENT
Department of Health and Human Services
$13.8M
NUTRITIONAL PRIMARY PREVENTION OF TYPE 1 DIABETES
Department of Health and Human Services
$13.5M
TRISTATE SENNET (LUNG AND HEART) TISSUE MAP AND ATLAS CONSORTIUM - SENESCENT CELLS ACCUMULATE WITH AGE AND ARE INCREASINGLY LINKED TO A VARIETY OF AGE-RELATED DISEASES. AT PRESENT, SENESCENT CELLS ARE OPERATIONALLY CHARACTERIZED BASED ON A SET OF MORPHOLOGICAL, BIOCHEMICAL, AND MOLECULAR PROPERTIES. HOWEVER, SENESCENCE IS UNLIKELY TO REPRESENT A SINGLE UNIFORM ENTITY. RATHER, ANALOGOUS TO WHAT HAS BEEN LEARNED FROM STUDYING TUMORS, THE CELL TYPE, IN CONJUNCTION WITH THE SPECIFIC ENDOGENOUS DRIVER OF SENESCENCE, WILL LIKELY DETERMINE THE UNIQUE MOLECULAR FINGERPRINT OF A GIVEN SENESCENT CELL. UNDERSTANDING THIS FINGERPRINT, LIKE OUR UNDERSTANDING OF THE SPECIFIC GENETIC ALTERATIONS IN A GIVEN TUMOR, WILL, IN TURN, INFORM PROGNOSIS AND RESPONSE TO THERAPY. MUCH OF OUR UNDERSTANDING OF THE BIOLOGY OF SENESCENCE HAS COME FROM EXPERIMENTAL ANIMAL MODELS, WHILE OUR UNDERSTANDING OF SENESCENCE IN HUMAN CELLS AND TISSUES REMAINS, AT BEST, INCOMPLETE. SIMILARLY, WHILE A NUMBER OF EXOGENOUS STRESSES CAN TRIGGER A SENESCENT PHENOTYPE FOR CELLS IN CULTURE, THE PHYSIOLOGICAL RELEVANT DRIVERS OF HUMAN SENESCENCE ARE NOT KNOWN. FINALLY, WHILE FOR PROLIFERATING CELLS, SENESCENCE IS CHARACTERIZED BY A PERMANENT WITHDRAWAL FROM THE CELL CYCLE, THE RELEVANT SENESCENT CELL MARKERS AND BIOLOGY FOR CRITICAL POST-MITOTIC CELLS (E.G., CARDIAC MYOCYTES, NEURONS) IS NOT WELL ESTABLISHED. TO BEGIN TO ADDRESS THESE SIGNIFICANT KNOWLEDGE GAPS, THE TRISTATE SENNET TISSUE MAPPING CENTER (TMC) WILL ANALYZE HUMAN LUNG AND HEART TISSUE TO PROVIDE A HIGH-RESOLUTION MAP OF THE SENESCENT CELL POPULATION IN THESE ORGANS. WITH THE COMBINED EXPERTISE OF THE UNIVERSITY OF PITTSBURGH AND CARNEGIE MELLON UNIVERSITY, OHIO STATE UNIVERSITY, AND THE UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE, THIS CONSORTIUM WILL PROVIDE A COMPREHENSIVE ASSESSMENT OF TWO ORGANS LINKED TO A VARIETY OF AGE-RELATED DISEASES, ONE OF WHICH IS LARGELY POST-MITOTIC. OUR ANALYSIS WILL INVOLVE IN SITU MAPPING USING ESTABLISHED TARGETED ASSAYS, AS WELL AS HIGH-CONTENT UNBIASED APPROACHES INVOLVING SINGLE CELL RNA/ATAC SEQUENCING, PROTEOMICS, AND SPATIAL TRANSCRIPTOMICS. IN ADDITION, AS PART OF OUR MAPPING ENDEAVOR, THE TRISTATE SENNET TMC WILL ANALYZE THE RELATIONSHIP BETWEEN THE INITIATING TRIGGER FOR SENESCENCE AND THE SUBSEQUENT BIOLOGY AND PHENOTYPE OF THE SENESCENT CELL. THIS RELATIONSHIP WILL BE PROBED USING PRECISION CUT TISSUE SECTIONS FROM HUMAN LUNGS AND HEARTS THAT WILL BE PERTURBED EX VIVO BY SPECIFIC SENESCENT TRIGGERS. THIS PROCEDURE WILL ALLOW US TO INCREASE THE PRECISION AND SENSITIVITY OF DETECTION AND LOCALIZATION OF SENESCENT CELLS IN THE LUNG AND HEART. FINALLY, WE WILL PURIFY AND ISOLATE SENESCENT AND NON- SENESCENT CELLS FROM AN INDIVIDUAL DONOR LUNG AND USED THESE ISOGENIC PRIMARY CELLS TO DECONVOLUTE THE PHYSIOLOGICALLY RELEVANT DRIVER OF HUMAN SENESCENCE AND DELINEATE THE MOLECULAR BASIS FOR THE OBSERVED SELECTIVITY OF SENOLYTIC THERAPY. TOGETHER, THIS COMBINED ANALYSIS OF TISSUE AND TISSUE SLICES/CELLS FROM THE SAME INDIVIDUAL WILL PROVIDE AN UNRIVALED, UNPRECEDENTED, IN-DEPTH, HIGH-RESOLUTION MAP OF THE SENESCENT CELL POPULATION IN THE HUMAN LUNG AND HEART, DEFINE THE PHYSIOLOGICAL DRIVERS OF SENESCENCE, AND PROVIDE A RATIONAL APPROACH TO UNDERSTAND THE THERAPEUTIC POTENTIAL OF SENOLYTIC THERAPY.
Department of Health and Human Services
$13.3M
PITTSBURGH CENTER FOR KIDNEY RESEARCH
Department of Health and Human Services
$13.2M
DRUG ABUSE VULNERABILITY: MECHANISMS AND MANIFESTATIONS
Department of Health and Human Services
$12.8M
CENTER FOR CAUSAL MODELING AND DISCOVERY OF BIOMEDICAL KNOWLEDGE FROM BIG DATA
Department of Health and Human Services
$12.7M
TAILORED RETENTION AND ENGAGEMENT FOR EQUITABLE TREATMENT OF OUD AND PAIN (TREETOP) - PROJECT SUMMARY/ABSTRACT: THE TAILORED RETENTION AND ENGAGEMENT FOR EQUITABLE TREATMENT OF OUD AND PAIN (TREETOP) CLINICAL RESEARCH CENTER AT THE UNIVERSITY OF PITTSBURGH (PITT) IS PART OF THE NIH IMPOWR NETWORK. TREETOP DRAWS ON THE NIDA CLINICAL TRIALS NETWORK APPALACHIAN (PENNSYLVANIA & WEST VIRGINIA) AND WESTERN STATES (OREGON) NODES AND THE COMMUNITY-BASED OUD AND PAIN ENHANCED TREATMENT (COPE) COLLABORATIVE (BALTIMORE, MARYLAND) TO DEVELOP EFFECTIVE, EQUITABLE, AND SUSTAINABLE INTERVENTIONS FOR CHRONIC PAIN AND OUD. OUR OVERALL GOAL IS TO IMPROVE TREATMENT FOR COMORBID CHRONIC PAIN AND OUD ACROSS THE OUD TREATMENT CASCADE, PRIORITIZING TWO DISPROPORTIONATELY IMPACTED COMMUNITIES FOR WHOM EQUITABLE IMPLEMENTATION OF EFFECTIVE INTERVENTIONS CAN BE CHALLENGING: RURAL AND BLACK COMMUNITIES. WE WILL ACHIEVE OUR OVERALL GOAL THROUGH THE INTEGRATED CONTRIBUTIONS OF 5 CENTER COMPONENTS AS FOLLOWS: 1) RESEARCH SITE OVERVIEW, MANAGEMENT, AND OPERATIONS - OUR DIVERSE MULTIDISCIPLINARY TEAM HAS EXTENSIVE EXPERIENCE WITH MULTISITE CLINICAL TRIALS AS WELL AS IN TREETOP’S TWO EMPHASIS AREAS, HEALTH EQUITY AND IMPLEMENTATION SCIENCE. 2) ENGAGEMENT AND OUTREACH - OUR TREETOP STAKEHOLDER CONSULTATION BOARD (SCB) INCLUDES REPRESENTATIVES WITH A VARIETY OF PERSPECTIVES AND LIVED EXPERIENCES FROM EACH CLINIC AND COMMUNITY PARTNERING IN OUR STUDIES AND WILL SERVE AS ACTIVE PARTICIPANTS ON THE RESEARCH TEAM. 3) ENGAGEMENT/RETENTION RESEARCH PROJECTS - BOTH PROJECTS SHARE THE CENTRAL PREMISE THAT TREATING CHRONIC PAIN IMPROVES PAIN AND OUD OUTCOMES, TAILOR A PAIN SELF-MANAGEMENT (PSM) INTERVENTION TO PATIENTS WITH CO-MORBID CHRONIC PAIN AND OUD, AND EVALUATE BOTH THE INTERVENTION EFFECTIVENESS AND THE BARRIERS AND FACILITATORS TO EQUITABLE AND SUSTAINED IMPLEMENTATION OF THE INTERVENTION THROUGH THE HEALTH EQUITY IMPLEMENTATION FRAMEWORK. SPECIFICALLY, THE ENGAGEMENT RESEARCH PROJECT INVESTIGATES WHETHER PSM CAN IMPROVE PAIN AND ENGAGE PRIMARY CARE PATIENTS IN MEDICATION TREATMENT FOR OUD, WHILE THE RETENTION PROJECT INVESTIGATES WHETHER PSM AND/OR FLEXIBLY DOSED BUPRENORPHINE/NALOXONE CAN IMPROVE PAIN AND RETENTION IN TREATMENT AMONG PATIENTS WHO HAVE ALREADY INITIATED CARE IN OFFICE-BASED ADDICTION TREATMENT PROGRAMS. 4) DATA COLLECTION, MANAGEMENT, AND HARMONIZATION - THE DATA CORE WILL BE LED BY INVESTIGATORS WITH A TRACK RECORD OF SUCCESS IN THE MEASUREMENT AND ANALYSIS OF PATIENT-REPORTED OUTCOMES AND IN LEADING CLINICAL TRIALS AND DATA COORDINATING CENTERS, AND INCLUDES NATIONAL LEADERS IN THE PROMIS HEALTH ORGANIZATION. 5) PILOT PROJECTS - OUR PILOT PROGRAM INCLUDES 3 INITIAL STUDIES ON PAIN MEASUREMENT, CHRONIC PAIN/OUD TREATMENT IMPLEMENTATION IN SPECIALTY SETTINGS, AND CHRONIC PAIN AND OUD STIGMA, AND THEN FOLLOWS A STANDARD PROTOCOL FOR SOLICITING AND REVIEWING FUTURE PILOT PROJECTS ADDRESSING HEALTH EQUITY AND IMPLEMENTATION SCIENCE. OVERALL IMPACT: OUR TREETOP INVESTIGATORS AND SCB WILL COLLABORATE TO ADVANCE THE SCIENCE OF SUSTAINABLY AND EQUITABLY MANAGING CHRONIC PAIN AND OUD, PRIORITIZING DISPROPORTIONATELY IMPACTED RURAL AND BLACK COMMUNITIES.
Department of Defense
$12.6M
MARSOC INJURY PREVENTION AND HUMAN PERFORMANCE RESEARCH
Department of Health and Human Services
$12.5M
COURSE AND OUTCOME FOR BIPOLAR DISORDER IN YOUTH
Department of Health and Human Services
$12.3M
ARTERIAL STIFFNESS, COGNITION, AND EQUOL (ACE) - PROJECT SUMMARY/ABSTRACT THIS APPLICATION, “ARTERIAL STIFFNESS, COGNITION AND EQUOL (ACE),” IS AN EARLY STAGE RANDOMIZED CONTROLLED TRIAL (RCT) DESIGNED TO TEST THE EFFECT OF A 24-MONTH INTERVENTION OF 10 MG/DAY EQUOL SUPPLEMENTATION ON COGNITIVE DECLINE, ARTERIAL STIFFNESS, AND WHITE MATTER LESIONS (WMLS) AMONG 400 INDIVIDUALS AGED 70+ WITHOUT DEMENTIA. RECENT STUDIES IN JAPAN REPORTED THAT A DIET HIGH IN SOY AND SOY ISOFLAVONES (ISFS) IS INVERSELY ASSOCIATED WITH INCIDENT COGNITIVE IMPAIRMENT AND DEMENTIA. THE WOMEN’S ISOFLAVONE SOY HEALTH (WISH) IN THE US, AN RCT OF ISFS, HOWEVER, SHOWED NO SIGNIFICANT EFFECT OF ISFS ON COGNITION. WE POSIT THAT THE DISCREPANT RESULT IS DUE TO THE DIFFERENCE IN EQUOL-PRODUCING CAPABILITY. EQUOL, A METABOLITE OF AN ISF DAIDZEIN TRANSFORMED BY THE GUT MICROBIOME, IS MOST BIOACTIVE AMONG ALL ISFS AND THEIR METABOLITES. 50-70% OF JAPANESE CONVERT DAIDZEIN TO EQUOL IN CONTRAST TO 20-30% OF AMERICANS. THE SUBGROUP ANALYSIS OF WISH SHOWED THAT EQUOL PRODUCERS HAD BETTER COGNITION THAN THE CONTROL GROUP, SUGGESTING THAT EQUOL MAY SLOW COGNITIVE DECLINE. IN ADDITION, ARTERIAL STIFFNESS, A SIGNIFICANT PREDICTOR OF COGNITIVE DECLINE, IS SIGNIFICANTLY IMPROVED IN A SHORT-DURATION RCT OF 10 MG/DAY EQUOL SUPPLEMENTATION IN MIDDLE-AGED SUBJECTS. FINALLY, WMLS ARE A RISK FACTOR FOR AGE-RELATED COGNITIVE DECLINE AND DEMENTIA. WE REPORTED A LONGITUDINAL ASSOCIATION OF EQUOL-PRODUCING STATUS WITH WML% (WML VOLUME NORMALIZED TO TOTAL BRAIN VOLUME) IN COGNITIVELY NORMAL ELDERLY IN JAPAN. SERUM EQUOL LEVELS WERE MEASURED USING SAMPLES COLLECTED AND STORED 6-9 YEARS BEFORE THE IMAGING STUDY; 50% WERE NON-EQUOL PRODUCERS AND EQUOL PRODUCERS WERE DIVIDED INTO TWO GROUPS (HIGH AND LOW). NON-EQUOL PRODUCERS HAD >100% GREATER WML% THAN HIGH PRODUCERS, SUGGESTING THAT SUPPLEMENTATION OF EQUOL MAY SLOW THE PROGRESSION OF WMLS. NO PREVIOUS STUDY HAS TESTED THE EFFECT OF EQUOL SUPPLEMENTATION ON COGNITIVE DECLINE, ARTERIAL STIFFNESS OR WMLS IN OLDER ADULTS. WE HYPOTHESIZE THAT SUPPLEMENTATION OF 10 MG/DAY EQUOL WILL SIGNIFICANTLY SLOWS BOTH COGNITIVE DECLINE (PRIMARY OUTCOME), AND THE PROGRESSION OF ARTERIAL STIFFNESS AND WML% (SECONDARY OUTCOMES). THE OVERALL IMPACT OF OUR TRIAL WILL BE TO DETERMINE THE ROLE OF EQUOL SUPPLEMENTATION IN IMPROVING COGNITIVE AND CEREBROVASCULAR OUTCOMES IN OLDER ADULTS. SHOULD A POSITIVE SIGNAL BE IDENTIFIED IN THIS EARLY-STAGE TRIAL, IT WOULD NOT ONLY LEAD TO A PHASE 3 TRIAL TO TEST A HYPOTHESIS THAT EQUOL SUPPLEMENTATION REDUCES RISK FOR COGNITIVE IMPAIRMENT AND DEMENTIA BUT ALSO TO AN RCT OF A DIET RICH IN ISFS BETWEEN EQUOL PRODUCERS AND NON-PRODUCERS, MOVING TOWARD A PRECISION HEALTH STRATEGY.
Department of Health and Human Services
$12.2M
NNLM ALL OF US PROGRAM CENTER - THE PROPOSED “NETWORK OF THE NATIONAL LIBRARY OF MEDICINE (NNLM) ALL OF US PROGRAM CENTER (NAPC)” WILL LEVERAGE A MULTI-YEAR HISTORY OF PRODUCTIVE COLLABORATION BETWEEN TWO PRIMARY INSTITUTIONS, THE UNIVERSITY OF PITTSBURGH AND THE UNIVERSITY OF IOWA, TO EMPLOY AN ENHANCED “TEAM SCIENCE” APPROACH TO ADDRESS THE COMMUNITY ENGAGEMENT, TRAINING, AND EDUCATION NEEDS OF THE NNLM ALL OF US PROGRAM. THE NAPC SERVES A CRITICAL ROLE IN COORDINATING ENGAGEMENT, PROGRAMS, PARTNERSHIPS, ACTIVITIES, AND TRAINING OFFERED BY NNLM IN SUPPORT OF THE NIH ALL OF US RESEARCH PROGRAM. NAPC WILL DEVELOP AND DISTRIBUTE A ROBUST PORTFOLIO OF COMMUNITY-BASED PROGRAMS AND SERVICES, CREATE OPPORTUNITIES FOR NATIONAL AND REGIONAL ENGAGEMENT, AND BUILD RELATIONSHIPS WITHIN NNLM AND THE ALL OF US ECOSYSTEM. IN DOING SO NAPC ENSURES THAT NNLM MEMBERS CAN BUILD CAPACITY TO IMPROVE HEALTH, DIGITAL, AND RESEARCH LITERACY IN THEIR COMMUNITIES, AND THAT INDIVIDUALS, PARTICULARLY POPULATIONS UNDERREPRESENTED IN BIOMEDICAL RESEARCH (UBR), WILL HAVE ACCESS TO THE KNOWLEDGE, RESOURCES, AND SKILLS NECESSARY TO UNDERSTAND PRECISION MEDICINE AND PARTICIPATE IN ALL OF US. AS PREVIOUS NNLM ALL OF US PILOT PROGRAM AWARDEES, THE UNIVERSITY OF PITTSBURGH AND THE UNIVERSITY OF IOWA BRING A UNIQUE UNDERSTANDING OF THE COMPLEXITY OF THE PROGRAM, QUALITY AND EXPERIENCED PERSONNEL, AND EXISTING PROFESSIONAL RELATIONSHIPS WITH NNLM, THE ALL OF US ECOSYSTEM, PUBLIC LIBRARIES, AND COMMUNITY ORGANIZATIONS. TOGETHER, THESE TWO INSTITUTIONS WILL CREATE A DYNAMIC AND COLLABORATIVE RESEARCH ENVIRONMENT, PROVIDE HIGH-QUALITY INNOVATIVE PROGRAM DELIVERABLES, AND IMPLEMENT INNOVATIVE WORKFLOWS, MECHANISMS, AND INITIATIVES TO GROW THE NNLM ALL OF US PROGRAM. THE NAPC WILL CONTINUE TO BUILD ON THE WORK OF THE NNLM ALL OF US PILOT BY USING DATA-INFORMED METHODS AND TOOLS TO IDENTIFY NEW OPPORTUNITIES TO REACH DIVERSE COMMUNITIES AND ORGANIZATIONS WITH LITTLE PREVIOUS ENGAGEMENT. WE WILL INCREASE CAPACITY, PROGRAMMING, AND ENGAGEMENT OPPORTUNITIES AROUND HEALTH, DIGITAL, AND RESEARCH LITERACY. WE WILL CONTINUE TO ASSESS AND SUPPORT THE TRAINING AND EDUCATION NEEDS OF THE ALL OF US CONSORTIUM AND ADVANCE THE SCIENCE OF ENGAGEMENT, COMMUNITY-BASED PARTICIPATORY RESEARCH, AND HUMAN-CENTERED DESIGN THROUGH TRAINING, PUBLICATIONS, PRESENTATIONS, AND OTHER MODES OF DISSEMINATION SO THAT OTHERS CAN INCORPORATE NAPC BEST PRACTICES INTO THEIR TRAINING AND COMMUNITY ENGAGEMENT PROGRAMS. THE NAPC HAS THREE OVERARCHING AIMS TO ACCOMPLISH THE GOALS OF THE NNLM ALL OF US PROGRAM: 1. INCREASE ALL OF US LEARNING OPTIONS FOR A WIDE VARIETY OF AUDIENCES IN COOPERATION WITH COMMUNITY PARTNERS, NNLM, THE ALL OF US CONSORTIUM TRAINING BOARD, AND THE ALL OF US ECOSYSTEM. 2. RAISE AWARENESS OF AND INTEREST IN ALL OF US. 3. BUILD CAPACITY TO IMPROVE THE PUBLIC’S KNOWLEDGE, RESOURCES, AND SKILLS TO MAKE INFORMED DECISIONS ABOUT HEALTH, CONTRIBUTE TO RESEARCH, AND ENGAGE WITH DIGITAL HEALTH INFORMATION AND RESEARCH.
Department of Health and Human Services
$12.1M
PRECONCEPTION STRESS EXPOSURE: IMPACT ON PREGNANCY AND OFFSPRING NEURODEVELOPMENT
Department of Health and Human Services
$11.9M
UNIVERSITY OF PITTSBURGH CLINICAL TRIALS UNIT
Department of Health and Human Services
$11.9M
CORE GRANT FOR VISION RESEARCH
Department of Health and Human Services
$11.9M
IP21-002, NEW VACCINE SURVEILLANCE NETWORK
Department of Health and Human Services
$11.9M
AIDS EDUCATION AND TRAINING CENTERS PROGRAM
Department of Health and Human Services
$11.5M
INHIBITION, OSCILLATIONS AND INFORMATION PROCESSING IN SCHIZOPHRENIA
Department of Health and Human Services
$11.4M
MIDAS INFORMATICS SERVICES GROUP (ISG)
Department of Health and Human Services
$11.3M
MEDICAL SCIENTIST TRAINING PROGRAM
Department of Health and Human Services
$11.3M
VALIDATION OF BIOMARKERS FOR EARLY DIAGNOSIS AND RISK PREDICTION OF PANCREATIC NEOPLASMS
Department of Health and Human Services
$11M
CENTER FOR NEUROANATOMY WITH NEUROTROPIC VIRUSES
Department of Health and Human Services
$11M
PSYCHOBIOLOGY OF SUICIDAL BEHAVIOR IN BORDERLINE PERSONALITY DISORDER
Department of Health and Human Services
$10.8M
AGING WELL, SLEEPING EFFICIENTLY: INTERVENTION STUDIES
Department of Health and Human Services
$10.8M
CORTICAL CELLS CIRCUITS CONNECTIVITY AND COGNITION IN SCHIZOPHRENIA
Department of Health and Human Services
$10.8M
COGNITIVE & BRAIN SYSTEMS MATURATION THROUGH ADOLESCENCE
Department of Defense
$10.5M
HIGH DEFINITION FIBER TRACKING BIOLOGICAL DIAGNOSIS OF TBI PROVIDING ACTIONABLE CLINICAL REPORT OF QUANTIFIED DAMAGE
Department of Health and Human Services
$10.5M
DEVELOPING AN INTERVENTION TO ADDRESS INTERSECTING PRESCRIPTION OPIOID AND CHRONIC PAIN STIGMA IN CANCER SURVIVORS: FORMATIVE WORK
Department of Health and Human Services
$10.4M
REGIONAL AIDS EDUCATION AND TRAINING CENTERS PROGRAM - PROJECT ABSTRACT: MIDATLANTIC AIDS EDUCATION & TRAINING CENTER UNIVERSITY OF PITTSBURGH, SCHOOL OF PUBLIC HEALTH DESCRIPTION: THE UNIVERSITY OF PITTSBURGH, SCHOOL OF PUBLIC HEALTH (SPH), DEPARTMENT OF INFECTIOUS DISEASES IS THE APPLICANT AND WILL PROVIDE OVERSIGHT OF PLANNING, PROGRAMS, BUDGETS, EVALUATION, AND PERFORMANCE MONITORING FOR THE PROJECT AND PARTNERS. IT IS A DYNAMIC AND PRODUCTIVE REGIONAL TEAM OF CLINICIANS, EDUCATORS, AND CAPACITY BUILDING EXPERTS HAVING DEMONSTRATED HIGH-QUALITY EDUCATION, TA, CAPACITY BUILDING AND IMPACT EVALUATION. THE TEAM HAS EXPERTISE IN HIV AND RELATED CONDITIONS AND CO-MORBIDITIES TO EDUCATE HCPS AND HP SCHOOL FACULTY AND STRONG RELATIONSHIPS WITH RYAN WHITE PROGRAMS, HEALTH DEPTS, FQHCS, AND OTHER SERVICES AND PROGRAMS WITHIN USPHS REGION 3. TARGETED POPULATION: PHYSICIANS, DENTISTS, NURSES, NURSE PRACTITIONERS, ADVANCED PRACTICE NURSES, PHYSICIAN ASSISTANTS, PHARMACISTS, SOCIAL WORKERS, CASE MANAGERS, ALLIED HEALTH, NAVIGATORS, COMMUNITY HEALTH WORKERS, FACULTY OF HEALTH PROFESSIONS SCHOOLS AND OTHER TEAM MEMBERS TO ASSURE ACCESS TO THE FULL CONTINUUM OF SERVICES FOR PERSONS WITH HIV TO IMPROVE ACCESS, OUTCOMES AND REDUCE DISPARITIES. GOALS AND MILESTONES: WILL PROVIDE (BASED ON NHAS, HEALTHY PEOPLE 2025, HRSA PRIORITIES) 1. FOUNDATIONS OF HIV PROVIDE TRAINING TO NOVICE/LESS EXPERIENCED CLINICIANS AND TEAM MEMBERS. 2. INTERPROFESSIONAL EDUCATION PROJECT (IPE) AND PARTNER WITH HP SCHOOLS TO TRAIN HP FACULTY AND THROUGH THEM, THEIR STUDENTS FOR WORKFORCE DEVELOPMENT. 3. PRACTICE TRANSFORMATION INTERVENTION TO SPECIFIC CLINICS TO IMPROVE CARE BY INTEGRATING PRINCIPLES OF PATIENT CENTERED MEDICAL HOMES TO INCREASE ACCESS, REDUCE DISPARITIES, AND QUALITY. 4. CAPACITY FOR EXPERTISE EXPANSION TO IMPROVE CLINICAL COMPETENCIES, STRUCTURES AND POLICIES THROUGH INTERVENTIONS IMPROVE PRACTICE OF CLINICIANS, CLINICS, SYSTEMS WITH A FOCUS ON FQHCS, RYAN WHITE, HBCUS, HEALTH DEPTS. TO IMPROVE QUALITY, EFFI CIENCY, COORDINATION, AND COST REDUCTION. 5. THROUGH THE MAI PROJECT PROVIDE TRAINING AND TA TO BUILD CAPACITY AND COMPETENCIES OF MINORITY AND MINORITY SERVING HPS TO IMPROVE QUALITY AND ACCESS. 6. THROUGH EHE IMPLEMENT APPROACHES TO INCREASE HIV/HEPC/STI CASE FINDING, PREP, AND FACILITATE LINKAGE TO CARE/TREATMENT IN EHE JURISDICTIONS. 7. IDENTIFY AND DISSEMINATE MODELS OF CARE FOR PRACTICES AND POLICIES THAT IMPROVE PATIENT OUTCOMES FOR THE CONTINUUM OF HIV CARE. 8. ENGAGE IN COLLABORATIVE PARTNERSHIPS WITH HRSA, EVALUATION CONTRACTOR, NCCC, NCRC AND OTHER AETCS FOR CURRICULA, ASSESSMENT, AND EVALUATION. OVERVIEW OF PROGRAM PLAN: THE APPROACH AIMS TO ADDRESS NOFO REQUIREMENTS AND REGIONAL UNMET NEEDS TO ADDRESS CAPACITY BUILDING FOR CLINICIANS AND OTHER CARE TEAM MEMBERS, CLINICS, AND SYSTEMS TO IMPROVE THE CARE CONTINUUM THROUGH TRAINING, TA AND DISSEMINATION OF HRSA, CDC GUIDELINES FOR HIV/HEP C AND CO-MORBIDITIES, SPNS MODELS, CLINICAL PERFORMANCE MEASURES, CQI, SERVICE INTEGRATION AND COORDINATION. THE PROGRAM SUPPORTS KNOWLEDGE AND PRACTICE ACQUISITION WITH INTERACTIVE TRAINING; PRECEPTORSHIPS; DECISION-SUPPORT; TA FOR CO-MANAGEMENT, EVIDENCED-BASED APPROACHES TO IMPROVE COMPETENCIES FOR PREVENTION, TREATMENT, MEDICAL CO-MORBIDITIES; INTERVENTION WITH SPECIAL POPULATIONS, PSYCHOSOCIAL CO-MORBIDITIES; DISSEMINATION OF NATIONAL CURRICULA, TA FOR CAPACITY BUILDING; DISTANCE-BASED TRAINING TO REACH RURAL/URBAN AREAS; TAILORING TRAINING FOR AUDIENCE, COLLABORATE WITH EVALUATION CONTRACTOR (METRICS), NCCC (TA), NQC (CQI), NCRC (DISSEMINATION), HRSA, HAB AND USPHS REGION 3 TO ADDRESS QUALITY AND SERVICE GAPS. PROJECT EVALUATION: ALL COMPONENTS WILL BE EVALUATED TO TRACK PROCESSES, OUTCOMES IN COLLABORATION WITH HRSA, USING EXISTING AND NEW METHODS/INSTRUMENTS TO CAPTURE THE IMPACT AND OUTCOMES OF ALL PROJECT COMPONENTS FOR CLINICIANS, CLINICS, AND SYSTEMS BY MEASURING QUALITY, REACH, ENGAGEMENT, BEST PRACTICES, COORDINATION, PRACTICE CHANGE, AND CLINICAL OUTC OMES.
Department of Health and Human Services
$10.4M
THE PEDIATRIC PRECISION SLEEP NETWORK - ABSTRACT PERI-ADOLESCENCE (AGES 10-13) HERALDS AN ALARMING ESCALATION IN PEDIATRIC MENTAL HEALTH (MH) RISK, MAKING THIS TRANSITIONARY TIME BETWEEN CHILDHOOD AND ADOLESCENCE A CRUCIAL WINDOW FOR EARLY DETECTION AND INTERVENTION. PREDICTIVE MODELS BUILT ON ELECTRONIC HEALTH RECORD (EHR) DATA ARE EMERGING AS PRACTICAL TOOLS TO AUTOMATE MH RISK STRATIFICATION IN PEDIATRIC PRIMARY CARE (PPC); HOWEVER, TO DATE THESE MODELS HAVE ONLY MODEST PREDICTIVE VALUE. COMMON, CAUSAL, AND MODIFIABLE TRANSDIAGNOSTIC MH RISK FACTORS ARE NEEDED TO IMPROVE ON EHR MODELS AND PAVE THE WAY FOR DEPLOYMENT OF PREVENTIVE CARE DURING PERI-ADOLESCENCE. SLEEP IS ONE SUCH RISK FACTOR: MORE THAN 50% OF PERI-ADOLESCENTS EXPERIENCE UNHEALTHY SLEEP PATTERNS, AND SLEEP PROBLEMS DURING PERI-ADOLESCENCE PROSPECTIVELY PREDICT NEGATIVE MH OUTCOMES MORE STRONGLY THAN AT OTHER TIMES IN DEVELOPMENT. HOWEVER, SEVERAL BARRIERS HAVE IMPEDED THE INCORPORATION OF SLEEP INTO PPC SCREENING AND RISK STRATIFICATION TOOLS: (1) THE HETEROGENEITY OF SLEEP CHARACTERISTICS HINDERS THE DIFFERENTIATION OF NORMATIVE VERSUS AT-RISK SLEEP PATTERNS; (2) THE MULTIDIMENSIONALITY AND MULTIMODALITY OF SLEEP DATA HAVE LED TO INCONSISTENCIES REGARDING WHICH PARTICULAR FEATURES AND MODALITIES ARE NEEDED FOR SCREENING; AND (3) UNTIL VERY RECENTLY, IT HAS BEEN IMPOSSIBLE TO CAPTURE CRUCIAL BEHAVIORAL AND PHYSIOLOGICAL MEASURES OF HABITUAL SLEEP IN SUFFICIENTLY LARGE SAMPLES. TO ADDRESS THESE CHALLENGES, WE PROPOSE THE PEDIATRIC PRECISION SLEEP NETWORK: A MULTI-SITE OBSERVATIONAL STUDY OF UNPRECEDENTED SCOPE AND SCALE, FOCUSED ON ESTABLISHING SLEEP SIGNATURES THAT PREDICT TRANSDIAGNOSTIC MH PROBLEMS AMONG YOUTH IN PPC. ACROSS THREE SITES, WE WILL RECRUIT A SAMPLE OF 1,200 YOUTH (10-13YR) WITH A RANGE OF SLEEP DISTURBANCES FROM PPC SETTINGS. WE WILL DEVELOP AND VALIDATE MULTIDIMENSIONAL AND MULTIMODAL SLEEP SIGNATURES (AIM 1) AND PRACTICAL AND SCALABLE TRANSDIAGNOSTIC MH RISK STRATIFICATION ALGORITHMS (AIM 2). AIMS 1-2 WILL EMPLOY A SEQUENTIAL, MULTIMODAL MACHINE LEARNING WORKFLOW TO ESTABLISH THE EXTENT TO WHICH EACH DATA MODALITY CAN INCREMENTALLY INFORM SIGNATURES AND IDENTIFY YOUTH AT GREATEST TRANSDIAGNOSTIC MH RISK. THESE FINDINGS WILL INFORM SCREENING, RISK STRATIFICATION, AND FUTURE DEVELOPMENTALLY-APPROPRIATE EFFECTIVENESS AND/OR EXPERIMENTAL THERAPEUTICS TRIALS. IN AIM 3, WE WILL COORDINATE WITH THE IMPACT-MH DATA COORDINATING CENTER TO EFFICIENTLY RECRUIT PARTICIPANTS, COLLECT DATA, HONE AND SHARE INNOVATIVE DATA PROCESSING PIPELINES, AND SECURELY TRANSFER DATA. WE ARE COMMITTED TO BRINGING SLEEP AND MH DATA TO OUR BROADER SCIENTIFIC COMMUNITY, ALONG WITH THE ACCOMPANYING TOOLS AND RESOURCES NEEDED TO PROCESS SLEEP DATA EFFICIENTLY. OUR LONG-TERM GOAL IS TO INFORM CLINICAL DECISION-MAKING ALGORITHMS FOR PPC THAT LEVERAGE SLEEP TO IMPROVE MH OUTCOMES AT A PIVOTAL DEVELOPMENTAL WINDOW.
Department of Health and Human Services
$10.4M
MELANOMA AND SKIN CANCER PROGRAM SPORE - PROJECT SUMMARY ABSTRACT: OVERALL SKIN CANCERS ARE THE MOST COMMON CANCERS IN THE US, INCLUDING MELANOMA AND CUTANEOUS SQUAMOUS CELL CARCINOMA (CSCC). DESPITE SUBSTANTIAL PROGRESS, MOST PATIENTS WITH ADVANCED MELANOMA DO NOT BENEFIT FROM TREATMENT, WHILE THE MOST POTENT THERAPIES OF MELANOMA ALSO CAUSE SERIOUS ADVERSE EVENTS. IN ADDITION, WE STILL NEED SAFE, EFFICIENT, AND COST-EFFECTIVE THERAPIES OF CSCCS IN IMMUNOCOMPETENT AND IMMUNODEFICIENT PATIENTS THAT COULD TRANSFORM TREATMENT AND OUTCOMES FOR THESE AT-RISK PATIENT POPULATIONS. THE OVERALL GOAL OF THE MELANOMA AND SKIN CANCER PROGRAM (MSCP SPORE) IS TO DEVELOP NOVEL TRANSLATIONAL RESEARCH TO OVERCOME THE HURDLES OF CURRENT THERAPIES OF MELANOMA AND CSCCS. EACH OF THE THREE PROJECTS RESULTS FROM SEMINAL AND INNOVATIVE FINDINGS MADE BY THE INVESTIGATORS OF THE MSCP SPORE, WHICH ARE TRANSLATED INTO NEW COMBINATORIAL IMMUNOTHERAPY TRIALS FOR PATIENTS WITH MELANOMA AND SKIN CANCERS. PROJECT 1 WILL ASSESS THE CLINICAL AND IMMUNOLOGICAL ACTIVITY OF ANTI-LAG3 ALONE AND IN COMBINATION WITH ANTI-PD1, FOR THE FIRST TIME, IN TREATMENT-NAÏVE MPS WHO HAVE NOT RECEIVED PRIOR ICB. PROJECT 2 WILL EVALUATE THE EFFICACY, AND IMMUNOGENICITY OF CMP-001 (CMP), A TYPE A CPG, IN PD1 NAÏVE METASTATIC MELANOMA IN THE CONTEXT OF A PHASE II/III RANDOMIZED CLINICAL TRIAL WITH INTRATUMORAL CMP AND NIVOLUMAB (CMP/NIVO) VS. NIVO. PROJECT 3 WILL TEST A NOVEL MICRONEEDLE ARRAY (MNA) DEVICE TO DELIVER BOTH A POTENT CHEMOTHERAPEUTIC AGENT TO INDUCE IMMUNOGENIC CELL DEATH AND AN INNATE IMMUNE STIMULANT INTO ACCESSIBLE CSCCS. THIS APPROACH WILL BE TESTED BOTH IN IMMUNOCOMPETENT AND IMMUNOSUPPRESSED CANCER PATIENTS.THE MSCP SPORE WILL USE INNOVATIVE STRATEGIES TO DETERMINE THE MECHANISMS OF RESPONSE AND RESISTANCE TO THE PROPOSED THERAPIES. THE INVESTIGATORS WILL BE SUPPORTED BY SHARED-FACILITY CORES TO PROVIDE STATE-OF-THE-ART EXPERTISE AND ECONOMIES-OF-SCALE IN 1) SAMPLE COLLECTION AND PROCESSING, TRANSLATIONAL PATHOLOGY, DATA ANNOTATION, BIOSPECIMEN REPOSITORY, AND IMMUNOMONITORING (CORE 1); AND 2) BIOSTATISTICS AND BIOINFORMATICS (CORE 2), SUPPORTING RIGOR AND REPRODUCIBILITY ACROSS ALL RESEARCH PROJECTS. THE CAREER ENHANCEMENT PROGRAM (CEP) AND DEVELOPMENT RESEARCH PROGRAM (DRP) WILL ATTRACT TALENTED BASIC, TRANSLATIONAL, AND CLINICAL INVESTIGATORS INTO MELANOMA RESEARCH. THE MSCP SPORE LEVERAGES HILLMAN CANCER CENTER (HCC) RESOURCES AND INSTITUTIONAL COMMITMENT WITH STATE-OF-THE-ART RESEARCH AND CLINICAL FACILITIES, CLINICAL REGULATORY SERVICES TO SUPPORT CLINICAL TRIAL COORDINATION, AND TRANSLATIONAL RESEARCH. THE MSCP SPORE INCLUDES OUTSTANDING EXTERNAL AND INTERNAL ADVISORY BOARDS (EAB, IAB), AN EXECUTIVE COMMITTEE THAT IS HIGHLY EXPERIENCED IN THE SUCCESSFUL MANAGEMENT OF SPORES AND PATIENT ADVOCATES. THE ORGANIZATIONAL STRUCTURE OF THE MSCP SPORE WILL FACILITATE THOROUGH FOLLOWING OF PROGRESS AND MANAGING OF POTENTIAL HURDLES FOR EACH PROJECT. THE MSCP SPORE WILL SHARE DATA WITH THE SCIENTIFIC COMMUNITY AND OTHER SPORES IN AGREEMENT WITH THE NIH POLICY. THE MSCP SPORE WILL BENEFIT FROM AND PROMOTE A LARGE NUMBER OF HORIZONTAL AND VERTICAL COLLABORATIONS WITH ACADEMIC INSTITUTIONS, NCI, PHARMACEUTICAL COMPANIES, AND COOPERATIVE GROUPS.
Department of Health and Human Services
$10.4M
PREDICTION OF PSYCHOSIS IN ALZHEIMER DISEASE
National Science Foundation
$10.3M
BII: UNCOVERING MECHANISMS OF AMPHIBIAN RESILIENCE TO GLOBAL CHANGE FROM MOLECULES TO LANDSCAPES
Department of Health and Human Services
$10.3M
APPALACHIAN TRI-STATE NODE
Department of Health and Human Services
$10.3M
CHANNELS, CALCIUM AND PEPTIDE SECRETION
Department of Health and Human Services
$10.2M
EARLY FAMILY PREVENTION OF ADOLESCENT ALCOHOL, DRUG USE AND PSYCHOPATHOLOGY
Department of Health and Human Services
$10.2M
MOLECULAR AND CELLULAR DETERMINANTS OF DISEASE HETEROGENEITY IN COPD
Department of Health and Human Services
$10M
LONGITUDINAL EXAMINATION OF NEIGHBORHOOD DISADVANTAGE, COGNITIVE AGING, AND ALZHEIMER'S DISEASE RISK IN DISINVESTED, AFRICAN AMERICAN NEIGHBORHOODS - PROJECT SUMMARY AFRICAN AMERICANS (AAS) HAVE DISPROPORTIONATELY HIGHER RATES AND EARLIER ONSET OF ALZHEIMER’S DISEASE AND RELATED DEMENTIAS (ADRD) RELATIVE TO WHITE AMERICANS. ALTHOUGH PRIOR RESEARCH HAS MADE SIGNIFICANT CONTRIBUTIONS TO OUR UNDERSTANDING OF RACIAL DISPARITIES IN ADRD, WE STILL LACK A COMPREHENSIVE UNDERSTANDING OF HOW THE INDIVIDUAL LIVED EXPERIENCE OF BEING AA, INCLUDING CUMULATIVE EXPOSURE TO STRUCTURAL RACISM, CONTRIBUTES TO ELEVATED ADRD RISK AND THE POTENTIAL MECHANISMS UNDERLYING THOSE RISKS. BUILDING ON THE EXISTING, COMMUNITY-BASED RESEARCH INFRASTRUCTURE DEVELOPED BY OUR TEAM’S PREVIOUSLY FUNDED STUDIES, WE WILL FOLLOW A COHORT OF RESIDENTS (N=1133) LIVING IN TWO HISTORICALLY DISINVESTED, PREDOMINANTLY AA COMMUNITIES TO UNDERSTAND HOW DYNAMIC NEIGHBORHOOD SOCIOECONOMIC CONDITIONS ACROSS THE LIFECOURSE CONTRIBUTE TO COGNITIVE OUTCOMES IN MID- AND LATE-LIFE ADULTS. THIS PROPOSAL RESTS ON THE PREMISE THAT NEIGHBORHOOD SEGREGATION AND SUBSEQUENT DISINVESTMENT CONTRIBUTES TO POOR COGNITIVE OUTCOMES FOR AAS VIA FACTORS INCLUDING A) LOWER ACCESS TO EDUCATIONAL OPPORTUNITIES AND B) HIGHER EXPOSURE TO RACE- AND SOCIOECONOMICALLY-RELEVANT STRESSORS, INCLUDING DISCRIMINATION, TRAUMA, AND ADVERSE CHILDHOOD EVENTS. IN TURN, THESE CUMULATIVE EXPOSURES FOSTER PSYCHOLOGICAL VIGILANCE IN RESIDENTS, LEADING TO CARDIOMETABOLIC DYSREGULATION AND SLEEP DISRUPTION, WHICH MAY MEDIATE ASSOCIATIONS BETWEEN NEIGHBORHOOD DISADVANTAGE AND ADRD RISK. WE ALSO WILL EXAMINE POTENTIAL PROTECTIVE FACTORS THAT MAY PROMOTE COGNITIVE HEALTH, INCLUDING NEIGHBORHOOD SOCIAL COHESION, SAFETY, AND SATISFACTION. THE PROPOSED STUDY WILL LEVERAGE OUR EXISTING LONGITUDINAL DATA ON RISK AND PROTECTIVE FACTORS, BIOBEHAVIORAL MEDIATORS, AND BASELINE COGNITIVE ASSESSMENTS, AND WILL INCLUDE: 1) THREE WAVES OF COGNITIVE ASSESSMENTS IN THE FULL COHORT OF PARTICIPANTS WHO ARE 50 YEARS+ (PARTICIPANTS WHO ARE AGED 35-49 YEARS WILL HAVE TWO ASSESSMENTS) AND CLINICAL ADJUDICATION OF ADRD IN PARTICIPANTS WHO ARE 50+ (N=906), 2) ADDITIONAL ASSESSMENTS OF BLOOD PRESSURE AND OBJECTIVE SLEEP, 3) A COMPREHENSIVE ASSESSMENT OF LIFE AND RESIDENTIAL HISTORY USING THE QUESTIONNAIRE FROM THE HEALTH AND RETIREMENT STUDY (HRS); AND 4) IN-DEPTH QUALITATIVE INTERVIEWS TO REVEAL LIFECOURSE OPPORTUNITIES AND BARRIERS EXPERIENCED BY AAS IN ACHIEVING OPTIMAL COGNITIVE HEALTH IN LATE LIFE. UNDERSTANDING HOW STRUCTURAL RACISM HAS INFLUENCED THE LIVED EXPERIENCE OF AAS INCLUDING DYNAMIC CHANGES IN NEIGHBORHOOD CONDITIONS OVER TIME IS CRITICAL TO INFORM MULTI-LEVEL INTERVENTION AND POLICY EFFORTS TO REDUCE PERVASIVE RACIAL AND SOCIOECONOMIC DISPARITIES IN ADRD.
National Science Foundation
$10M
NSF INCLUDES ALLIANCE: STEM PUSH (PATHWAYS FOR UNDERREPRESENTED STUDENTS TO HIGHER EDUCATION) NETWORK
Department of Health and Human Services
$9.9M
BASIC AND CLINICAL STUDIES OF CYSTIC FIBROSIS
Department of Health and Human Services
$9.9M
MIDDLE EAR PRESSURE REGULATION IN HEALTH AND DISEASE
Department of Defense
$9.9M
ENHANCING SOLDIER PROTECTION AND PERFORMANCE
Department of Defense
$9.7M
"PREHOSPITAL AIR MEDICAL PLASMA (PAMPER) TRIAL"
Department of Health and Human Services
$9.7M
PITTSBURGH LIVER RESEARCH CENTER
Department of Health and Human Services
$9.6M
PREDICTORS OF ALTERED CNS STRUCTURE, FUNCTION, AND CONNECTOMICS IN THE ELDERLY USING A HEALTH DISPARITIES FRAMEWORK - ABSTRACT THE GOAL OF THIS PROJECT IS TO LEVERAGE THE DIVERSE SAMPLE IN OUR HUMAN CONNECTOME PROJECT (HCP) STUDY, CONNECTOMICS IN BRAIN AGING (COBRA) , TO INVESTIGATE THE ROLE(S) OF STRUCTURAL AND SOCIAL DETERMINANTS OF HEALTH IN THE NATURAL HISTORY OF ALZHEIMER’S DISEASE (AD) UTILIZING A HEALTH EQUITY FRAMEWORK. WE PROPOSE THAT RACIAL INEQUITIES IN THE DEVELOPMENT OF COGNITIVE IMPAIRMENTS IN THE CONTEXT OF AD ARE DRIVEN BY PERVASIVE STRUCTURAL AND INSTITUTIONALIZED INEQUITIES THAT SHAPE RISK AND DISADVANTAGE AT MULTIPLE LEVELS, INCLUDING BIOLOGICAL, ENVIRONMENTAL, BEHAVIORAL, SOCIOCULTURAL, AS PROPOSED IN THE NIA HEALTH DISPARITIES RESEARCH FRAMEWORK. OUR ORGANIZING PRINCIPLE IS THAT THE EXPRESSION OF COGNITIVE DYSFUNCTION IN THE ELDERLY IS THE RESULT OF TWO INDEPENDENT PROCESSES AFFECTING THE CONNECTOME — THE FIRST IS THE NEUROPATHOLOGY ASSOCIATED WITH AD. THE SECOND PROCESS HISTORICALLY HAS BEEN REFERRED TO AS “MODIFIABLE INDIVIDUAL RISK FACTORS”, HOWEVER, THIS FAILS TO RECOGNIZE THAT INDIVIDUAL RISK IS INFLUENCED BY FACTORS THAT ARE OUTSIDE OF AN INDIVIDUAL’S CONTROL, AND WHICH WILL BE MEASURED USING A HEALTH EQUITY FRAMEWORK. WE WILL AUGMENT OUR EXISTING SAMPLE (50% BLACK, 65% FEMALE) WITH AN ADDITIONAL 150 PARTICIPANT (TOTAL SAMPLE ~400 WITH UP TO FOUR STUDY VISITS). EACH OF THE PARTICIPANTS WILL CONTRIBUTE THE HCP-SPECIFIED DEMOGRAPHIC, BEHAVIORAL AND LABORATORY DATA. ALL OF THE PARTICIPANTS WILL UNDERGO EXTENSIVE BRAIN IMAGING BIANNUALLY INCLUDING MRI AND PET (AMYLOID AND TAU TRACERS). ALL OF THE MRI DATA WILL BE UPLOADED TO THE CONNECTOME COORDINATING FACILITY, AND THE BEHAVIORAL/COGNITIVE, PET DATA WILL BE UPLOADED TO THE NIMH DATA ARCHIVE. LOCALLY, WE WILL USE THESE DATA TO ADDRESS SPECIFIC QUESTIONS RELATED TO STRUCTURE, FUNCTION, AD, AGING AND VASCULAR DISEASE IN MULTI-MODALITY STUDIES LEVERAGING THE DIFFERENTIAL ADVANTAGES OF MRI, FMRI, AND IN VIVO ASS AND TAU IMAGING.
Department of Health and Human Services
$9.6M
DEFINING MECHANISMS OF PAIN RELIEF ASSOCIATED WITH DORSAL ROOT GANGLION AND SPINAL CORD STIMULATION - CHRONIC PAIN IS A DEBILITATING CONDITION FOR WHICH THERE IS A PRESSING NEED FOR SAFE, EFFECTIVE TREATMENTS AS IS HIGHLIGHTED BY THE ONGOING OPIOID CRISIS. ONE POTENTIAL SOLUTION TO THIS PROBLEM ARE NEUROMODULATORY DEVICES SUCH AS SPINAL CORD STIMULATORS AND DORSAL ROOT GANGLION STIMULATORS THAT ARE CURRENTLY APPROVED BY THE FDA FOR THE TREATMENT OF PAIN. WHILE THESE DEVICES HAVE CONSISTENTLY GENERATED PROMISING RESULTS, THEY ARE ONLY USED IN A FRACTION OF CHRONIC PAIN PATIENTS AS AN INTERVENTION OF LAST RESORT. ONE OF THE REASONS THAT THESE DEVICES ARE NOT USED MORE BROADLY IS BECAUSE THEIR MECHANISM OF ACTION IS LARGELY UNKNOWN. HERE WE PROPOSE A SERIES OF PARALLEL AND COMPLEMENTARY EXPERIMENTS TO INVESTIGATE THE MECHANISMS OF PAIN RELIEF FOR SPINAL CORD (SCS) AND DORSAL ROOT GANGLION (DRGS) STIMULATION, WHERE CONVENTIONAL STIMULATION PARAMETERS WILL BE USED FOR DRGS, AND CONVENTIONAL, BURST AND KILOHERTZ (KHZ) STIMULATION WILL BE USED FOR SCS. WE WILL FOCUS ON THE TWO PREVAILING MODELS USED TO EXPLAIN THE THERAPEUTIC EFFICACY OF THESE DEVICES: 1) GATE-CONTROL, WHEREIN STIMULATION OF LARGE DIAMETER AFFERENT FIBERS ACTIVATES INHIBITORY INTERNEURONS THAT BLOCK NOCICEPTIVE SIGNALS FROM REACHING THE BRAIN; AND 2) T-JUNCTION FILTERING, WHEREIN STIMULATION OF SENSORY NEURONS LEADS TO CONDUCTION FAILURE AT THE T-JUNCTION IN NOCICEPTIVE FIBERS IN THE DRG, BLOCKING NOCICEPTIVE INPUTS FROM REACHING THE SPINAL CORD. EXPERIMENTS DESIGNED TO TEST THESE MODELS ARE DESCRIBED UNDER FOUR SPECIFIC AIM IN MICE AND RATS WITH AND WITHOUT CHRONIC PAIN INDUCED WITH CHRONIC COMPRESSION OF THE DRG, AND IN A HUMAN DRG NERVE PREPARATION. IN AIM 1 WE WILL DETERMINE WHICH NEURONS (PRIMARY AFFERENT AND/OR DORSAL HORN) ARE ACTIVATED BY SCS AND DRGS WITH 2P-CALCIUM IMAGING IN MICE, AND SINGLE UNIT RECORDING IN RATS AND HUMAN TISSUE. WE WILL USE THE DATA GENERATED AT AN UNPRECEDENTED LEVEL OF DETAIL TO REFINE COMPUTATIONAL MODELS OF THE CELLS AND CIRCUITS ENGAGED BY THESE DEVICES. IN AIM 2 WE WILL CONFIRM THE EFFICACY OF DRGS AND SCS NEUROMODULATION ON SIMPLE REFLEXIVE RESPONSES AND COMPLEX NOCICEPTIVE BEHAVIORS IN RATS AND MICE. THE TIMING AND RELATIVE EFFICACY OF THE SITE AND PARAMETERS OF NEUROMODULATION WILL INFORM COMPUTATIONAL MODELS AND MECHANISTIC STUDIES. IN AIM 3 WE WILL DIRECTLY TEST THE GATE-CONTROL MODEL USING A NOVEL STRATEGY OF 2P CA2+ IMAGING IN MICE ENABLING IDENTIFICATION OF SUBPOPULATIONS OF INHIBITORY, EXCITATORY, AND PROJECTION NEURONS IN THE SAME PREPARATION. THIS WILL BE COMBINED WITH SINGLE UNIT AND MEA RECORDINGS FROM RATS AND MICE, ALL DONE IN AN ITERATIVE FASHION WITH COMPUTATIONAL MODELING. IN AIM 4 WE WILL TEST THE T-JUNCTION FILTERING MODEL WITH DIRECT MEASUREMENTS OF TRANSMISSION EFFICIENCY IN RAT AND HUMAN TISSUE. PHARMACOLOGICAL STUDIES AND COMPUTATIONAL MODELING WILL INVESTIGATE SPECIFIC MECHANISMS RESPONSIBLE FOR THIS FILTERING. THE RESULTS FROM THESE CONCEPTUALLY AND TECHNICALLY INNOVATIVE STUDIES WILL PROVIDE A MAJOR ADVANCE IN OUR UNDERSTANDING OF THE MECHANISMS UNDERLYING THE EFFECTIVENESS OF THESE NEUROMODULATORY DEVICES AND POTENTIALLY OFFER NEW TREATMENT STRATEGIES FOR IMPROVED PAIN RELIEF.
Department of Health and Human Services
$9.6M
IDENTIFYING COGNITIVE MARKERS OF LATE-LIFE SUICIDE
Department of Defense
$9.6M
PROTEOMICS AND BIOINFORMATICS CORE FACILITIES
Department of Health and Human Services
$9.5M
TRANSDISCIPLINARY STUDIES OF CBT FOR ANXIETY IN YOUTH
Department of Health and Human Services
$9.4M
ROLE OF TIM MOLECULES IN REGULATORY AND INFLAMMATORY B CELLS IN ALLO ANDAUTOIMMUNITY
Department of Health and Human Services
$9.4M
BARIATRIC SURGERY CLINICAL RESEARCH CONSORTIUM
Department of Health and Human Services
$9.2M
MENTAL HEALTH IN AUTISTIC ADULTS: AN RDOC APPROACH - CENTER OVERVIEW ABSTRACT THE UNIVERSITY OF PITTSBURGH AUTISM CENTER OF EXCELLENCE (ACE) DIRECTLY ADDRESSES THE INTERAGENCY AUTISM COORDINATING COMMITTEE’S CALL FOR RESEARCH ON ADULT MENTAL HEALTH TO IMPROVE SAFETY AND QUALITY OF LIFE, AND TO REDUCE PREMATURE MORTALITY. WE DO SO BY GENERATING THE MEASURES AND MECHANISTIC TARGETS NEEDED TO IMPROVE MENTAL HEALTH AND REDUCE SUICIDE RISK IN AUTISTIC ADULTS. WE ADDRESS THIS UNDERSTUDIED AND CRITICAL TOPIC IN AUTHENTIC PARTNERSHIP WITH AUTISTIC ADULTS AND THEIR ALLIES. WE EMPHASIZE MECHANISTIC TRANSLATION, BRING NEW RESEARCHERS TO WORK ON AUTISM, AND PROVIDE AN ACADEMIC HOME FOR JUNIOR RESEARCHERS GETTING STARTED IN THIS AREA. WE WILL ASSEMBLE A PITTSBURGH ACE COHORT OF 200 AUTISTIC AND 100 NON-AUTISTIC 18- TO 65-YEAR-OLD ADULTS (= 50 WITH RECENT SUICIDALITY IN EACH GROUP) WHO WILL COMPLETE THREE PROJECTS THAT ARE FOCUSED ON DIFFERENT UNITS OF ANALYSIS (SELF-REPORT, BEHAVIOR AND AMBULATORY PHYSIOLOGY, AND NEURAL CIRCUITS), TIME SCALES, AND PRIMARY OUTCOMES, ALL RELATED TO ADULT MENTAL HEALTH. PROJECT 1 WILL PROVIDE THE FIRST DIMENSIONAL SELF-REPORT QUESTIONNAIRE OF SUICIDALITY DEVELOPED FOR ASD AND THE FIRST LONGITUDINAL CHARACTERIZATION OF SUICIDALITY IN AUTISTIC ADULTS. PROJECT 2’S INNOVATIVE PHYSIOLOGICALLY-TRIGGERED ECOLOGICAL MOMENTARY DESIGN WILL CHARACTERIZE PROXIMAL RISK PROCESSES FOR SUICIDAL IDEATION, NON-SUICIDAL SELF-INJURY, AND IMPULSIVE AGGRESSION IN A TEMPORALLY SENSITIVE MANNER TO ALLOW FOR FUTURE INTERVENTIONS PRIOR TO ESCALATION OF EMOTION DYSREGULATION AND HARMFUL OUTCOMES. PROJECT 3 TESTS A NEURAL MECHANISTIC MODEL OF EARLY NEURAL HYPER-REACTIVITY TO STIMULI FOLLOWED BY DECREASED RECRUITMENT OF REGULATORY RESOURCES AND CONSEQUENT PHYSIOLOGICAL, SUBJECTIVE, AND BEHAVIORAL HYPO-REACTIVITY. OUR CLINICAL CORE PROVIDES DATA TO ALL OF THE PROJECTS TO CHARACTERIZE THE SAMPLE, INCLUDING NOVEL PHENOTYPIC MEASURES (E.G., A BIOMARKER OF AGING BASED ON STRUCTURAL BRAIN IMAGES). OUR CENTER STRUCTURE ENABLES US TO INTEGRATE DATA FROM ALL SOURCES TO ENHANCE THE IMPACT OF INDIVIDUAL PROJECTS. FOR EXAMPLE, WE WILL SPEED TRANSLATION BY CONNECTING A BIOLOGICAL CAUSAL MECHANISM TO LIVED EXPERIENCE AND LONGITUDINAL OUTCOMES. WE WILL POOL ALL DATA TO IDENTIFY THE MOST SALIENT PREDICTORS OF SUICIDALITY TRAJECTORIES, PROVIDING A SIGNIFICANT ADVANCE OVER APPROACHES THAT CONSIDER SMALL SETS OF PREDICTORS AND ENABLING DETERMINATION OF RELATIVE CONTRIBUTIONS TO RISK. WE WILL SHED LIGHT ON HETEROGENEITY IN OUTCOMES BY CONNECTING SUBGROUPS BASED ON DAILY DYNAMICS OF EMOTION AND PHYSIOLOGICAL REACTIVITY AND REGULATION TO NEURAL REACTIVITY AND SUICIDALITY. OUR AGE RANGE AND TRANSDIAGNOSTIC, SUICIDAL COMPARISON GROUP ALLOWS US TO DETERMINE WHAT IS UNIQUE ABOUT MENTAL HEALTH IN ASD AND HOW AGING MAY PLAY A ROLE. WE WILL EMPLOY NOVEL MEANS TO DISSEMINATE THIS CRITICAL INFORMATION TO THE COMMUNITY WITH THE HELP OF OUR TEAM OF AUTISTIC PARTNERS FROM DIVERSE BACKGROUNDS. THIS PROCESS WILL ENSURE THAT OUR CENTER WILL NOT ONLY ENGAGE INDIVIDUALS FROM GROUPS THAT HAVE BEEN MARGINALIZED, BUT WILL ALSO CREATE AND MAINTAIN MUTUALLY BENEFICIAL AND REWARDING RELATIONSHIPS THAT WILL ENHANCE AND ENRICH OUR RESEARCH SAMPLE, OUTCOMES, AND OVERALL IMPACT.
Department of Health and Human Services
$9.2M
MOLECULAR PHYSIOLOGY OF THE LUNG
Department of Health and Human Services
$9.1M
FUNCTIONAL NEUROANATOMY CORRELATES OF WORRY IN OLDER ADULTS
Department of Health and Human Services
$9.1M
IDENTIFICATION OF TDP-43 MODIFIERS THROUGH SINGLE-CELL TRANSCRIPTIONAL AND EPIGENOMIC DISSECTION OF ALS AND FTLD-MND - ABSTRACT AMYOTROPHIC LATERAL SCLEROSIS (ALS) AND FRONTOTEMPORAL LOBAR DEGENERATION (FTLD) ARE TWO FATAL NEURODEGENERATIVE CONDITIONS WITH NO CURRENT TREATMENT TO PREVENT, DECELERATE OR STOP NEURONAL DEATH IN PATIENTS. ALS AND FTLD ARE CLINICALLY DISTINCT BUT SHOW AN OVERLAP IN POSTMORTEM BRAIN PATHOLOGY AND GENETIC FACTORS: NUCLEAR CLEARANCE AND CYTOPLASMIC ACCUMULATION OF TDP-43 IN AFFECTED CENTRAL NERVOUS SYSTEM (CNS) REGIONS IS OBSERVED IN 98% OF ALS AND 50% OF FTLD PATIENTS. WHILE INITIAL SYMPTOMS LEAD TO THE DIAGNOSIS OF EITHER ALS OR FTLD, UP TO 50% OF ALS PATIENTS EVENTUALLY DEVELOP SYMPTOMS OF FTLD, WITH ~15% OF PATIENTS ULTIMATELY RECEIVING BOTH DIAGNOSES (FTLD WITH MOTOR NEURON DISEASE, FTLD/MND). MUTATIONS IN THE GENE ENCODING TDP-43 (TARDBP) LEAD TO RARE CASES OF ALS, WHILE TDP-43 PATHOLOGY IS OBSERVED IN PATIENTS CARRYING MORE PREVALENT MUTATIONS, SUCH AS A PATHOLOGICAL C9ORF72 HEXANUCLEOTIDE REPEAT EXPANSION (C9ORF72+)—THE MOST COMMON GENETIC CAUSE OF ALS AND FTLD IDENTIFIED THUS FAR. TDP-43 THEREFORE APPEARS TO BE A PIVOTAL AND CONVERGENT FACTOR IN THE PATHOGENESIS OF BOTH ALS AND FTLD. DESPITE THIS, HOWEVER, THE REASONS FOR SELECTIVE VULNERABILITY OF MOTOR NEURONS, THE MECHANISMS RESPONSIBLE FOR TDP-43 MISLOCALIZATION, AND THE IMPACT ON NEURONAL HEALTH OF NUCLEAR TDP-43 EXCLUSION AND ABERRANT LIQUID-LIQUID PHASE SEPARATION UNDERLYING CYTOPLASMIC DEMIXING REMAIN UNKNOWN. TO ADDRESS THIS CHALLENGE, IN AIM 1, WE SYSTEMATICALLY PROFILE THE TRANSCRIPTIONAL AND EPIGENOMIC ALTERATIONS OF ALS AND FTLD/MND PATIENTS AT SINGLE-CELL RESOLUTION USING POST-MORTEM CNS SAMPLES. IN AIM 2, WE INTEGRATE THE RESULTING DATASETS TO STUDY THE LINK BETWEEN GENETIC, EPIGENOMIC, TRANSCRIPTIONAL, AND CELLULAR SIGNATURES OF ALS AND FTLD/MND. WE ASSOCIATE THESE LINKS WITH AVAILABLE CLINICAL INFORMATION, ELUCIDATE THE GENES AND BIOLOGICAL PATHWAYS ALTERED IN EACH, AND PREDICT NEW THERAPEUTIC TARGETS. IN AIM 3, WE VALIDATE THE MOLECULAR AND CELLULAR EFFECTS OF THESE TARGETS BY ASSESSING THEIR IMPACT ON NEURONAL VIABILITY AND TDP-43 FUNCTIONS/AGGREGATION USING HIGH-THROUGHPUT DIRECTED PERTURBATION EXPERIMENTS. WE STUDY BOTH CELL-AUTONOMOUS AND NON-CELL-AUTONOMOUS EFFECTS OF THESE PERTURBATIONS IN HUMAN DURA FIBROBLAST-DERIVED IPSC NEURONS AND ASTROGLIA. IN AIM 4, WE PERFORM NEUROPATHOLOGICAL ANALYSES OF TDP-43 MODIFIERS IN ALS AND FTLD/MND POSTMORTEM TISSUES, AND ENDEAVOR TO RESCUE IN VIVO PATHOLOGY AND PHENOTYPES IN A MOUSE MODEL. THE RESULTING DATASETS, ANALYSES, AND DURA-DERIVED IPSCS WILL PROVIDE AN INVALUABLE RESOURCE TO UNDERSTAND THE MECHANISMS OF TDP-43 PATHOLOGY IN ALS AND FTLD/MND, AND MAY REVEAL PUTATIVE THERAPEUTIC TARGETS ABLE TO MITIGATE TDP-43 PATHOLOGY THROUGH GENETIC MANIPULATION.
Department of Defense
$9M
TAS::57 3600::TAS "(MURI-10) QUANTUM PISTON: QUANTUM PRESERVATION SIMULATION AND TRANSFER IN OXIDE NANOSTRUCTURES "
Department of Health and Human Services
$8.9M
PRECONCEPTION STRESS EXPOSURE: IMPACT ON PREGNANCY AND OFFSPRING NEURODEVELOPMENT
Department of Health and Human Services
$8.9M
NEW CONCEPTS, METHODOLOGIES AND SCAFFOLDS FOR DIVERSITY-ORIENTED ORGANIC SYNTHES
Department of Health and Human Services
$8.9M
FAMILIES OF COHORT SURVIVORS OVER 90 - STUDY CENTER
Department of Health and Human Services
$8.8M
CARDIOVASCULAR AND HIV/AIDS EFFECTS ON BRAIN STRUCTURE/FUNCTION AND COGNITION
Department of Health and Human Services
$8.7M
NCI ET-CTN WITH PHASE I EMPHASIS AT UPCI
Department of Health and Human Services
$8.5M
SARCOIDOSIS AND A1AT GENOMICS & INFORMATICS CENTER
Department of Health and Human Services
$8.4M
MODELING THE GENETIC BASIS FOR HUMAN CONGENITAL HEART DISEASE IN MICE
Department of Health and Human Services
$8.4M
GENETIC ARCHITECTURE OF ALZHEIMER?S DISEASE PROTEINOPATHIES - THIS IS A COLLABORATIVE STUDY BETWEEN LEADING EXPERTS IN THE FIELD TO EXTEND OUR ONGOING EFFORTS TO DELINEATE THE COMPLETE GENETIC BASIS OF THE TWO AD-SPECIFIC PROTEINOPATHIES (ASS AND PATHOLOGIC TAU) BY WHOLE GENOME SEQUENCING (WGS) USING WELL-CHARACTERIZED AND LARGE AMYLOID-PET AND CSF ASS42/TAU DATASETS WITH CLINICAL OUTCOMES OF DEMENTIA FOLLOWED BY TESTING THE EFFECTS OF IDENTIFIED SIGNIFICANT VARIANTS ON DOWNSTREAM NEURODEGENERATION MARKERS, AND PERFORMING EXTENSIVE BIOINFORMATICS AND FUNCTIONAL STUDIES. THE PRIMARY OBJECTIVE OF THIS APPLICATION IS TO PERFORM AND ANALYZE WGS IN ADEQUATELY POWERED LARGE DISCOVERY SAMPLES WITH WELL-CHARACTERIZED ASS AND TAU DATA ALONG WITH CLINICAL OUTCOMES OF DEMENTIA TO IDENTIFY PUTATIVE FUNCTIONAL VARIANTS ASSOCIATED WITH ASS AND TAU PATHOLOGIES.
Department of Health and Human Services
$8.4M
REGULATORY IMMUNE CELL THERAPY, PROMOTION OF TOLERANCE AND UNDERLYING MECHANISMS IN NHP RENAL TRANSPLANTATION
Department of Health and Human Services
$8.3M
LOOK AHEAD: ACTION FOR HEALTH IN DIABETES
Department of Health and Human Services
$8.3M
CONDUCT DISORDER & DEPRESSION IN GIRLS: PRECURSORS, DEVELOPMENT AND COMORBIDITY
Department of Health and Human Services
$8.2M
MOLECULAR BIOLOGY OF HEMORRHAGIC SHOCK
Department of Defense
$8.2M
STUDY OF TRANEXAMIC ACID DURING AIR MEDICAL PREHOSPITAL TRANSPORT TRIAL (STAAMP TRIAL)
Department of Health and Human Services
$8.2M
ACISR FOR LATE-LIFE DEPRESSION PREVENTION
Department of Health and Human Services
$8.1M
PITT RBL - OVERALL ABSTRACT: THE REGIONAL BIOCONTAINMENT LABORATORY (RBL) WITHIN THE CENTER FOR VACCINE RESEARCH (CVR) AT THE UNIVERSITY OF PITTSBURGH IS THE BIOSAFETY LEVEL-3 (BSL-3) HUB FOR INFECTION BIOLOGY. THE MISSION OF THE RBL IS THREEFOLD, TO WORK ON PATHOGEN EMERGENCE, EVOLUTION AND HOST-TO-HOST TRANSMISSION, TO STUDY THE PATHOGENESIS OF EMERGING INFECTIOUS DISEASES AND TO ACCELERATE PRE-CLINICAL DEVELOPMENT OF NOVEL INTERVENTIONS AND MEDICAL COUNTERMEASURES FOR PANDEMIC PREPAREDNESS AND BIODEFENSE. OUR VISION IS TO BE A GLOBALLY RECOGNIZED, HIGHLY- COLLABORATIVE, CREATIVE AND FORWARD-FACING TEAM OF INFECTION BIOLOGISTS WHO ARE POISED TO RESPOND TO EMERGING BIOLOGICAL THREATS BOTH AT THE NATIONAL AND INTERNATIONAL LEVEL. THE ENTIRE FACILITY IS REGISTERED WITH THE DIVISION OF SELECT AGENTS AND TOXINS (DSAT). IT BRINGS TOGETHER INFECTION BIOLOGISTS AND CLINICIANS FROM A VARIETY OF DISCIPLINES WHO REQUIRE BSL-3 AND ANIMAL (A)BSL-3 FACILITIES FOR THEIR WIDE RANGING VIRAL AND BACTERIAL RESEARCH PROGRAMS. WE PROPOSE TO ESTABLISH OPERATIONS, PRACTICES AND INTEGRATED SERVICES CORES AND FORMALLY OPERATIONALIZE OUR EXISTING STRUCTURES. THESE HAVE EVOLVED FROM THE TIME THE RBL WAS ESTABLISHED, AND ALTHOUGH THEY HAVE SERVED THEIR PURPOSE, REQUIRE MODERNIZATION TO ENSURE THEY WILL REMAIN CURRENT AND OPERATIONALLY FIT-FOR-PURPOSE. THE OPERATIONS CORE WILL HAVE OVERALL MANAGEMENT AND BUDGETARY RESPONSIBILITY FOR THE RBL. IT WILL ADMINISTER THE DAILY, WEEKLY, MONTHLY AND YEARLY BSL-3 ACTIVITIES ESSENTIAL FOR THE SUPPORT AND SERVICES ARMS OF THE RBL TO FUNCTION. THIS WILL ENSURE THAT THE BSL-3 LABORATORIES ARE RUN AND MAINTAINED AT THE HIGHEST STANDARDS AND THEY ARE SAFE AND SECURE. THE PRACTICES CORE WILL SUPPORT ALL THE BASIC FUNCTIONS OF THE RBL ENABLING SCIENTIFIC PROGRAMS TO BE RIGOROUSLY MANAGED AND ENSURING OVERALL DATA INTEGRITY FOR REPRODUCIBLE OUTCOMES. IT WILL PROVIDE THE REQUISITE THEORETICAL AND PRACTICAL TRAININGS TO ONBOARD NEW RBL INVESTIGATORS AND THEIR TEAMS WHO WISH TO WORK IN BSL-3 AND ABSL-3 BIOCONTAINMENT. IT WILL PROVIDE BIOSAFETY AND BIOSECURITY SUPPORT AND GUARANTEE THE FACILITY MEETS ALL CURRENT COMPLIANCE REGULATIONS FOR TIER 1 SELECT AGENT REGISTERED LABORATORIES. THE INTEGRATED SERVICES CORE WILL DELIVER A WIDE RANGE OF HIGH QUALITY BSL-3 AND ABSL-3 SERVICES FOR INTERNAL USERS AND EXTERNAL COLLABORATORS. THESE WILL BE RIGOROUSLY OVERSEEN BY ACADEMIC AND SERVICE LEADS AND REVIEWED ANNUALLY WITH THE ASSISTANCE OF AN EXTERNAL RBL DIRECTOR, OTHER BSL-3 EXPERTS AND AN INTERNAL SCIENTIFIC ADVISORY GROUP. OPERATIONAL SUPPORT FOR THE RBL IN PITTSBURGH WILL ENSURE WE ARE READY TO SUPPORT ANY NATIONAL RESPONSE TO A RANGE OF EMERGING INFECTIOUS DISEASES IN THE EVENT OF ANOTHER PANDEMIC OR BIOTERRORISM ATTACK. SUPPORTING THIS COHORT OF BSL-3 SCIENTISTS, WHO CAN PIVOT TO WORK ON NEW PATHOGENS IN AN EMERGENCY, IS CERTAIN TO PAY DIVIDENDS.
Department of Health and Human Services
$8M
OUTPATIENT VE FOR SEASONAL FLU, PANDEMIC FLU AND RSV IN A LARGE, DIVERSE NETWORK
Department of Health and Human Services
$8M
NATIVE-LIKE ENVELOPE TRIMER THERAPEUTIC VACCINATION FOR INDUCTION OF BROADLY NEUTRALIZING ANTIBODIES TO FACILITATE HIV FUNCTIONAL CURE
Department of Defense
$8M
NEUROIMMUNOENDOCRINE INTERFACE: EXPLORING A UNIFYING AXIS FOR PRECISION CARE IN PH AND TBI (NEXUS)
Department of Health and Human Services
$8M
ROLE OF WNT/BETA-CATENIN SIGNALING IN LIVER DEVELOPMENT
Department of Health and Human Services
$7.9M
CARDIOVASCULAR BEHAVIORAL MEDICINE RESEARCH TRAINING
Department of Health and Human Services
$7.9M
A NEW STATISTICAL PARADIGM FOR MEASURING PSYCHOPATHOLOGY DIMENSIONS IN YOUTH
Department of Health and Human Services
$7.9M
MECHANISMS/TREATMENTS OF LOWER URINARY TRACT DYSFUNCTION AFTER SPINAL CORD INJURY
Department of Health and Human Services
$7.9M
COVID-19 MODELING URGENT GRANT PROGRAM FOR THE MODELING OF INFECTIOUS DISEASE AGENT STUDY
Department of Health and Human Services
$7.9M
RFA-IP-22-004, EVALUATING RESPIRATORY VIRUS VACCINE EFFECTIVENESS IN A LARGE, DIVERSE HEALTHCARE SYSTEM
Department of Health and Human Services
$7.9M
MURINE MEMORY B CELL DEVELOPMENT AND FUNCTION
Department of Health and Human Services
$7.8M
BIOLOGICAL AND INFORMATION PROCESSING MECHANISMS UNDERLYING AUTISM
Department of Health and Human Services
$7.7M
PET IMAGING OF CORTICAL DOPAMINE TRANSMISSION IN COCAINE ADDICTION
Department of Health and Human Services
$7.7M
VIRUS-CELL INTERACTIONS AFFECTING HSV GENE EXPRESSION
Department of Health and Human Services
$7.7M
REHABILITATION MEDICINE SCIENTIST TRAINING (RMST) PROGRAM
Department of Health and Human Services
$7.7M
UNIVERSITY OF PITTSBURGH CLINICAL AND TRANSLATIONAL SCIENCE INSTITUTION
Department of Health and Human Services
$7.7M
SEARCH FOR THE ALZHEIMER'S GENE ON CHROMOSOME 10
Department of Health and Human Services
$7.6M
NCI NCTN-NETWORK LEAD ACADEMIC PARTICIPATING SITE AT UPMC HILLMAN CANCER CENTER
Department of Health and Human Services
$7.6M
UNIVERSITY OF PITTSBURGH PREPAREDNESS AND EMERGENCY RESPONSE RESEARCH CENTER
Department of Health and Human Services
$7.6M
PRECISION APPROACH TO HEALTHCARE ENROLLMENT SITE (PA CARES)
Department of Health and Human Services
$7.6M
NATIONAL CONSORTIUM ON ALCOHOL AND NEURODEVELOPMENT IN ADOLESCENCE:PITTSBURGH
Department of Health and Human Services
$7.6M
ENHANCED DETECTION SYSTEM FOR HEALTHCARE-ASSOCIATED TRANSMISSION OF INFECTION
Department of Health and Human Services
$7.5M
MEDICAL SCIENTIST TRAINING PROGRAM - OUR UNIVERSITY OF PITTSBURGH-CARNEGIE MELLON UNIVERSITY MSTP PREPARES MD-PHD TRAINEES WITH THE EXPERTISE AND VERSATILITY TO HAVE HIGHLY PRODUCTIVE CAREERS AS PHYSICIAN SCIENTISTS AND LEADERS IN AN EVOLVING SCIENTIFIC AND MEDICAL ENVIRONMENT. STUDENTS IN OUR BI-INSTITUTIONAL MSTP BENEFIT FROM A WORLD-CLASS RESEARCH AND CLINICAL COMMUNITY AND A CORE GROUP OF 158 WELL-FUNDED MENTORS IN 22 AFFILIATED GRADUATE PROGRAMS IN WHICH PRIOR MSTP TRAINEES HAVE THRIVED WITH A 62% F30 SUCCESS RATE AND MEDIAN OF SIX PUBLICATIONS OVER THE LAST FIVE YEARS. CURRENTLY, OUR MSTP HAS 94 TRAINEES, 55% OF WHOM ARE WOMEN AND 15% FROM UNDERREPRESENTED BACKGROUNDS. UNIQUE FEATURES OF THE MSTP INCLUDE A REQUIRED CORE CURRICULUM OF SEVEN COURSES BEYOND MEDICAL AND GRADUATE SCHOOL COURSEWORK THAT BUILD SPECIFIC RESEARCH, TRANSLATIONAL, AND PROFESSIONAL COMPETENCIES REQUIRED FOR DURABLE SUCCESS AS PHYSICIAN SCIENTISTS. TRAINING IN RIGOR AND REPRODUCIBILITY, RESPONSIBLE CONDUCT OF RESEARCH, AND HEALTH EQUITY ARE INTEGRATED THROUGHOUT THE CURRICULUM AND RESEARCH AND CLINICAL TRAINING EXPERIENCES. OUR FACULTY ARE ALSO TRAINED IN THESE AREAS AND ENGAGE IN CASE-BASED WORKSHOPS TO LEARN AND SHARE BEST-PRACTICES IN MENTORING MSTP TRAINEES. ADDITIONAL FEATURES INCLUDE ONE-ON-ONE EXECUTIVE COACHING SESSIONS FOR STUDENTS, EACH STUDENT'S PERSONAL CAREER ADVISOR WHO SERVES AS ADVOCATE, GUIDE, AND IDP REVIEWER FROM MATRICULATION TO GRADUATION AND BEYOND, AND THE PROGRAMMATIC AND INTELLECTUAL INTEGRATION OF CLINICAL AND RESEARCH TRAINING. OBJECTIVES INCLUDE: (1) IMPARTING TRANSFORMATIONAL KNOWLEDGE AND THINKING SKILLS. WE BUILD STUDENTS' ABILITY TO FRAME TESTABLE HYPOTHESES ADDRESSING SIGNIFICANT RESEARCH QUESTIONS THAT CAN BE LINKED TO CLINICAL KNOWLEDGE AND PREPARE TRAINEES TO PLAN, CONDUCT, ANALYZE, AND PUBLISH SIGNIFICANT, RIGOROUS HIGH-QUALITY, REPRODUCIBLE RESEARCH AND OBTAIN FUNDING TO SUPPORT IT. (2) EXPANDING TRAINEE'S TOOLKIT. WE POSITION TRAINEES TO MEET EVOLVING CHALLENGES IN HEALTH AND DISEASE AS WELL AS THE DEMANDS ON THE PHYSICIAN SCIENTIST WORKFORCE, PREPARING THEM FOR CRITICAL APPRAISAL AND USE OF NEW TECHNOLOGIES AND INFORMATICS. (3) BUILDING SKILLS FOR FORGING PRODUCTIVE PARTNERSHIPS. WE TRAIN STUDENTS TO DEVELOP AND REFINE IDEAS WHILE ENGAGING STAKEHOLDERS, WORK EFFECTIVELY IN TEAMS, COMMUNICATE AND LEARN FROM DIVERSE AUDIENCES, AND CONVEY THE JOY OF DISCOVERY. IN ADDITION TO MEASURING DELIVERABLES AND CAREER MILESTONES AS OUTCOMES, WE WILL TEST THE ABILITY OF THE PROGRAM TO BUILD STUDENT CONFIDENCE IN RESEARCH SELF-EFFICACY AND PROFESSIONAL SELF-EFFICACY. EXPERT INPUT IS ENGAGED FOR LEARNING ASSESSMENT AND STRATEGIC PLANNING TO ALLOW OUR MSTP TO REMAIN DYNAMIC AND INCLUSIVE AND ADAPT TO THE SCIENTIFIC LANDSCAPE.
Department of Health and Human Services
$7.5M
NEXT GENERATION ASSOCIATION STUDIES OF ADIPOSITY IN SAMOANS ENHANCED BY A SAMOAN-SPECIFIC WHOLE GENOME SEQUENCE REFERENCE PANEL
Department of Defense
$7.5M
TOPOLOGICAL SPIN QUBITS BASED ON GRAPHENE NANORIBBONS
Department of Health and Human Services
$7.5M
EXCISION REPAIR OF ENVIRONMENTAL TELOMERE DAMAGE
Department of Health and Human Services
$7.5M
LONGITUDINAL ASSESSMENT OF MANIC SYMPTOMS (LAMS)
Department of Health and Human Services
$7.5M
ENHANCING THE SAFETY, EFFICIENCY, AND RESEARCH CAPACITY OF THE UNIVERSITY OF PITTSBURGH REGIONAL BIOCONTAINMENT LABORATORY TO STUDY VIRUS FAMILIES OF GREATEST PANDEMIC CONCERN - ABSTRACT. IN 2008, THE UNIVERSITY OF PITTSBURGH OPENED A REGIONAL BIOCONTAINMENT LABORATORY (RBL). RESEARCH AT THE RBL HAS GROWN SIGNIFICANTLY SINCE THEN, WITH INVESTIGATORS WORKING ON SEVERAL HIGHLY INFECTIOUS MICROBIAL AGENTS REQUIRING BSL2 AND ABSL2 FACILITIES. CURRENT RBL RESEARCH PROJECTS COVER MULTIPLE VIRUSES IN 5 OF THE 7 RNA VIRUS FAMILIES OF PANDEMIC CONCERN AS DEFINED BY NIH, INCLUDING, BUNYAVIRALES, CORONAVIRIDAE, FLAVIVIRIDAE, PARAMYXOVIRIDAE, AND TOGAVIRIDAE. THE RBL IS AN INVALUABLE RESOURCE FOR THE UNIVERSITY OF PITTSBURGH, WESTERN PENNSYLVANIA, AND INSTITUTIONS IN THE US, EUROPE AND SOUTH AMERICA. INDEED, THE RBL RECEIVED THE SARS-COV-2 VIRUS IN MID-FEBRUARY, 2020, AND RECEIVED ALMOST $5M IN MARCH 2020 FROM THE INTERNATIONAL COALITION FOR EPIDEMIC PREPAREDNESS INNOVATIONS TO PURSUE VACCINE DEVELOPMENT FOR COVID-19. THE CONTINUED SUCCESS OF THE RBL IS ESSENTIAL FOR THE US TO CONDUCT THE NECESSARY RESEARCH TO BE PREPARED FOR THE RAPID DEVELOPMENT AND TESTING OF VACCINES AND THERAPEUTICS IN RESPONSE TO FUTURE PANDEMICS SIMILAR TO THE RECENT SARS-COV-2. OVER THE LAST 14 YEARS, THE INFRASTRUCTURE AND FACILITIES IN THE RBL HAVE BEGUN TO DEGRADE, WITH SOME REACHING THE END OF THEIR USEFULNESS. THE FOCUS OF THIS APPLICATION IS TO MODERNIZE THE RBL THROUGH BOTH UPGRADES AND RENOVATIONS THAT ARE DESIGNED TO ALLOW FOR CONTINUING CUTTING-EDGE RESEARCH ON INFECTIOUS AGENTS OF PANDEMIC CONCERN FOR MANY YEARS TO COME. AN EFFECTIVE AND EFFICIENT RBL IS A VITAL TOOL FOR PANDEMIC PREPAREDNESS. TO ACCOMPLISH OUR GOALS, 3 AREAS OF RBL FUNCTIONALITY AND EFFICIENCY WILL BE ADDRESSED. FIRST, WE WILL ENHANCE RBL SAFETY AND LONGEVITY. REPAIRS OR REPLACEMENTS WILL BE MADE TO THE BIO- CONTAINMENT FLOORING, THE SUPPLY AIR SYSTEM, THE EXHAUST SYSTEM, VARIABLE FREQUENCY DRIVES, CHILLER CONTROLS, STEAM WATER HEATERS, DIESEL ENGINE GENERATOR FUEL SYSTEM CONTROLS, FIRE ALARM SYSTEM, BUILDING AUTOMATION SYSTEM, WALK-IN COOLER, AND BIOMETRIC SECURITY. SECOND, THE EFFICIENCY OF RBL OPERATIONS WILL BE ENHANCED BY REPLACEMENT OF EXISTING SYSTEM LIGHTING WITH ENERGY-EFFICIENT LED LIGHTS AND REMOVAL OF A GAS PLASMA STERILIZER TO GENERATE MUCH NEEDED SPACE. THIRD, THE RESEARCH CAPACITY OF THE RBL WILL BE ENHANCED BY INCREASING RODENT HOUSING CAPACITY AND PURCHASING ADDITIONAL CAGING FOR NON-HUMAN PRIMATES, RABBITS, AND FERRETS. THE ULTIMATE GOAL OF THIS PROPOSAL IS TO ENSURE THE RBL REMAINS FUNCTIONAL, EFFICIENT, AND READY FOR RAPID RESPONSE TO FUTURE EMERGING PANDEMICS.
Department of Health and Human Services
$7.5M
HOST FACTORS IN FUNGAL ALLERGY AND FIBROSIS
Department of Health and Human Services
$7.4M
FUNCTIONAL GENOMICS OF CHEMICAL -INDUCED ACUTE LUNG INJURY
Department of Health and Human Services
$7.4M
BIOBEHAVIORAL INFLEXIBILITY AND RISK FOR JUVENILE-ONSET DEPRESSION
Department of Health and Human Services
$7.4M
COMPARISON OF DENDRITIC CELL-BASED THERAPEUTIC VACCINE STRATEGIES FOR HIV FUNCTIONAL CURE
Department of Health and Human Services
$7.3M
RT INHIBITOR CSIC AND ENTRY INHIBITOR RETROCYCLIN RC101 AS MICROBICIDES
Department of Health and Human Services
$7.2M
PROTOCOLIZED CARE FOR EARLY SEPTIC SHOCK (PROCESS)
Department of Health and Human Services
$7.2M
ENDOTHELIAL DYSFUNCTION AND RESTORATION IN TRAUMA INDUCED COAGULOPATHY - PROJECT SUMMARY/ABSTRACT: TRAUMA-INDUCED COAGULOPATHY (TIC) IS A LEADING DRIVER OF MORBIDITY AND MORTALITY FOLLOWING SEVERE INJURY. AFFECTING AS MANY AS 30% OF CRITICALLY ILL TRAUMA PATIENTS, TIC REPRESENTS A SPECTRUM OF COAGULATION PHENOTYPES RANGING FROM EARLY IMPAIRED HEMOSTASIS TO LATER MICRO AND MACROVASCULAR THROMBOTIC COMPLICATIONS. WE HAVE IDENTIFIED THAT PATIENTS WITH TIC HAVE EVIDENCE OF SEVERE ENDOTHELIAL DAMAGE, AND THESE MARKERS OF ENDOTHELIAL INJURY CORRELATE CLOSELY WITH OUTCOMES IN TRAUMA. FURTHER, THROUGH RANDOMIZED CONTROLLED TRIALS TESTING PRE- HOSPITAL PLASMA AS A RESUSCITATION TOOL, WE HAVE IDENTIFIED THAT PLASMA TRANSFUSION CAN REDUCE ENDOTHELIAL INJURY, EVEN IN THE PATIENTS WITH THE HIGHEST INJURY SEVERITY. PLASMA TRANSFUSION REDUCES MORTALITY AFTER SEVERE TRAUMA, BUT THE EXACT MECHANISM OF BENEFIT IS UNKNOWN. IN THE PRESENT PROPOSAL, WE ADDRESS THE CENTRAL HYPOTHESIS THAT THE ENDOTHELIUM IS A CENTRAL REGULATOR OF TIC. WE PROPOSE TO CHARACTERIZE THE ROLE OF THE ENDOTHELIUM AS THE REGULATOR OF MALADAPTIVE RESPONSE AND A CRUCIAL INTERFACE FOR THROMBOSIS-INFLAMMATION CROSSTALK. OUR STRATEGY WILL FOCUS ON IDENTIFYING KEY CIRCULATING MEDIATORS AFTER TRAUMA THAT INDUCE ENDOTHELIAL INJURY. WE WILL UTILIZE A “CUE, SIGNAL, RESPONSE” FRAMEWORK TO ROBUSTLY CHARACTERIZE THE MOLECULAR PATHWAYS ACTIVATED IN THE ENDOTHELIAL AND HOW THE ENDOTHELIAL RESPONSE INTERFACES WITH CHANGES IN THE COAGULATION RESPONSE. FINALLY, WE WILL DEFINE THE “REPARATIVE PHENOTYPE” THAT PLASMA TRANSFUSION CREATES, RESTORING THE ENDOTHELIUM TO HOMEOSTASIS. WE WILL USE THIS TO TEST TARGETED THERAPIES TO ADDRESS THE UNMET NEEDS IN TRAUMA RESUSCITATION TARGETING ENDOTHELIAL HEALTH. THE APPROACH WILL LEVERAGE STATE-OF-THE-SCIENCE AND NOVEL TECHNIQUES IN PROTEOMICS, TRANSCRIPTOMICS, METABOLOMICS, ADVANCED MICROVASCULAR IMAGING, AND PRE-CLINICAL MODELS OF TRAUMA AND HEMORRHAGE IN ADDITION TO A LARGE REPOSITORY OF PREVIOUSLY COLLECTED TRAUMA PATIENT SAMPLES.
Department of Health and Human Services
$7.2M
THE PEDIATRIC PRECISION SLEEP NETWORK - ABSTRACT PERI-ADOLESCENCE (AGES 10-13) HERALDS AN ALARMING ESCALATION IN PEDIATRIC MENTAL HEALTH (MH) RISK, MAKING THIS TRANSITIONARY TIME BETWEEN CHILDHOOD AND ADOLESCENCE A CRUCIAL WINDOW FOR EARLY DETECTION AND INTERVENTION. PREDICTIVE MODELS BUILT ON ELECTRONIC HEALTH RECORD (EHR) DATA ARE EMERGING AS PRACTICAL TOOLS TO AUTOMATE MH RISK STRATIFICATION IN PEDIATRIC PRIMARY CARE (PPC); HOWEVER, TO DATE THESE MODELS HAVE ONLY MODEST PREDICTIVE VALUE. COMMON, CAUSAL, AND MODIFIABLE TRANSDIAGNOSTIC MH RISK FACTORS ARE NEEDED TO IMPROVE ON EHR MODELS AND PAVE THE WAY FOR DEPLOYMENT OF PREVENTIVE CARE DURING PERI-ADOLESCENCE. SLEEP IS ONE SUCH RISK FACTOR: MORE THAN 50% OF PERI-ADOLESCENTS EXPERIENCE UNHEALTHY SLEEP PATTERNS, AND SLEEP PROBLEMS DURING PERI-ADOLESCENCE PROSPECTIVELY PREDICT NEGATIVE MH OUTCOMES MORE STRONGLY THAN AT OTHER TIMES IN DEVELOPMENT. MOREOVER, YOUTH FROM MINORITIZED RACIAL AND ETHNIC BACKGROUNDS ARE EVEN MORE SEVERELY IMPACTED BY POOR SLEEP HEALTH THAN NON- MINORITIZED YOUTH. HOWEVER, SEVERAL BARRIERS HAVE IMPEDED THE INCORPORATION OF SLEEP INTO PPC SCREENING AND RISK STRATIFICATION TOOLS: (1) THE HETEROGENEITY OF SLEEP CHARACTERISTICS HINDERS THE DIFFERENTIATION OF NORMATIVE VERSUS AT-RISK SLEEP PATTERNS; (2) THE MULTIDIMENSIONALITY AND MULTIMODALITY OF SLEEP DATA HAVE LED TO INCONSISTENCIES REGARDING WHICH PARTICULAR FEATURES AND MODALITIES ARE NEEDED FOR SCREENING; AND (3) UNTIL VERY RECENTLY, IT HAS BEEN IMPOSSIBLE TO CAPTURE CRUCIAL BEHAVIORAL AND PHYSIOLOGICAL MEASURES OF HABITUAL SLEEP IN SUFFICIENTLY LARGE SAMPLES. TO ADDRESS THESE CHALLENGES, WE PROPOSE THE PEDIATRIC PRECISION SLEEP NETWORK: A MULTI-SITE OBSERVATIONAL STUDY OF UNPRECEDENTED SCOPE AND SCALE, FOCUSED ON ESTABLISHING SLEEP SIGNATURES THAT PREDICT TRANSDIAGNOSTIC MH PROBLEMS AMONG YOUTH IN PPC. ACROSS THREE SITES, WE WILL RECRUIT A DIVERSE SAMPLE OF 1,200 YOUTH (10-13YR) WITH A RANGE OF SLEEP DISTURBANCES FROM PPC SETTINGS. WE WILL DEVELOP AND VALIDATE MULTIDIMENSIONAL AND MULTIMODAL SLEEP SIGNATURES (AIM 1) AND PRACTICAL AND SCALABLE TRANSDIAGNOSTIC MH RISK STRATIFICATION ALGORITHMS (AIM 2). AIMS 1-2 WILL EMPLOY A SEQUENTIAL, MULTIMODAL MACHINE LEARNING WORKFLOW TO ESTABLISH THE EXTENT TO WHICH EACH DATA MODALITY CAN INCREMENTALLY INFORM SIGNATURES AND IDENTIFY YOUTH AT GREATEST TRANSDIAGNOSTIC MH RISK. THESE FINDINGS WILL INFORM SCREENING, RISK STRATIFICATION, AND FUTURE DEVELOPMENTALLY-APPROPRIATE EFFECTIVENESS AND/OR EXPERIMENTAL THERAPEUTICS TRIALS. IN AIM 3, WE WILL COORDINATE WITH THE IMPACT-MH DATA COORDINATING CENTER TO EFFICIENTLY RECRUIT PARTICIPANTS, COLLECT DATA, HONE AND SHARE INNOVATIVE DATA PROCESSING PIPELINES, AND SECURELY TRANSFER DATA. WE ARE COMMITTED TO BRINGING SLEEP AND MH DATA TO OUR BROADER SCIENTIFIC COMMUNITY, ALONG WITH THE ACCOMPANYING TOOLS AND RESOURCES NEEDED TO PROCESS SLEEP DATA EFFICIENTLY. OUR LONG-TERM GOAL IS TO INFORM CLINICAL DECISION-MAKING ALGORITHMS FOR PPC THAT LEVERAGE SLEEP TO IMPROVE MH OUTCOMES AND REDUCE MH DISPARITIES AT A PIVOTAL DEVELOPMENTAL WINDOW.
Department of Health and Human Services
$7.1M
IMPROVING QUALITY AND EQUITY OF OPIOID USE DISORDER TREATMENT USING A MULTI-STATE MEDICAID RESEARCH NETWORK - PROJECT SUMMARY MEDICAID COVERS THE MAJORITY OF INDIVIDUALS WHO NEED OPIOID USE DISORDER (OUD) TREATMENT AND DISPROPORTIONATELY COVERS MINORITIZED POPULATIONS AND THOSE WITH SOCIOECONOMIC RISK FACTORS. IMPROVING OUD TREATMENT QUALITY IN MEDICAID THUS CAN REACH LARGE NUMBERS AND INFORM EFFORTS TO REDRESS INEQUITIES IN CARE. STATE MEDICAID PROGRAMS HAVE CHANGED POLICY TO EXPAND THE CONTINUUM OF CARE, REMOVE BARRIERS TO TREATMENT, AND IMPROVE THE QUALITY OF OUD CARE. HOWEVER, STATES HAVE TAKEN THESE ACTIONS AMIDST OUD QUALITY MEASUREMENT SYSTEMS THAT ARE UNDERDEVELOPED LIMITING OPPORTUNITIES FOR TARGETED INTERVENTION AND ROBUST EVALUATION OF POLICY EFFECTS. CURRENT OUD QUALITY MEASURES ARE LIMITED IN THREE KEY WAYS. FIRST, OUD QUALITY MEASURES ARE SELDOM CONSTRUCTED AT THE PROVIDER-LEVEL, DESPITE THE FACT THAT CLINICIANS, PRACTICES, AND FACILITIES ARE THE MOST LIKELY LOCUS OF INTERVENTION FOR QUALITY IMPROVEMENT PROGRAMS. SECOND, FEW MEASURES INCORPORATE OUD PATIENT-REPORTED OUTCOMES OR EXPERIENCES OF CARE. THIRD, QUALITY MEASURES ARE TYPICALLY NOT REPORTED BY POPULATION SUB-GROUP AND THUS FAIL TO IDENTIFY INEQUITIES IN TREATMENT BASED ON RACE AND ETHNICITY AMENABLE TO POLICY AND PROGRAMMATIC CHANGES. THE MEDICAID OUTCOMES DISTRIBUTED RESEARCH NETWORK (MODRN) HAS SUPPORTED MEDICAID AGENCY EFFORTS TO IMPROVE OUD TREATMENT BY DEVELOPING NOVEL MEASURES OF TREATMENT QUALITY AND EXAMINING EFFECTS OF TREATMENT QUALITY ON OVERDOSE. MODRN WILL DEVELOP EQUITY AND QUALITY IMPROVEMENT FOR MEDICAID PROGRAMS (EQUIP) AND DRAW ON OUR ROBUST UNIVERSITY-STATE PARTNERSHIPS IN 12 STATES ACCOUNTING FOR 24% OF THE US MEDICAID POPULATION. OUR OVERARCHING GOAL IS TO DEVELOP OUD QUALITY MEASURES THAT CAN BE CONSTRUCTED AT THE PROVIDER-LEVEL, INCORPORATE PATIENT EXPERIENCE, AND CENTER HEALTH EQUITY. EFFICIENT AND SUSTAINABLE OUD QUALITY MEASURES DEVELOPED AND IMPLEMENTED BY MODRN-EQUIP WILL GUIDE QUALITY IMPROVEMENT INITIATIVES AND MEDICAID POLICY DECISIONS. OUR GOAL WILL BE ACHIEVED THROUGH THREE INTEGRATED RESEARCH PROJECTS AIMING TO: 1) DEVELOP PROVIDER-LEVEL OUD QUALITY MEASURES USING MEDICAID ADMINISTRATIVE DATA; 2) MEASURE OUD PATIENT- REPORTED OUTCOMES AND EXAMINE ASSOCIATIONS WITH CLAIMS-BASED QUALITY MEASURES TO GUIDE QUALITY AND EQUITY IMPROVEMENT, AND 3) IMPLEMENT AND EXAMINE THE EFFECTIVENESS OF A PRACTICE-LEVEL QUALITY IMPROVEMENT INTERVENTION FOR OUD. A STATE STEERING COMMITTEE OF MEDICAID LEADERS WILL OVERSEE MODRN-EQUIP, DRAWING ON INFRASTRUCTURE SUPPORTED BY PRIOR NIDA GRANTS (R01DA055585 AND R01DA048029). THESE RESEARCH PROJECTS WILL BE EXECUTED BY A COORDINATING CENTER, A METHODS CORE AND AN ENGAGEMENT AND DISSEMINATION CORE THAT DRAWS ON THE EXPERTISE OF MEDICAID BENEFICIARIES, PROVIDERS, MANAGED CARE ORGANIZATIONS AND POLICYMAKERS TO DEVELOP QUALITY MEASUREMENT AND MANAGEMENT SYSTEMS TO TRANSFORM SUBSTANCE USE TREATMENT. WE WILL DISSEMINATE OUR FINDINGS THROUGH STATE POLICY NETWORKS TO REACH BEYOND OUR 12 STATES TO OTHER MEDICAID PROGRAMS.
Department of Health and Human Services
$7.1M
DATA COORDINATING CENTER FOR THE HALT-POLYCYSTIC KIDNEY DISEASE TRIALS
Department of Health and Human Services
$7.1M
GENETICALLY ENGINEERED RODENT CARE
Department of Health and Human Services
$7.1M
CLINICAL RESEARCH TRAINING IN CHILD PSYCHIATRY
Department of Health and Human Services
$7.1M
CORTICAL EXCITATORY-INHIBITORY BALANCE IN SCHIZOPHRENIA
Department of Health and Human Services
$7.1M
A BIOMIMETIC APPROACH TOWARDS A DEXTEROUS NEUROPROSTHESIS
Department of Health and Human Services
$7.1M
DEVELOPING A NAMPT ACTIVATOR FOR ALZHEIMER?S DISEASE - CURRENTLY THERE ARE NO THERAPIES THAT CAN SLOW OR REVERSE THE COGNITIVE DECLINE SEEN IN LATE-ONSET ALZHEIMER'S DISEASE (LOAD). THE SINGLE GREATEST RISK FACTOR FOR THIS CONDITION IS CHRONOLOGICAL AGE AND AS THE GLOBAL POPULATION AGES, THE NUMBER OF AD CASES IS EXPECTED TO CONTINUE TO RAPIDLY INCREASE. THIS AGE-DEPENDENT ASSOCIATION HAS LED MANY TO SUGGEST THAT STRATEGIES THAT SLOW OR REVERSE ASPECTS OF BRAIN AGING MIGHT BE OF PARTICULAR USE IN PATIENTS WITH LOAD. IN NORMAL HUMAN SUBJECTS, THERE IS AN AGE-DEPENDENT DECLINE IN BRAIN NAD+ LEVELS AND IN ANIMAL MODELS, A DECLINE IN BRAIN NAD+ IS STRONGLY ASSOCIATED WITH AGING AND COGNITIVE DECLINE, WHILE RESTORING NAD+ CAN IMPROVE COGNITIVE FUNCTION. MOREOVER, EVIDENCE SUGGESTS THAT IN PRE-CLINICAL AD MODELS, THERE IS AN ACCELERATED LOSS OF NAD+ AND THAT NEURONS ARE PARTICULARLY VULNERABLE TO A REDUCTION IN INTRACELLULAR NAD+ LEVELS. IT IS WELL ESTABLISHED THAT THE RATE LIMITING ENZYME IN THE NAD SALVAGE PATHWAY IS NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE (NAMPT) AND THAT THE ENZYMATIC ACTIVITY OF NAMPT LARGELY DETERMINES THE LEVEL OF NAD+ WITHIN CELLS. HERE, WE DESCRIBE AN EARLY STAGE DRUG DEVELOPMENT PROPOSAL TO ADVANCE A BRAIN PENETRANT, SMALL MOLECULE THAT AUGMENTS NAMPT ACTIVITY, THUS INCREASING NEURONAL NAD+ LEVELS AND COMBATING BRAIN AGING. WE DESCRIBE THE DEVELOPMENT PLAN OF THIS MOLECULE UP TO THE IND FILING STAGE. THE ULTIMATE CLINICAL INDICATION FOR SUCH A MOLECULE WOULD BE IN PATIENTS WITH LOAD AND MILD COGNITIVE IMPAIRMENT. WE HAVE ASSEMBLED A TEAM WITH EXTENSIVE DRUG DEVELOPMENT AND AD EXPERIENCE, BOTH IN THE PRE-CLINICAL AND CLINICAL ARENA. THIS PROPOSAL DESCRIBES A SERIES OF MILESTONES AND GO/NO GO DECISION POINTS TO ADVANCE OUR CURRENT SET OF THREE DISTINCT CHEMICAL SERIES, ALL OF WHICH DIRECTLY BIND TO NAMPT AND INCREASE ENZYMATIC ACTIVITY, TO A SINGLE FINAL CLINICAL CANDIDATE THAT WOULD BE READY TO ADVANCE TO PHASE I TESTING IN HUMAN SUBJECTS. THIS COMPOUND WOULD BE A FIRST- IN-CLASS SMALL MOLECULE THAT SEEKS TO REVERSE THE AGE-DEPENDENT DECLINE IN NAD+ LEVELS AS A MEANS TO TREAT MILD COGNITIVE IMPAIRMENT IN LOAD PATIENTS.
Department of Health and Human Services
$7M
PROSPECTIVE STUDIES OF CANCER ETIOLOGY AND PREVENTION IN SHANGHAI AND SINGAPORE
Department of Health and Human Services
$7M
PREDICTING PATIENT INSTABILITY NONINVASIVELY FOR NURSING CARE (PPINNC)
Department of Health and Human Services
$7M
SIV PATHOGENESIS IN AFRICAN GREEN MONKEYS AND PIGTAILED MACAQUES
Department of Health and Human Services
$6.9M
TRAINING IN TRAUMA AND SEPSIS RESEARCH
Department of Health and Human Services
$6.9M
DIABETES PREVENTION PROGRAM
Department of Health and Human Services
$6.9M
ANATOMICAL AND FUNCTIONAL PROPERTIES OF AUDITORY NERVE SYNAPSES
Department of Defense
$6.9M
ADAPTIVE SELF-ASSEMBLED SYSTEMS: EXPLOITING MULTIFUNCTIONALITY FOR BOTTOM-UP LARGE-SCALE ENGINEERING (ASSEMBLE)
Department of Health and Human Services
$6.9M
INVESTIGATING THE NEURAL CIRCUITS OF ITCH
Department of Health and Human Services
$6.9M
XENOBIOTIC RECEPTORS IN MEDIATING THE ENVIRONMENTAL EFFECTS ON HUMAN DISEASE AND MORBIDITY
Department of Health and Human Services
$6.9M
CELL TYPE SPECIFIC AAVS TO STUDY REWARD AND COGNITION - ADENO-ASSOCIATED VIRUSES (AAVS) ARE POTENT GENE DELIVERY VECTORS FOR NEUROSCIENCE STUDIES AND GENE THERAPY APPLICATIONS. HOWEVER, NATURALLY OCCURRING AAVS ARE NOT CELL TYPE SPECIFIC: THEY MUST BE COMBINED WITH OTHER TECHNOLOGIES, SUCH AS TRANSGENIC ANIMALS, TO ACHIEVE CELL TYPE SPECIFIC GENE EXPRESSION. THIS REQUIREMENT LIMITS THE USE GENETICALLY CODED ‘CIRCUIT-BREAKING’ TOOLS TO STUDY BEHAVIOR IN NONHUMAN PRIMATES (NHPS) – THE EXPERIMENTAL ANIMAL MODEL WITH THE GREATEST SIMILARITY TO HUMANS – AND HINDERS DEVELOPMENT OF CELL TYPE SPECIFIC TARGETING STRATEGIES FOR ACHIEVING DIRECT CLINICAL BENEFITS. TO EXPAND CELL TYPE SPECIFIC ACCESS IN NHPS AND LAY THE FOUNDATION FOR CIRCUIT SPECIFIC GENE THERAPY, WE PROPOSE TO CREATE, TEST, AND VALIDATE NEXT GENERATION, CELL TYPE SPECIFIC AAVS. FIRST, WE WILL DEFINE CELL TYPE SPECIFIC ENHANCERS – DISTAL REGULATORY ELEMENTS THAT HAVE DEMONSTRATED CONSIDERABLE PROMISE AS CELL TYPE SPECIFIC AAV DRIVERS. IN PRELIMINARY DATA, WE COLLECTED TRANSCRIPTOMIC AND CHROMATIN ACCESSIBILITY (I.E. “MULTI-OMIC”) SINGLE CELL DATA FROM THE STRIATUM, DORSOLATERAL PREFRONTAL CORTEX (DLPFC), PRIMARY MOTOR CORTEX (M1), INSULA, AND VENTRAL MIDBRAIN OF 2 RHESUS MACAQUE MONKEYS. WE COMBINED THE RHESUS MONKEY DATA SET WITH EXISTING HUMAN AND MOUSE DATA AND USED CONVOLUTIONAL NEURAL NETWORKS (CNNS) TO RANK OPEN CHROMATIN SEQUENCES ACCORDING TO THEIR POTENTIAL AS CELL TYPE SPECIFIC ENHANCERS. WE PACKAGED AAVS WITH THE TOP CANDIDATE ENHANCERS, INJECTED THEM INTO NHP STRIATUM, AND WE HAVE OBSERVED CELL TYPE SPECIFIC, ENHANCER DRIVEN EXPRESSION IN STRIOSOMES – A CELL TYPE SPECIFIC STRIATAL COMPARTMENT RELATED TO REWARD PROCESSING. TO BROADLY ADVANCE THIS AGENDA AND DEVELOP AAVS THAT DRIVE ROBUST, CELL TYPE-SPECIFIC EXPRESSION, WE PROPOSE TO EXPAND OUR MULTI-OMIC SINGLE CELL DATABASE WITH ADDITIONAL DATA FROM MACAQUE AND MARMOSET. WE WILL LEVERAGE THIS UPDATED, SEX-BALANCED DATABASE, WITH WILL INCLUDE DATA FROM 8 NHPS TO IDENTIFY CELL TYPE SPECIFIC ENHANCERS THAT ARE LIKELY TO DRIVE ROBUST EXPRESSION IN PRIMATES. IN PARALLEL, WE WILL USE OUR VALIDATED SCAAVENGR PIPELINE TO SCREEN AAV CAPSID MUTANTS FOR CELL-TYPE BIASED INFECTION PATTERNS IN THE NHP COGNITIVE AND REWARD SYSTEMS. WE WILL COMBINE THE TOP CELL TYPE SPECIFIC ENHANCERS WITH THE MOST BIASED AAV CAPSIDS TO GENERATE NEW, CELL TYPE SPECIFIC AAVS FOR TARGETING NEURONS IN THE NHP COGNITIVE AND REWARD SYSTEMS. WE WILL VALIDATE AAV SPECIFICITY USING FLUORESCENT IN SITU HYBRIDIZATION (FISH). THIS DATA WILL BE COMBINED WITH ULTRA-HIGH RESOLUTION MRI SCANS TO CREATE A RHESUS MACAQUE BRAIN ATLAS, AND THE VALIDATED VECTORS WILL BE STORED AND DISTRIBUTED BY THE UNIVERSITY OF PITTSBURGH BIOFORGE INITIATIVE. NHPS ARE CRITICAL FOR STUDYING HUMAN COGNITION AND DISEASE, AND THUS THERE IS A PRESSING NEED TO DEFINE THE MOLECULAR PROPERTIES OF NHP CELL TYPES AND STUDY THEIR BEHAVIORAL FUNCTIONS. THIS PROPOSAL WILL GENERATE A UNIQUE NHP MULTI-OMIC SINGLE CELL DATABASE, PROVIDE CELL TYPE SPECIFIC AAVS FOR NEURON TYPES IN COGNITIVE AND REWARD SYSTEMS, AND ESTABLISH A NEW MULTIMODAL RHESUS BRAIN ATLAS. THESE CONTRIBUTIONS WILL SIGNIFICANTLY ADVANCE CIRCUIT MANIPULATION CAPABILITIES IN THE PRIMATE BRAIN AND PROMOTE FUNDAMENTAL RESEARCH IN BASIC AND PRECLINICAL SCIENCE.
Department of Health and Human Services
$6.8M
WOMENS HEALTH ACROSS THE NATION
Department of Health and Human Services
$6.8M
AMYLOID PATHOLOGY AND COGNITION IN NORMAL ELDERLY
Department of Health and Human Services
$6.8M
REFINEMENT AND DISCOVERY OF NUCLEAR MATRIX PROTEIN MARKERS FOR COLORECTAL CANCER
Department of Health and Human Services
$6.8M
INTERVENTIONS TO REDUCE HYPERCOAGULABILITY IN OLD SIV-INFECTED NHPS
Department of Health and Human Services
$6.8M
THE UCLID CENTER AT THE UNIV OF PITTSBURGH
Department of Health and Human Services
$6.8M
DIRECTING TUMOR-SPECIFIC T CELLS TO TUMORS
Source: Federal Audit Clearinghouse (fac.gov)
Total Audits
10
Clean Audits
10
Material Weakness
No
Noncompliance Issues
No
| Year | Status | Financial Report | Federal Expenditure | Low Risk | Accepted |
|---|---|---|---|---|---|
| 2025 | Clean | Unmodified (Clean) | $1.4B | Yes | 2026-03-19 |
| 2024 | Clean | Unmodified (Clean) | $1.3B | Yes | 2025-03-29 |
| 2023 | Clean | Unmodified (Clean) | $1.3B | Yes | 2024-03-29 |
| 2022 | Clean | Unmodified (Clean) | $1.2B | Yes | 2023-03-28 |
| 2021 | Clean | Unmodified (Clean) | $1.1B | Yes | 2022-09-26 |
| 2020 | Clean | Unmodified (Clean) | $1B | Yes | 2021-09-26 |
| 2019 | Clean | Unmodified (Clean) | $1B | Yes | 2020-03-25 |
| 2018 | Clean | Unmodified (Clean) | $1B | Yes | 2019-03-24 |
| 2017 | Clean | Unmodified (Clean) | $978.9M | Yes | 2018-03-25 |
| 2016 | Clean | Unmodified (Clean) | $944.8M | Yes | 2017-03-28 |
Financial Report
Unmodified (Clean)
Federal Expenditure
$1.4B
Financial Report
Unmodified (Clean)
Federal Expenditure
$1.3B
Financial Report
Unmodified (Clean)
Federal Expenditure
$1.3B
Financial Report
Unmodified (Clean)
Federal Expenditure
$1.2B
Financial Report
Unmodified (Clean)
Federal Expenditure
$1.1B
Financial Report
Unmodified (Clean)
Federal Expenditure
$1B
Financial Report
Unmodified (Clean)
Federal Expenditure
$1B
Financial Report
Unmodified (Clean)
Federal Expenditure
$1B
Financial Report
Unmodified (Clean)
Federal Expenditure
$978.9M
Financial Report
Unmodified (Clean)
Federal Expenditure
$944.8M
Tax Year 2022 · Source: IRS e-Filed Form 990Schedule J available
Individuals serving as officers, directors, or trustees of the organization.
| Name | Title | Hrs/Wk | Compensation | Related Orgs | Other |
|---|
Source: IRS Publication 78, Auto-Revocation List & e-Postcard Data
Tax-deductible contributions: Yes
Deductibility code: PC
990-N (e-Postcard) Filing History
This organization files simplified Form 990-N (annual gross receipts ≤ $50,000).
Sources: IRS e-Filed Form 990 (XML) & ProPublica Nonprofit Explorer
Scroll →
| Year | Revenue | Contributions | Expenses | Assets | Net Assets |
|---|---|---|---|---|---|
| 2023 | $3.1B | $565.5M | $3.1B | $9.7B | $6.9B |
| 2022IRS e-File | $3.1B | $565.5M | $3.1B | $9.7B | $6.9B |
| 2021 | $3.2B | $504.7M | $2.7B | $9.7B | $6.5B |
| 2020 | $2.8B | $302.7M | $2.8B |
Sources: ProPublica Nonprofit Explorer & IRS e-File Index
| Tax Year | Form Type | Source | Documents |
|---|---|---|---|
| 2024 | 990 | IRS e-File | PDF not yet published by IRSView Filing → |
| 2023 | 990 | DataIRS e-File | PDF not yet published by IRSView Filing → |
| 2022 | 990 | DataIRS e-File |
Financial data: IRS e-Filed Form 990 (Tax Year 2022)
Leadership & compensation: IRS e-Filed Form 990, Part VII (Tax Year 2022)
Federal grants: USAspending.gov (live)
Organization info: IRS Business Master File
Tax-deductibility: IRS Publication 78
| Total |
|---|
| Anantha Shekhar | Svc Health Sciences | 40 | $1.4M | $0 | $157.8K | $1.5M |
| Jeffer Choudhry | Chief Investment Officer | 40 | $1.3M | $0 | $22.5K | $1.4M |
| Patrick D Gallagher | Chancellor / CEO | 40 | $679.4K | $25K | $140K | $844.4K |
| Paul Lawrence | Treasurer | 40 | $723.9K | $0 | $79.6K | $803.5K |
| Ann E Cudd | Provost/sr Vice Chancellor | 40 | $489.3K | $0 | $70K | $559.3K |
| Robin A Rutenbar | Sr Vice Chancellor- Research | 40 | $442.7K | $0 | $62.3K | $505K |
| David N Dejong | Svc Business Ops | 40 | $420.5K | $0 | $83.7K | $504.3K |
| Geovette E Washington | Svc & Chief Legal Officer | 40 | $444.9K | $0 | $47.7K | $492.6K |
| Narahari Sastry | Cfo/sr Vice Chancellor | 40 | $403.9K | $0 | $57K | $460.9K |
| Rosalyn E Jones | Vc/secretary Of The Bot | 40 | $254.3K | $0 | $30.9K | $285.2K |
| Douglas M Browning | Chair Of The Bot | 5 | $0 | $0 | $0 | $0 |
Anantha Shekhar
Svc Health Sciences
$1.5M
Hrs/Wk
40
Compensation
$1.4M
Related Orgs
$0
Other
$157.8K
Jeffer Choudhry
Chief Investment Officer
$1.4M
Hrs/Wk
40
Compensation
$1.3M
Related Orgs
$0
Other
$22.5K
Patrick D Gallagher
Chancellor / CEO
$844.4K
Hrs/Wk
40
Compensation
$679.4K
Related Orgs
$25K
Other
$140K
Paul Lawrence
Treasurer
$803.5K
Hrs/Wk
40
Compensation
$723.9K
Related Orgs
$0
Other
$79.6K
Ann E Cudd
Provost/sr Vice Chancellor
$559.3K
Hrs/Wk
40
Compensation
$489.3K
Related Orgs
$0
Other
$70K
Robin A Rutenbar
Sr Vice Chancellor- Research
$505K
Hrs/Wk
40
Compensation
$442.7K
Related Orgs
$0
Other
$62.3K
David N Dejong
Svc Business Ops
$504.3K
Hrs/Wk
40
Compensation
$420.5K
Related Orgs
$0
Other
$83.7K
Geovette E Washington
Svc & Chief Legal Officer
$492.6K
Hrs/Wk
40
Compensation
$444.9K
Related Orgs
$0
Other
$47.7K
Narahari Sastry
Cfo/sr Vice Chancellor
$460.9K
Hrs/Wk
40
Compensation
$403.9K
Related Orgs
$0
Other
$57K
Rosalyn E Jones
Vc/secretary Of The Bot
$285.2K
Hrs/Wk
40
Compensation
$254.3K
Related Orgs
$0
Other
$30.9K
Douglas M Browning
Chair Of The Bot
$0
Hrs/Wk
5
Compensation
$0
Related Orgs
$0
Other
$0
Highest compensated employees who are not officers or directors.
| Name | Title | Hrs/Wk | Compensation | Related Orgs | Other | Total |
|---|---|---|---|---|---|---|
| Patrick R Narduzzi | Head Football Coach | 40 | $6.4M | $0 | $256.3K | $6.7M |
| F Jeffrey Capel Iii | Head Men's Basketball Coach | 40 | $3.5M | $0 | $44.2K | $3.6M |
| Heather R Lyke | Director Of Athletics | 40 | $1.6M | $0 |
Patrick R Narduzzi
Head Football Coach
$6.7M
Hrs/Wk
40
Compensation
$6.4M
Related Orgs
$0
Other
$256.3K
F Jeffrey Capel Iii
Head Men's Basketball Coach
$3.6M
Hrs/Wk
40
Compensation
$3.5M
Related Orgs
$0
Other
$44.2K
Heather R Lyke
Director Of Athletics
$1.7M
Hrs/Wk
40
Compensation
$1.6M
Related Orgs
$0
Other
$130.4K
Members of the governing board. Board members often serve without compensation.
| Name | Title | Hrs/Wk | Compensation | Related Orgs | Other | Total |
|---|---|---|---|---|---|---|
| Adam C Walker | Trustee | 5 | $0 | $0 | $0 | $0 |
| Bradley J Franc Thru 1122 | Trustee | 5 | $0 | $0 | $0 | $0 |
| David C Chavern | Trustee | 5 | $0 | $0 | $0 | $0 |
| Dawne S Hickton | Trustee | 5 | $0 | $0 | $0 | $0 |
| Deborah J Gillotti | Trustee | 5 | $0 | $0 | $0 | $0 |
| Diane P Holder | Trustee |
Adam C Walker
Trustee
$0
Hrs/Wk
5
Compensation
$0
Related Orgs
$0
Other
$0
Bradley J Franc Thru 1122
Trustee
$0
Hrs/Wk
5
Compensation
$0
Related Orgs
$0
Other
$0
David C Chavern
Trustee
$0
Hrs/Wk
5
Compensation
$0
Related Orgs
$0
Other
$0
Individuals who previously served as officers or key employees.
| Name | Title | Hrs/Wk | Compensation | Related Orgs | Other | Total |
|---|---|---|---|---|---|---|
| Arthur S Levine | Fmr Svc Health Sciences Thru 6/1/20 | 40 | $1.5M | $0 | $53.4K | $1.6M |
Arthur S Levine
Fmr Svc Health Sciences Thru 6/1/20
$1.6M
Hrs/Wk
40
Compensation
$1.5M
Related Orgs
$0
Other
$53.4K
| $8B |
| $5B |
| 2019 | $2.8B | $274.3M | $2.6B | $7.2B | $5.2B |
| 2018 | $2.5B | $299.8M | $2.4B | $6.9B | $5.1B |
| 2017 | $2.5B | $262.3M | $2.3B | $6.6B | $4.7B |
| 2016 | $2.3B | $253M | $2.3B | $6.2B | $4.2B |
| 2015 | $2.4B | $266.5M | $2.2B | $6.3B | $4.4B |
| 2013 | $2.3B | $254.4M | $2B | $5.8B | $3.8B |
| 2011 | $2.2B | $294.7M | $2B | $5.4B | $3.5B |
| 2021 | 990 | Data | PDF not yet published by IRS |
| 2020 | 990 | Data |
| 2019 | 990 | Data |
| 2018 | 990 | Data |
| 2017 | 990 | Data |
| 2016 | 990 | Data |
| 2015 | 990 | Data |
| 2014 | 990 | — |
| 2013 | 990 | Data |
| 2012 | 990 | — |
| 2011 | 990 | Data |
| 2010 | 990 | — |
| 2009 | 990 | — |
| 2008 | 990 | — |
| 2007 | 990 | — |
| 2006 | 990 | — |
| 2005 | 990 | — |
| 2004 | 990 | — |
| 2003 | 990 | — |
| 2002 | 990 | — |
| 2001 | 990 | — |
| $130.4K |
| $1.7M |
| Randy V Bates | Assistant Football Coach | 40 | $868.5K | $0 | $69.4K | $937.9K |
| Frank Cignetti | Assistant Football Coach | 40 | $753.5K | $0 | $43K | $796.5K |
Randy V Bates
Assistant Football Coach
$937.9K
Hrs/Wk
40
Compensation
$868.5K
Related Orgs
$0
Other
$69.4K
Frank Cignetti
Assistant Football Coach
$796.5K
Hrs/Wk
40
Compensation
$753.5K
Related Orgs
$0
Other
$43K
| 5 |
| $0 |
| $0 |
| $0 |
| $0 |
| Edward J Grefenstette | Trustee | 5 | $0 | $2.1M | $1.9M | $4M |
| Erin W Mcdowell | Trustee | 5 | $0 | $0 | $0 | $0 |
| Eva Tansky Blum | Trustee | 5 | $0 | $0 | $0 | $0 |
| Gary T Brownlee | Trustee | 5 | $0 | $0 | $0 | $0 |
| Jack T Tighe Iii | Trustee | 5 | $0 | $0 | $0 | $0 |
| Jake Wheatley Jr | Trustee | 5 | $0 | $0 | $0 | $0 |
| James P Covert | Trustee | 5 | $0 | $0 | $0 | $0 |
| Jay Costa Jr | Trustee | 5 | $0 | $0 | $0 | $0 |
| John A Barbour | Trustee | 5 | $0 | $0 | $0 | $0 |
| John A Maher Iii | Trustee | 5 | $0 | $0 | $0 | $0 |
| John H Pelusi Jr | Trustee | 5 | $0 | $0 | $0 | $0 |
| John J Verbanac | Trustee | 5 | $0 | $0 | $0 | $0 |
| Larry J Merlo | Trustee | 5 | $0 | $0 | $0 | $0 |
| Lisa A Golden | Trustee | 5 | $0 | $0 | $0 | $0 |
| Louis R Cestello | Trustee | 5 | $0 | $0 | $0 | $0 |
| Michael G Wells | Trustee | 5 | $0 | $0 | $0 | $0 |
| Natalie Mihalek | Trustee | 5 | $0 | $0 | $0 | $0 |
| Patricia D Horoho | Trustee | 5 | $0 | $0 | $0 | $0 |
| Peter C Varischetti | Trustee | 5 | $0 | $0 | $0 | $0 |
| Robert Ritson Jr | Trustee | 5 | $0 | $0 | $0 | $0 |
| Roberta A Luxbacher | Trustee | 5 | $0 | $0 | $0 | $0 |
| S Jeffrey Kondis | Trustee | 5 | $0 | $0 | $0 | $0 |
| Salisa Berrien | Trustee | 5 | $0 | $0 | $0 | $0 |
| Sundaa Bridgett-Jones | Trustee | 5 | $0 | $0 | $0 | $0 |
| Sy Holzer Thru 1122 | Trustee | 5 | $0 | $0 | $0 | $0 |
| Valerie Njie | Trustee | 5 | $0 | $0 | $0 | $0 |
| Vaughn S Clagette | Trustee | 5 | $0 | $0 | $0 | $0 |
| William K Lieberman | Trustee | 5 | $0 | $0 | $0 | $0 |
| William Ward Jr | Trustee | 5 | $0 | $0 | $0 | $0 |
Dawne S Hickton
Trustee
$0
Hrs/Wk
5
Compensation
$0
Related Orgs
$0
Other
$0
Deborah J Gillotti
Trustee
$0
Hrs/Wk
5
Compensation
$0
Related Orgs
$0
Other
$0
Diane P Holder
Trustee
$0
Hrs/Wk
5
Compensation
$0
Related Orgs
$0
Other
$0
Edward J Grefenstette
Trustee
$4M
Hrs/Wk
5
Compensation
$0
Related Orgs
$2.1M
Other
$1.9M
Erin W Mcdowell
Trustee
$0
Hrs/Wk
5
Compensation
$0
Related Orgs
$0
Other
$0
Eva Tansky Blum
Trustee
$0
Hrs/Wk
5
Compensation
$0
Related Orgs
$0
Other
$0
Gary T Brownlee
Trustee
$0
Hrs/Wk
5
Compensation
$0
Related Orgs
$0
Other
$0
Jack T Tighe Iii
Trustee
$0
Hrs/Wk
5
Compensation
$0
Related Orgs
$0
Other
$0
Jake Wheatley Jr
Trustee
$0
Hrs/Wk
5
Compensation
$0
Related Orgs
$0
Other
$0
James P Covert
Trustee
$0
Hrs/Wk
5
Compensation
$0
Related Orgs
$0
Other
$0
Jay Costa Jr
Trustee
$0
Hrs/Wk
5
Compensation
$0
Related Orgs
$0
Other
$0
John A Barbour
Trustee
$0
Hrs/Wk
5
Compensation
$0
Related Orgs
$0
Other
$0
John A Maher Iii
Trustee
$0
Hrs/Wk
5
Compensation
$0
Related Orgs
$0
Other
$0
John H Pelusi Jr
Trustee
$0
Hrs/Wk
5
Compensation
$0
Related Orgs
$0
Other
$0
John J Verbanac
Trustee
$0
Hrs/Wk
5
Compensation
$0
Related Orgs
$0
Other
$0
Larry J Merlo
Trustee
$0
Hrs/Wk
5
Compensation
$0
Related Orgs
$0
Other
$0
Lisa A Golden
Trustee
$0
Hrs/Wk
5
Compensation
$0
Related Orgs
$0
Other
$0
Louis R Cestello
Trustee
$0
Hrs/Wk
5
Compensation
$0
Related Orgs
$0
Other
$0
Michael G Wells
Trustee
$0
Hrs/Wk
5
Compensation
$0
Related Orgs
$0
Other
$0
Natalie Mihalek
Trustee
$0
Hrs/Wk
5
Compensation
$0
Related Orgs
$0
Other
$0
Patricia D Horoho
Trustee
$0
Hrs/Wk
5
Compensation
$0
Related Orgs
$0
Other
$0
Peter C Varischetti
Trustee
$0
Hrs/Wk
5
Compensation
$0
Related Orgs
$0
Other
$0
Robert Ritson Jr
Trustee
$0
Hrs/Wk
5
Compensation
$0
Related Orgs
$0
Other
$0
Roberta A Luxbacher
Trustee
$0
Hrs/Wk
5
Compensation
$0
Related Orgs
$0
Other
$0
S Jeffrey Kondis
Trustee
$0
Hrs/Wk
5
Compensation
$0
Related Orgs
$0
Other
$0
Salisa Berrien
Trustee
$0
Hrs/Wk
5
Compensation
$0
Related Orgs
$0
Other
$0
Sundaa Bridgett-Jones
Trustee
$0
Hrs/Wk
5
Compensation
$0
Related Orgs
$0
Other
$0
Sy Holzer Thru 1122
Trustee
$0
Hrs/Wk
5
Compensation
$0
Related Orgs
$0
Other
$0
Valerie Njie
Trustee
$0
Hrs/Wk
5
Compensation
$0
Related Orgs
$0
Other
$0
Vaughn S Clagette
Trustee
$0
Hrs/Wk
5
Compensation
$0
Related Orgs
$0
Other
$0
William K Lieberman
Trustee
$0
Hrs/Wk
5
Compensation
$0
Related Orgs
$0
Other
$0
William Ward Jr
Trustee
$0
Hrs/Wk
5
Compensation
$0
Related Orgs
$0
Other
$0